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Abstract 	  
PKA is a ubiquitous kinase whose activity is controlled by the second messenger 
cAMP downstream of GPCR signalling. PKA is a tetrameric holoenzyme composed 
of a homodimer of regulatory subunits (PKAR) which each bind and inhibit a 
catalytic subunit (PKAC). In this conformation the enzyme is inactive. Upon cAMP 
binding to the regulatory subunits, the catalytic subunits are released and can 
phosphorylate their substrates. Regulation of PKA is mainly centred around PKAR, 
in a large part via binding of the A-kinase anchoring proteins (AKAPs). Here I 
characterise a novel Rho GAP, ARHGAP36, and describe how it directly binds the 
PKA catalytic subunits. This binding is via a pseudosubstrate motif, which inhibits 
PKAC activity by blocking access to substrates. In addition to this, ARHGAP36 also 
mediates polyubiquitylation and degradation of PKAC. This is the first description of 
ubiquitin-mediated degradation of PKAC. Surprisingly for a cytosolic protein, 
degradation is not mediated by the proteasome but by the endolysosomal pathway, 
which is usually reserved for transmembrane proteins. This bimodal antagonism of 
PKAC by ARHGAP36 leads to suppression of a variety of PKA signalling responses 
downstream. I found that ARHGAP36 expression is developmentally regulated and 
restricted to embryonic skeletal muscle. It is, however, upregulated in 
neuroblastoma cell lines, where I could show that ARHGAP36 modulates PKAC 
activity and stability in an endogenous setting.  
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  1.1. Signal Transduction Pathways 
 
Cellular behaviour is controlled by the concerted action of signal transduction 
pathways, which relay signals from the outside in. These pathways were once 
believed to be linear and unidirectional, however crosstalk between pathways and 
complex regulatory feedback loops are now known to be the norm. Amongst the key 
players in signal generation are kinases and GTPases. These signalling cascades 
are not just switched on or off; the signals these proteins propagate must also be 
precisely regulated in a spatiotemporal manner. Where, when and for how long 
these signalling proteins are active is of extreme importance. Thus they can be 
recruited to specific subcellular localisations and assembled in macromolecular 
complexes together with particular regulators that can tightly control their activity.  
 
Signals must be generated, however they must also be dynamically regulated. The 
interplay of proteins controlling activation and attenuation is key. Reversible post-
translational modification (PTM) of proteins is a versatile way to modify protein 
behaviour. PTMs can be used to initiate, terminate or tweak signalling responses. 
The best-studied PTM is phosphorylation, where the action of kinases is reversed 
by phosphatases. 
 
A further layer of regulation is the degradation of signalling components themselves. 
This is controlled by another reversible PTM, ubiquitylation, which mediates 
subsequent targeting of proteins to the respective degradation machineries. This is 
also a tightly regulated, dynamic process. Phosphorylation can prime for 
ubiquitylation and ubiquitin itself can be phosphorylated, thus allowing further 
complexity in the regulation of protein turnover and thus signalling.  
 
In this thesis I will describe the regulation of a signalling protein, Protein Kinase A 
(PKA), by both inhibitory and degradative mechanisms. I will begin by introducing 
first the regulation of Rho GTPases, second ubiquitylation and its roles in 
proteasomal and lysosomal degradation, and lastly phosphorylation and kinases 
with a particular focus on Protein Kinase A. 
 
 
 
 
14
	  1.2. Rho GTPases 
 
Rho GTPases are master regulators of the actin cytoskeleton. Like other small 
GTPases of the Ras-like superfamily, they are molecular switches that cycle 
between inactive GDP and active GTP bound states. Only in the latter state can 
they bind and relay signals to downstream signalling proteins.  
 
Rho GTPases were first linked to the actin cytoskeleton through the pioneering 
studies by Anne Ridley and Alan Hall: Injection of RhoA, Rac1 and Cdc42 into 
Swiss 3T3 cells led to formation of stress fibres, lamellipodia and filopodia 
respectively (Hall, 1998; Ridley & Hall, 1992). However, in the last 20 years it has 
become increasingly obvious that Rho signalling is not so simple. In contrast to the 
classical models where RhoA, Rac1 and Cdc42 were thought to cause distinct 
cellular behaviours, and to be active in different parts of the migrating cell (Ridley, 
2001; Raftopoulou & Hall, 2004), recent studies using FRET biosensors showed all 
three Rho proteins to be activated at the leading edge (Machacek et al, 2009). The 
Rho proteins have also been implicated in a wide range of other cellular processes, 
such as cell cycle progression, cell survival, vesicular trafficking and transcriptional 
regulation (Vega & Ridley, 2008). So how is signalling specificity achieved? 
 
The GTPase cycle is tightly controlled by three main factors: GTPase activating 
proteins (GAPs), Guanine nucleotide exchange factors (GEFs), and Rho guanine 
dissociation inhibitors (GDIs) (Figure 1.1) (Bos et al, 2007). GEF proteins are 
positive regulators, catalysing GTP loading (Rossman et al, 2005), whereas GAP 
proteins and GDI proteins act as negative regulators. GAPs increase the rate of 
GTP hydrolysis, whilst GDIs extract the Rho proteins from the membrane competent 
signalling pool and keep them bound in the inactive GDP state (Tcherkezian & 
Lamarche-Vane, 2007; Garcia-Mata et al, 2011). Of the twenty Rho proteins, 12 of 
them are classically activated and can be differentially regulated by GAPs and 
GEFs. In contrast, eight of the Rho proteins are atypical and are mostly GTP bound 
(Heasman & Ridley, 2008). Spatio-temporal control of the Rho GTPases is required 
to achieve the right signalling outcome. Approximately 80 GAPs, 60 GEFs and three 
GDIs provide numerous possibilities for fine-tuning classical Rho protein activity 
(Figure 1.2). These multi-domain regulatory proteins have the potential to specify 
signalling by targeting Rho proteins to distinct cellular localisations, and act as 
molecular scaffolds to recruit further signalling proteins. Determining the GTPase 
specificity, localisation and binding partners of these proteins will help to establish   
15
GAP
Rho
GDP
. Rho
GTP
. onoff
Pi
Rh
o
G
D
P.GD
I effector-
proteins
GEF
GTP
Figure 1.1 The Rho GTPase activation cycle
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Figure 1.2 Modular domain architecture of the human RhoGEF and 
RhoGAP proteins. Rho guanine nucleotide exchange factors 
(RhoGEFs) and Rho GTPase activating proteins (RhoGAPs) are multi-
domain scaffold proteins that provide subcellular targeting information 
and connect Rho GTPases to other signaling pathways, thereby specify-
ing Rho signalling. Figure kindly provided by Oliver Rocks.
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  mechanisms of Rho regulation, and the crosstalk with other signalling pathways. 
Many of these proteins are uncharacterised. 
 
Prior to the start of my PhD, my supervisor Oliver Rocks had carried out a 
systematic screen to characterise all the Rho GAP and GEF proteins, especially 
their binding proteins. This was done by mass spectrometry using epitope tagged 
GAP and GEF proteins as bait. In this interactome screen, an uncharacterised GAP, 
ARHGAP36, was found to interact with Protein Kinase A, as well as E3 ubiquitin 
ligases (Rocks and Pawson, manuscript in preparation). The regulation of PKAC 
activity and stability by ARHGAP36 will be the focus of this thesis.  
 
1.3. Ubiquitylation and cellular degradation pathways 
 
Nowadays it is widely accepted that protein lifetimes are dynamically regulated, 
however, this was not always the case. Seminal experiments by Rudolf 
Schoenheimer challenged the commonly held belief that proteins are stable entities 
and paved the way for modern day protein turnover experiments. He fed mice with 
stable isotope labelled amino acids and found that while some were excreted in 
urine others were incorporated into tissues. This was the first indication that protein 
turnover is dynamically regulated (Schoenheimer et al, 1939).  
 
The lysosome was then discovered in 1953 (De Duve et al, 1953; De Duve & 
Wattiaux, 1966) and was thought to be responsible for all cellular protein 
degradation. However only a fraction of proteins were stabilised upon inhibition of 
the lysosome using weak bases (Poole et al, 1977). Reticulocytes were still able to 
degrade haemoglobin, despite being devoid of lysosomes (Rabinovitz & Fisher, 
1964). This process also required ATP and took place at neutral pH as opposed to 
the acidic pH required for lysosomal degradation (Etlinger & Goldberg, 1977). It was 
thus hypothesised that another non-lysosomal mechanism for degradation must 
exist. This led to the eventual discovery of the proteasome (Tanaka et al, 1983; 
Hough et al, 1986; Hough & Rechsteiner, 1986; Ciechanover, 2005). Later on I will 
describe the three main pathways that eukaryotic cells use to degrade proteins: 
proteasomal degradation, endolysosomal degradation, and autophagy. But first I will 
turn to the unifying feature that is central to all of them: ubiquitin (Clague & Urbé, 
2010). 
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  1.3.1. Ubiquitin 
Ubiquitylation involves the post-translational addition of the 76 amino acid protein 
ubiquitin to a lysine residue within the substrate protein. This results in the formation 
of an isopeptide bond between the lysine side chain and the exposed carboxyl 
terminal glycine tail of ubiquitin (Vijay-Kumar et al, 1987; Pickart & Eddins, 2004). 
Ubiquitylation was first recognised as a signal targeting proteins for proteasomal 
degradation, however, today it is known to regulate a variety of cellular events, by 
affecting protein activity, localisation and interaction (Komander & Rape, 2012). 
 
Addition of one ubiquitin molecule to a substrate is termed monoubiquitylation. 
Complexity in the ubiquitin system is achieved by the ability of multiple ubiquitin 
molecules to be conjugated to a substrate. Multi-monoubiquitylation can occur via 
addition of single ubiquitin molecules to multiple different lysines within a substrate. 
Ubiquitin itself contains seven lysines: K6 K11, K27, K29, K33, K48, K63. Each of 
these lysines can be utilised for conjugation of further ubiquitin molecules. Linear 
ubiquitylation can also be achieved via a peptide bond between the C-terminal 
glycine of one ubiquitin and the N-terminal methionine (M1) of another (Walkzak et 
al 2012). Polyubiquitin chains can then be formed in a homotypic or heterotypic 
manner. Homotypic when the same linkage is utilised within a chain, heterotypic 
when differential linkage types are utilised. Heterotypic chains can be branched, if 
one ubiquitin is ubiquitylated at two or more sites (Ikeda and Dikic 2008, Behrends 
and Harper 2011) (Figure 1.3). The recent discovery that ubiquitin itself can be post-
translationally modified, via phosphorylation or acetylation, further diversifies the 
ubiquitin code (Herhaus and Dikic 2015, Swatek and Komander 2016). 
 
All chain linkages have been identified in HEK293 cells, with K48 (52%) and K63-
linked chains (38%) being most abundant (Dammer et al, 2011). From the total 
ubiquitin pool in HEK293 cells, 26% was free ubiquitin, 11% incorporated in 
polyubiquitin chains, and the majority was identified as monoubiquitylated-
conjugates (Kaiser et al, 2011).   
 
Different ubiquitin chain linkages have different structural properties and thus allow 
differential recognition by ubiquitin binding domains (UBDs) of which there are over 
20 different types in the human genome (Dikic et al, 2009; Scott et al, 2015). K48 
and K11 linked chains are tightly packed together with the different ubiquitin 
molecules contacting each other (Cook et al, 1994; Bremm et al, 2010). In contrast, 
K63 and M1-linked chains are much more open with no contact between the   
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Figure 1.3 Types of ubiquitylation
Proteins can be mono- or multi-monoubiquitylated or polyubiquitylated. 
There are then eight different types of ubiquitin chain linkage, with different 
topologies that can be formed. Polyubiquitylation can be homotypic or 
heterotypic. Heterotypic chains can be nonbranched (shown is K63 and K11), 
or branched (shown is K48 and K6). Adapted from (Kulathu & Komander, 
2012; Heride et al, 2014).
20
	  different ubiquitin molecules (Komander et al, 2009b). However even with these 
similarities, there are UBDs that have specificity for K63 or M1-linked chains 
(Husnjak & Dikic, 2012). Many UBDs bind a hydrophobic patch in ubiquitin around 
Ile44, which may suggest that binding of several ubiquitin binding proteins to the 
same ubiquitin is mutually exclusive.  
 
1.3.2. The ubiquitylation cascade 
Ciechanover, Hershko, Rose and colleagues characterised the machinery by which 
a chain of ubiquitin molecules are conjugated to a substrate leading to its 
degradation (Hershko et al, 1980). They discovered that ubiquitylation requires the 
action of three different classes of enzymes in a multistep process (Ciechanover et 
al, 1981, 1982; Hershko et al, 1983). The number of enzymes in each class 
increases dramatically; there are two E1 ubiquitin activating enzymes, around 40 E2 
ubiquitin conjugating enzymes and over 600 E3 ubiquitin ligase enzymes. (Figure 
1.4) 
 
The two E1 enzymes, UBA1 and UBA2, catalyse the ATP dependent activation of 
the C-terminus of ubiquitin via acyl-adenylation. This is followed by the conjugation 
of the activated ubiquitin to the active site cysteine of the E1 via a thioester linkage. 
The ubiquitin is then transferred to a similar cysteine within the active site of the E2 
via a trans-thioesterification reaction. The E3 ligase, in one way or another, then 
allows the transfer of ubiquitin to the substrate. The high number of E3 ligases is 
thought to allow substrate specificity. 
 
E3 ligases can be split into three main families, HECT, RING or RING-like, and 
RBR. HECT (Homology to E6AP carboxy terminus) family E3 ligases have a two-
step mechanism. They contain a catalytic cysteine, which accepts the ubiquitin from 
the E2 before transferring it to the substrate. They catalyse a wide range of chain 
linkages (Kim & Huibregtse, 2009). 
 
RING (really interesting new gene) family E3 ligases transfer the ubiquitin directly 
from the E2 to the substrate. The same is true for RING-like U-box E3 ligases 
(Metzger et al, 2014). They therefore act mostly as scaffolds, and together with the 
E2 determine linkage specificity (David et al, 2011). As well as single functioning 
units, RING E3 ligases can also exist as multi-subunit E3 ligases (Li et al, 2008), 
such as the Cullin-Ring ligases, which associate with substrate receptors and   
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(a) E1 ubiquitin activating enzymes mediate adenylation and thioesterification 
of ubiquitin. Ubquitin is then transferred from the E1 to the E2 ubiquitin conju-
gating ezyme by a trans-thioesterification reaction. There are three different 
types of E3 ligase. HECT ligases accept the ubiquitin from the E2 before trans-
ferring it to the substrate. RING ligases transfer ubiquitin directly from the E2 to 
the substrate.  Ring-between-RING (RBR) ligases bind E2s via a RING domain 
but also accept ubiquitin before transferring it to substrates in a HECT like 
manner. (b) The number of enzymes increases dramatically in each class. 
Adapted from (Winklhofer, 2014; Heride et al, 2014)
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  adapter proteins (Petroski & Deshaies, 2005). In the case of the SCF complex 
(Skp1, Cullin1, F-box), Skp1 acts as an adaptor between Cul1 and the F-box-
protein, which then provides substrate specificity, whilst the Cullin protein links to 
the Ring E3 Rbx1 (Cardozo & Pagano, 2004). ßTRCP is one such F-box protein 
that mediates the degradation of a large number of signaling proteins, including the 
Gli and β-catenin transcription factors (see below 1.4.3.3 and 4.3.8). 
 
RBR (RING-between-RING) family ligases, of which there are 18 in the human 
genome, were only recently identified as a distinct group (Eisenhaber et al, 2007). 
They have properties of both RING and HECT ligases (Aguilera et al, 2000). They 
bind E2s via a RING domain but also require a conserved catalytic cysteine to 
transfer ubiquitin to substrates (Wenzel et al, 2011). 
 
1.3.3. Deubiquitylases 
Ubiquitylation is a reversible process. Deubiquitylating enzymes (DUBs) oppose the 
action of E3 ligases. DUBs play various roles in ubiquitin regulation. Ubiquitin is 
transcribed from four different genes, and is expressed either as a linear fusion of 
multiple ubiquitin molecules, or ubiquitin fused to the ribosomal proteins (Wiborg et 
al, 1985; Baker & Board, 1991). DUB activity is thus required to generate free 
ubiquitin. DUBs are known to associate with the degradation machineries and 
recycle ubiquitin from substrates committed for degradation in order to contribute to 
ubiquitin homeostasis (Kimura et al, 2009; Clague et al, 2012). They can also 
rescue substrates from their fate by removing or editing ubiquitin chains. DUBs are 
known to associate with E3 ligases and these interactions may play a role in chain 
editing or protect E3s from degradation due to autoubiquitylation. The latter is the 
case for USP7 and the E3 ligase Mdm2, which is responsible for regulating p53 
stability (Li et al, 2003).  
 
There are around 80 active DUBs in the human genome that fall into five classes. 
Four of them are cysteine proteases: Ubiquitin C terminal hydrolases (UCH), 
Ubiquitin specific peptidases (USP), ovarian tumour proteases (OTU) and the 
Josephins (Komander et al, 2009a). The final class, the JAMM/MPN+ DUBs, are 
zinc metalloproteases. DUBs can cleave the isopeptide bond of the terminal 
ubiquitin of a chain (exopeptidase activity) or also cut within the chain 
(endopeptidase activity). DUBs have different specificities for chain linkages, with 
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  some only cleaving one chain-type, whereas others will non-discriminately cleave all 
linkages (Clague et al, 2013; Mevissen et al, 2013).  
 
Substrate specificity and roles of the DUBs can also be regulated by their 
subcellular localisation. Many have intrinsic localisation properties and can be found 
at distinct locations in the cell, such as the plasma membrane, nucleolus, 
centrosome, microtubules, ER, and mitochondria (Urbé et al, 2012). For example, 
USP33 is a DUB that is associated with the ER, COP coated vesicles and the cis-
Golgi (Thorne et al, 2011). USP19 and USP30 are the only mammalian DUBs that 
contain transmembrane domains. USP19 is tethered at the ER and plays a role in 
ER associated degradation (ERAD) there (Hassink et al, 2009). USP30 is targeted 
to the outer mitochondrial membrane where it opposes ubiquitylation of Parkin 
substrates and can also regulate mitochondrial morphology (Nakamura & Hirose, 
2008; Bingol et al, 2014; Liang et al, 2015). 
 
1.3.4. The Proteasome 
The majority of cytosolic proteins are degraded by the proteasome, a large 
multimeric complex that is essentially an assembly of proteases (Figure 1.5). It is 
composed of two subunits: the 20S core particle and the 19S regulatory particle. 
The core particle is made up of α  and β  subunits, arranged as a four-stacked ring 
structure α7β7β7α7. The β-rings form an inner hydrolytic chamber and the outer α-
rings form a gate to the inner chamber where degradation occurs. The core particle 
combines three different proteolytic activities contributed by the β 1, β 2 and β5 
subunits, which cleave proteins after acidic, basic or hydrophobic residues 
respectively (Finley et al, 2016). Proteasome activity can thus be inhibited by 
compounds targeting these subunits, such as epoxomicin, which inhibits the 
chymotrypsin-like activity (Meng et al, 1999; Kisselev & Goldberg, 2001). 
Bortezomib, another inhibitor of the chymotrypsin-like activity, has successfully been 
used in the clinic in the treatment of multiple myeloma  (Goldberg, 2012). 
 
The regulatory particle is composed of a hexameric ring of AAA-ATPases, which 
mediate the unfolding of substrates and control entry into the core particle. This 
unfolding is a key prerequisite for proteasomal substrates, and also prevents the 
non-discriminate degradation of cytosolic proteins. The core particle can be capped 
at one or both ends by a regulatory particle (Voges et al, 1999). Aside from the six 
AAA-ATPases the regulatory particle contains 13 other components. Three of these,   
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Ubiquitylation is a unifying feature of the different degradation pathways. Endocy-
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and therefore inhibitors have an effect on both pathways. Adapted from (Clague & 
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  Rpn10, Rpn13 and Rpn1, have been shown to bind both polyubiquitin chains and a 
DUB each (van Nocker et al, 1996; Husnjak et al, 2008; Finley et al, 2016; Shi et al, 
2016). Rpn11, a JAMM/MPN+ metalloprotease DUB, is also a component of the 
regulatory particle and associates with Rpn10. It is able to cleave the isopeptide 
bond between the substrate and the final ubiquitin and thus removes chains ‘en 
bloc’ from substrates before their degradation (Yao & Cohen, 2002). Two further 
DUBs are associated with the regulatory particle, USP14 and UCH37. These are 
thought to be involved in rescuing substrates from degradation via chain editing (Qiu 
et al, 2006; Lee et al, 2011; Finley, 2009). The receptor for UCH37 is Rpn13 (Qiu et 
al, 2006), whilst the yeast orthologue of USP14, Ubp6 is recruited to Rpn1, thus 
suggesting chain recognition is coupled to deubiquitylation (Husnjak et al, 2008; 
Chen & Walters, 2015; VanderLinden et al, 2015; Sahtoe et al, 2015; Shi et al, 
2016).  
 
The canonical ubiquitin chains associated with proteasomal degradation are linked 
via K48, and K48 linked tetra-ubiquitin is sufficient to target substrates for 
proteasomal degradation (Thrower et al, 2000). However, all chain linkages except 
for K63 were found to accumulate in HEK293T cells upon proteasome inhibition 
(Dammer et al, 2011). Interestingly all the DUBs of the proteasome can cleave K63 
linked chains, which may provide a proof reading mechanism to prevent 
proteasomal degradation of substrates with this chain type (Jacobson et al, 2009).  
 
K11 linked chains formed by the anaphase promoting complex (APC) E3 ligase in 
association with the K11-specific E2 UBE2S have been shown to mediate 
proteasomal degradation of cell cycle regulators during mitosis (Jin et al, 2008; 
Williamson et al, 2009; Matsumoto et al, 2010; Song & Rape, 2010). K27 linked 
chains have also been suggested to regulate proteasomal degradation of Parkin 
substrates during mitophagy (Geisler et al, 2010). K6 linked chains have been 
implicated in Parkin-mediated mitophagy (Durcan et al, 2014; Ordureau et al, 2015).  
 
In addition to playing a clear role in endolysosomal degradation (see below), K63-
linked chains have been shown to have non-degradative roles in some signal 
transduction pathways (Conze et al, 2008; Komander & Rape, 2012). This is 
particularly well established for the NFkB signaling cascade which also employs M1 
linked chains (Iwai & Tokunaga, 2009; Tokunaga et al, 2009).  K63 and K6-linked 
chains have also been implicated in DNA damage repair mechanisms (Morris & 
Solomon, 2004; Thorslund et al, 2015). K29 and K33 linked chains have been 
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  shown to have an inhibitory effect on AMPK (AMP-activated protein kinase) (Al-
Hakim et al, 2008). Finally, K33 linked chains have also been implicated in T cell 
receptor signalling and post-Golgi trafficking (Huang et al, 2010; Yuan et al, 2014). 
 
1.3.5. Endolysosomal degradation 
The endolysosomal pathway is the main route by which plasma membrane proteins, 
such as receptors and channels, are turned over by the cell. Endocytosed 
membrane proteins enter an early endosomal compartment from where they can 
either be recycled back to the plasma membrane or be sorted for degradation in the 
lysosome (Figure 1.6). The lysosome contains a collection of proteases, which 
require an acidic pH for their action (Haider & Segal, 1972). The acidic environment 
of the lysosome is achieved via the vacuolar H+-ATPase (v-ATPase) (Schneider, 
1981). Lysosomal degradation can be inhibited in a variety of manners (Figure 1.5). 
Bafilomycin can be used to specifically inhibit the v-ATPase, thus preventing 
acidification of the lysosome (Yoshimori et al, 1991). Weak bases such as 
chloroquine and NH4Cl which accumulate in the lysosome can also be used to 
abolish acidification (Poole et al, 1977). Alternatively, leupeptin can be used to 
inhibit lysosomal proteases (Libby & Goldberg, 1978).  
 
Trafficking along the endocytic pathway is controlled by the endosomal sorting 
complexes required for transport (ESCRT) machinery, which can be split into four 
groups: ESCRT-0 –I –II –III. The first three ESCRT complexes all contain ubiquitin-
binding motifs (UBD) with which they engage with ubiquitylated cargo (Williams & 
Urbé, 2007; Hurley & Stenmark, 2011).  
 
ESCRT-0 is composed of two proteins, HRS and STAM, which initially select 
ubiquitylated cargo at the endosomal membrane. They bind to each other via coiled 
coil domains (Asao et al, 1997; Prag et al, 2007) and to ubiquitin via their ubiquitin 
interacting motifs (UIM) and VHS domains (Urbé et al, 2003; Mizuno et al, 2003; 
Hong et al, 2009; Ren & Hurley, 2010). Together they contain four (mammals) or 
five (yeast) ubiquitin binding modules. HRS is targeted to early endocytic 
compartments via its FYVE domain that binds with high specificity to 
Phosphatidylinositol 3-phosphate (PI3P), the main phosphoinositide on early 
endosomes (Gillooly et al, 2000; Raiborg et al, 2001). HRS then binds clathrin and 
mediates the sorting of proteins into clathrin-coated microdomains of early  
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Figure 1.6 The Endolysosomal Pathway
Membrane proteins, such as activated transmembrane receptors, can be 
removed from the plasma membrane via endocytosis. From the early/sorting 
endosomes they can either be recycled back to the plasma membrane or 
trafficked along the endocytic pathway for eventual degradation in the lyso-
some. ESCRT-0 mediates the selection of ubiquitylated cargo, and the 
concerted action of ESCRT-I -II and -III leads to the internalisation of cargo into 
intraluminal vesicles of MVBs. The fusion of the lysosome and MVBs then 
allows the delivery of the lysosomal proteases which mediate subsequent deg-
radation. Adapted from (Williams & Urbé, 2007).
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  endosomes (Raiborg et al, 2002; Lloyd et al, 2002; Clague, 2002). STAM is also 
thought to bind clathrin (McCullough et al, 2006). HRS then recruits the ESCRT-I 
complex via its interaction with Tsg101 (Lu et al, 2003; Bache et al, 2003).  
 
ESCRT-I and ESCRT-II have been proposed to be involved in initial membrane 
deformation to form buds that confine cargo (Wollert & Hurley, 2010). ESCRT-II 
initiates the ordered assembly of the ESCRT-III complex (Teis et al, 2008; Henne et 
al, 2012). ESCRT-III proteins are found in an autoinhibited state in the cytoplasm, 
then upon recruitment to the endosome they have the ability to oligomerise 
(Zamborlini et al, 2006). ESCRT-III is thought to gather and confine ubiquitylated 
cargo and endosomal ubiquitin receptors at sites of internal vesicle formation and to 
initiate the scission of intraluminal vesicles (Wollert et al, 2009; Wollert & Hurley, 
2010; Hurley & Hanson, 2010; Chiaruttini et al, 2015). The ESCRT-III component 
Vps2 recruits the AAA-ATPase Vps4, which is required for the recycling of ESCRT 
components and for the formation of intraluminal vesicles, two processes that may 
thus be coupled (Bishop & Woodman, 2000; Sachse et al, 2004). ESCRT-III does 
not contain an intrinsic UBD but rather engages with DUBs to deubiquitylate cargo 
prior to the inward budding of the intraluminal vesicles and thus allows ubiquitin 
recycling (Williams & Urbé, 2007). Multivesicular bodies (MVBs) can then fuse with 
lysosomes which deliver the acidic hydrolases responsible for degradation of the 
cargo (Luzio et al, 2010; Wartosch et al, 2015). 
 
Lysosomal targeting is preferentially mediated via K63 linked polyubiquitylation. 
ESCRT-0 binds with slightly higher affinity to K63 than K48 linked chains (Ren & 
Hurley, 2010). K63 linked chains also accumulate rapidly upon lysosomal inhibition 
(Dammer et al, 2011). This linkage has been shown to be critical for degradation of 
the epidermal growth factor receptor (EGFR), TrkA and dopamine receptors 
(Geetha et al, 2005; Huang et al, 2006, 2013; Vina-Vilaseca & Sorkin, 2010). 
Monoubiquitylation is thought to be sufficient to promote internalization of 
membrane proteins like EGFR but K63 linked polyubiquitylation is required for 
lysosomal sorting by the ESCRT machinery (Huang et al, 2013). It has also been 
shown in yeast that monoubiquitylation of the Gap1 permease is sufficient for its 
internalization, but K63 linked polyubiquitylation is required for its sorting into MVBs  
(Lauwers et al, 2009). A combination of K11 and K63 chains have been implicated 
in the degradation of MHC-I (Boname et al, 2010), whilst K29 linked ubiquitin chains 
have been shown to regulate endolysomal trafficking of Notch pathway components 
(Chastagner et al, 2006). 
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  DUBs are thought to play distinct roles at different stages of the endocytic pathway. 
As well as interacting with ESCRT-III, the K63-linkage specific DUB AMSH and the 
non-discriminating DUB USP8 can bind to the SH3 domain of STAM via their 
microtubule interacting and transport (MIT) domains (McCullough et al, 2006; 
Clague & Urbé, 2006; Komander et al, 2009a; Faesen et al, 2011). At this early 
stage they are thought to determine the fate of cargo between recycling and 
degradation. Depletion of AMSH has been shown to promote degradation of EGFR, 
suggesting that it usually favours receptor recycling (McCullough et al, 2004). USP8 
has pleotropic roles including the stabilisation of ESCRT-0 (Row et al, 2006, 2007), 
and has been shown to promote recycling of some plasma membrane proteins 
including the Hedgehog receptor Smoothened (Li et al, 2012; Xia et al, 2012). USP8 
has also recently been shown to be required for the correct trafficking of mannose-
6-phosphate receptor and thus for the delivery of newly synthesised lysosomal 
proteases to the endocytic pathway (MacDonald et al, 2014). 
 
1.3.6. Autophagy 
The word autophagy literally means 'self-eating': it is derived from the Greek words 
‘auto’ meaning self and ‘phagein’ meaning eating. This was originally thought to be 
a non-specific process that mediates the bulk degradation of cytosolic material. 
However it is now known that there are many different types of autophagy which 
serve to sequester proteins in both non-selective and selective manners, including 
macroautophagy, microautophagy and chaperone-mediated autophagy (CMA) 
(Klionsky, 2005).  
 
In classical macroautophagy cytosolic material is surrounded by a double-limiting 
membrane that then closes to form an autophagosome. The autophagosome then 
fuses with the lysosome, to degrade engulfed material. This involves over 30 
autophagy-related genes (atg) that were originally identified in yeast and are mostly 
conserved in mammals (Klionsky et al, 2003; Reggiori & Klionsky, 2002). In contrast 
to the classical macroautophagy, microautophagy and CMA do not require the 
formation of an autophagosome nor do they involve the atg genes. However, all of 
these mechanisms rely on the lysosome to terminally degrade proteins. 
 
CMA is mainly thought to be mediated by the cytosolic chaperone Hsc70, which 
recognises substrates with the sequence KFERQ (Chiang & Dice, 1988; Chiang et 
al, 1989). Through the action of LAMP-2A (lysosome-associated membrane protein 
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  2A), the so-called CMA receptor, substrates are then unfolded and translocated 
through the lysosomal membrane with the aid of a luminal form of Hsc70 (Cuervo & 
Dice, 1996; Agarraberes et al, 1997; Salvador et al, 2000). This does not involve 
ubiquitylation of the cargo (Kaushik & Cuervo, 2012). Recently another process was 
described called chaperone-assisted selected autophagy (CASA). This also involves 
Hsc70, as well as other chaperones. However, it further requires ubiquitylation 
mediated by Stub1, the autophagic ubiquitin adaptor p62 and formation of an 
autophagosome (Arndt et al, 2010; Ulbricht & Höhfeld, 2013) 
 
Microautophagy involves the sequestration of cargo directly into the lysosome via 
membrane invagination (Marzella et al, 1981; Kunz et al, 2004). This has only been 
described in yeast, however recently microautophagy by late endosomes has been 
postulated in mammals (endosomal microautophagy, e-MI) (Sahu et al, 2011). This 
is thought to require components of the ESCRT pathway, specifically Tsg101 and 
Vps4. This can occur in a selective manner via Hsc70 mediated recruitment of 
KFERQ motif containing proteins. In contrast to CMA, this does not involve LAMP-
2A or cargo unfolding. Hsc70 is thought to associate with the endosomal limiting 
membrane via an electrostatic interaction mediated by a basic region in its C-
terminus. This process is not thought to require ubiquitin. Apparently eMI can also 
occur in a non-selective fashion in which cytosolic proteins are incorporated 
passively and trapped in MVBs upon intraluminal vesicle budding (Sahu et al, 2011). 
 
Macroautophagy can be either non-selective or selective. Non-selective autophagy 
occurs in response to different types of cellular stress and amino acid starvation, 
through inhibition of mammalian target of rapapmycin (mTOR). (Yang & Klionsky, 
2010). Multiple selective macroautophagy pathways have now been identified and 
are named after their specific cargo: Mitophagy (mitochondria), aggrephagy 
(aggregates), proteophagy (proteasomes) among others (Khaminets et al, 2016).  
 
General macroautophagy starts with the initiation of a phagopore, which then 
expands and closes to give the double-membrane autophagosome.  Initiation and 
development of an autophagosome requires the sequential action of four different 
groups of proteins (Mizushima et al, 2011; Klionsky & Schulman, 2014). Nucleation 
of the phagopore is mediated by the ULK1-kinase complex, followed by the PtdIns-
3-kinase (PI3K) complex composed of Vps34, p150, Beclin and ATG14L. A second 
Vps34, Beclin and UVRAG containing PI3K complex is thought to be involved in the 
autophagosome maturation process (Vanhaesebroeck et al, 2010). PI3K inhibitors 
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  such as wortmannin can therefore be used to block the pathway, however this also 
inhibits progression along the endolysosomal pathway (Figure 1.5). The 
transmembrane protein Atg9 is thought to be involved in trafficking of membrane 
sources to the phagopore assembly site. Ubiquitin-like proteins (UBLs) are then 
involved in the autophagosome expansion process. Specifically, these are Atg8 
(LC3 and GAPARAP in mammals) and Atg12. Atg12 is conjugated to Atg5 in a 
process that requires the action Atg7 and Atg10, which are E1 and E2 like enzymes. 
An Atg5-Atg12-Atg16 complex then acts in an E3-like manner to mediate the 
conjugation of Atg8 to the lipid phosphatidylethanolamine (PE). This process also 
requires the action of the E1 and E2 like enzymes Atg7 and Atg3 (Klionsky & 
Schulman, 2014). 
 
For selective autophagy, recognition of cargo is achieved via a variety of autophagy 
receptors, which contain LC3 interacting regions (LIR) and can deliver cargo to the 
autophagic membrane (Stolz et al, 2014). Ubiquitin has now been widely implicated 
in the regulation of many selective autophagy mechanisms (Kirkin et al, 2009; 
Khaminets et al, 2016). This involves autophagic receptors which contain UBDs and 
thus can specifically recognize ubiquitylated cargo and also simultaneously bind the 
LC3/GABARAP proteins (Khaminets et al, 2016). For example, the UBDs of 
autophagy receptors OPTN and NDP52 are required for mitophagy (Lazarou et al, 
2015). Most recently, phosphorylated ubiquitin has been shown to act as a signal to 
trigger mitophagy (Durcan & Fon, 2015). In aggrephagy, K63 linked ubiquitylation 
has been implicated in targeting of Tau and Sod1 aggregates for degradation by the 
autophagosome (Tan et al, 2008).  
 
1.4. Phosphorylation and Kinases 
Phosphorylation is a reversible post-translational modification. Kinases catalyse the 
transfer of the gamma-phosphate group from ATP onto substrates, usually onto Ser, 
Thr and Tyr residues. Phosphatases reverse this reaction. The first kinase was 
described in 1954 and was later identified as casein kinase 2 (Burnett & Kennedy, 
1954). The seminal studies by Krebs and Fischer that later won them the Nobel 
Prize then described how phosphorylation was a reversible process and could 
modulate the activity of enzymes (Krebs & Fischer, 1956). It is now known that there 
are over 500 protein kinases encoded in the human genome (Manning et al, 2002), 
and a staggering 700,000 potential phosphorylation sites (Ubersax & Ferrell, 2007). 
The interplay of different kinases in regulating the same substrate by multi-step 
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  phosphorylation processes is commonplace.  Phosphorylation has now been shown 
to modulate all aspects of protein biology, affecting catalytic activity, protein-protein 
interaction, stability, and subcellular localisation. It is thus no surprise that 
phosphorylation plays a central role in a variety of signalling processes (Cohen, 
2000).  
 
1.4.1. PKA  
Protein Kinase A (PKA) was the second ever kinase to be identified (Walsh et al, 
1968). It is a broad spectrum Ser/Thr kinase of the AGC subfamily (PKA, PKG, 
PKC) (Pearce et al, 2010). PKA is a tetrameric holoenzyme comprised of a 
homodimer of regulatory (PKAR) subunits that each bind a catalytic (PKAC) subunit. 
In this conformation the enzyme is inactive, as PKAR binds PKAC via its catalytic 
domain, blocking access to substrates. PKA is then activated upon cAMP binding to 
PKAR, leading to the release of PKAC (Figure 1.7a) (Reimann et al, 1971; Corbin et 
al, 1975).  PKA was thus initially known as the cAMP-dependent kinase. 
 
1.4.1.1. PKAR 
There are four PKAR isoforms PKARIα, PKARIβ, PKARIIα and PKARIIβ. Depending 
on the regulatory subunit makeup, the holoenzyme is termed either type I or type II 
PKA. PKARIα and PKARIIα are ubiquitously expressed. PKARIβ is expressed 
predominantly in the central nervous system. PKARIIβ is expressed mainly in the 
brain, as well as in neuroendocrine, adipose and reproductive tissues (Skalhegg & 
Tasken, 2000).  
 
All PKAR subunits are composed of an N-terminal D/D domain for dimerization and 
two C-terminal cAMP binding domains (Taylor et al, 2012). A flexible linker region in 
between these N and C terminal domains contains the PKAC binding site. This 
resembles a peptide substrate of PKAC. Whereas the RI subunits are 
pseudosubstrate inhibitors, containing an Ala or a Gly, the RII subunits are actual 
substrates, containing an acceptor Ser (Johnson & Lewis, 2001). This site is auto-
phosphorylated within the holoenzyme. 
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Figure 1.7 PKA activation and cAMP generation (a) PKA is a tetrameric 
holoenzyme composed of a heterodimer of regulatory subunits (R) which 
each bind and inhibit a catalytic subunit (C). cAMP (represented by the pink 
dots) binding to PKAR leads to the release of PKAC, which is already phos-
phorylated (represented by the yellow dots) in the catalytic site and thus 
active. (b) Ligand binding to GPCRs mediates dissociation of the heterotri-
meric G proteins. Activated GTP bound Gαs stimulates the adenyl cyclase 
(AC) to produce cAMP. cAMP can then bind PKAR and thus release PKAC. 
Adapted from (Pearce et al, 2010)
a.
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  1.4.1.2. PKAC 
PKAC itself is constitutively active. Most protein kinases are regulated by dynamic 
phosphorylation of the activation loop, however for PKAC this activation loop 
phosphorylation occurs soon after synthesis, and is very stable (Steichen et al, 
2010, 2012). Thr197 is phosphorylated by PDK1 or, in trans, by another PKAC 
molecule. PKAC activity is thus not regulated by turnover of this phosphorylation but 
solely by binding to PKAR. 
 
PKAC also undergoes cis-autophosphorylation at Ser338, which occurs at the 
ribosome and is required for its maturation and subsequent activating Thr197 
phosphorylation (Keshwani et al, 2012). PKAC is also myristoylated at its N-
terminus. This enhances its structural stability (Yonemoto et al, 1993; Bastidas et al, 
2012) and is also thought to contribute to membrane association of both the 
holoenzyme and the catalytic subunit alone (Gangal et al, 1999; Gaffarogullari et al, 
2011). 
 
PRKACα and PRKACβ are the two main isoforms of the PKAC subunits in human 
and are highly conserved. In humans another isoform was detected, PRKACγ, that 
is found specifically in the testis (Beebe et al, 1990). Two other related kinases have 
also been identified in humans, PRKX and PRKY, which are encoded on the X and 
Y chromosomes respectively. PRKX was found to bind the regulatory subunits and 
become activated by cAMP (Zimmermann et al, 1999), however it is unclear if the 
same is the case for PRKY (Schiebel et al, 1997). Interestingly PRKX is thought 
only to form holoenzyme complexes with RI subunits (Zimmermann et al, 1999). 
 
PRKACα and PRKACβ can then be differentially spliced to give Cα1, Cα2, Cβ1 and 
Cβ2. For PRKACα the canonical Cα1 is ubiquitously expressed and the best 
studied. In contrast Cα2 is found only in male germ cells (also termed CaS). A third 
variant has also been described but has not been characterised (Strausberg et al, 
2002). For PRKACβ, Cβ1 is ubiquitously expressed in mouse, albeit at much lower 
levels than Cα1. Cβ2 is predominantly found in the brain (Uhler et al, 1986). 
Additional PRKACβ splice variants are thought to exist in humans (Ørstavik et al, 
2001). 
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  1.4.2. PKA regulation 	  
1.4.2.1. cAMP production 
cAMP (cyclic adenosine monophosphate) was identified over 60 years ago 
(Sutherland & Rall, 1958). This discovery and the fact that cAMP production is 
coupled to hormone signalling led to Earl Sutherland receiving the Nobel Prize in 
1971. cAMP is a ubiquitous second messenger. We now know its production is 
stimulated by ligand binding to G protein coupled receptors (GPCRs), of which there 
are over 800 in the genome (Figure 1.7a) (O’Hayre et al, 2013). They comprise 
seven transmembrane domains, as well as a N-terminal extracellular domain and a 
C-terminal intracellular domain. As their name suggests, they signal via 
heterotrimeric G proteins, which link the receptor to its downstream effectors. G 
proteins are made up of α, β , and γ  subunits (Pierce et al, 2002). Ligand binding 
activates the receptor, which can then act as a Guanine nucleotide exchange 
factors (GEF) to mediate GDP dissociation from and GTP-binding to the Gα subunit, 
resulting in the dissociation of the beta-gamma subunits and recruitment of 
downstream effectors to the alpha subunits (Gilman, 1987; Johnston & Siderovski, 
2007). There are four classes of α subunit: Gαs, Gαi, Gαq and Gα12. Gαs stimulates 
activity of the adenyl cyclase whereas Gαi inhibits it (Gilman, 1987). Gαq and Gα12 
couple to phospholipase C and Rho GEFs respectively.  Upon G protein activation 
the β and γ subunits remain associated as a heterodimer, and can also modulate 
adenyl cyclase activity as well as other downstream effectors (Tang & Gilman, 
1991).  
 
There are nine membrane-associated isoforms of the adenyl cyclase (AC1-9) 
(Sunahara & Taussig, 2002). These consist of 12 transmembrane passes, which are 
split into two tandem repeating domains of six transmembrane passes, each 
followed by a cytosolic catalytic loop (Krupinski et al, 1989). G proteins are thought 
to bind at the interface of these loops to stimulate activation (Hurley, 1999). The 
activity of some isoforms can also be differentially modulated by Ca2+ (Halls & 
Cooper, 2011). PKA itself can phosphorylate and inhibit AC5/6, which is thought to 
contribute to a refractory period (Iwami et al, 1995; Chen et al, 1997). PKA 
phosphorylation of the GPCR can also lead to inhibition of signalling via G protein 
switching. This has been shown for the β-adrenergic receptor and also the 
prostacyclin receptor (Daaka et al, 1997; Lawler et al, 2001).  
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  It should also be noted that there is one soluble isoform of the adenyl cyclase 
(sAC/AC10), which is predominantly expressed in testis and is not responsive to G 
proteins (Braun & Dods, 1975; Buck et al, 1999). This is rather regulated by 
intracellular calcium and has been postulated to be a bicarbonate sensor (Chen et 
al, 2000; Steegborn et al, 2005). 
 
cAMP levels are negatively regulated by phosphodiesterases. There are 11 different 
members of the phosphodiesterase family (Conti & Beavo, 2007; Omori & Kotera, 
2007). These are encoded for by different genes and undergo differential splicing, 
leading to a large number of isoforms.  Some are specific for cAMP (PDE4, PDE7, 
PDE8), some for cGMP (PDE5, PDE6, PDE9) while the rest catalyse the hydrolysis 
of both (Houslay, 2010). 
 
cAMP synthesis can be stimulated by Forskolin, a natural compound isolated from 
the Indian medical plant Coleus forskohlii (Metzger & Lindner, 1981). It directly 
activates all membrane bound adenyl cyclases, except AC9. IBMX can also be used 
to increase cAMP levels, which inhibits phosphodiesterase activity in a non-selective 
manner (Costa et al, 1975). Maximal stimulation can be obtained by combined use 
of Forskolin and IBMX. 
 
PKA is the main cellular effector of cAMP, however it was later found that the EPAC 
(Exchange proteins activated by cAMP) proteins are also activated by cAMP (de 
Rooij et al, 1998). These are GEFs for the small GTPase Rap (de Rooij et al, 1998). 
Specific cAMP analogues have been developed that can selectively activate EPAC 
proteins in order to dissect the distinct roles of PKA and EPAC proteins downstream 
of cAMP, such as 8-pCPT-2-O-Me-cAMP, also known as 007 (Gloerich & Bos, 
2010).  
 
1.4.2.2. AKAPs 
Compartmentalised signalling by PKAC was first hypothesised in the 1970s. 
Prostaglandin and epinephrine stimulation both caused a similar increase in cAMP 
levels and PKA activity in the rat heart, however only epinephrine led to an increase 
in glycogen phosphorylase activity (Keely, 1977). This suggested differential 
activities of PKAC within the same cell. Cellular PKA activities were later shown to 
be compartmentalised by the action of A-kinase anchoring proteins (AKAPs). 
AKAPs bind R subunits and thus target the PKA holoenzyme to specific subcellular   
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Figure 1.8 AKAPs provide tailored PKA signalling nodes
AKAPs bind PKAR and can thus target the holoenzyme to different subcellu-
lar locations, such as the plasma membrane, placing PKA close to particular 
substrates. They can also bind further proteins that can regulate PKA signal-
ling. Such as GPCRs, the adenyl cyclase (AC) for cAMP production, phos-
phodiesterases (PDE) for cAMP hydrolysis, phosphateses to reverse 
substrate phosphorylation and other kinases allwoing for crosstalk with other 
pathways. cAMP levels can be modulated by Forskolin which stimulates the 
adenyl cyclase, and IBMX which inhibits phospodiesterases. Adapted from 
(Skroblin et al, 2010)
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  locations, providing spatial information and placing PKA in the vicinity of particular 
substrates (Skroblin et al, 2010). The first AKAP was identified in 1982, when 
Protein kinase A was found to co-purify with microtubule associated protein 2 
(MAP2) from microtubule preparations isolated from rat brain (Vallee et al, 1981). It 
was subsequently shown that MAP2 binds RII subunits and thereby recruits PKA to 
microtubules (Theurkauf & Vallee, 1982).  
 
Over 50 AKAPs have now been identified. They are similar only in the way they bind 
PKA regulatory subunits, whereas they target PKA to different subcellular 
compartments via distinct mechanisms. AKAPs bind the N-terminal D/D domain of 
PKA regulatory subunits via an amphipathic helix of 14-18 residues (Skroblin et al, 
2010). AKAPs in general preferentially bind RII subunits, however both dual 
specificity and RI specific AKAPs have been described. These proteins also have 
numerous other binding partners and thus act as scaffolds to recruit other proteins 
that modulate PKA signalling (Figure 1.8). These include adenyl cyclases and 
phosphodiesterases for cAMP generation and turnover respectively, protein 
phosphatases to reverse PKA substrate phosphorylation and other protein kinases, 
allowing for the integration of other signalling pathways. AKAPs therefore provide 
different PKA signalling modules for particular signalling contexts, allowing for 
modular specialisation of this ubiquitously used pathway. The same AKAP can also 
bind different sets of proteins at different times, further adding to the complexity of 
their role in PKA signalling. Since the identification of MAP2 as a microtubule 
targeting AKAP, AKAPs have been found that target PKA to diverse cellular 
locations, such as the nucleus, centrosome, plasma membrane, Golgi and 
mitochondria (Skroblin et al, 2010). AKAP mediated PKA signalling is thought to be 
the key mechanism by which specific cAMP signalling outcomes are achieved. 
 
1.4.2.3. PKAC binding proteins 
In contrast there are few proteins that bind directly to the C subunits, as most 
regulation is thought to be via the regulatory proteins. The protein kinase inhibitor 
protein (PKI) is the most famous of these proteins, mainly as it is widely used 
experimentally to inhibit PKAC. PKI binds directly to PKAC and inhibits it via a 
pseudosubstrate motif, similar to that found in PKAR (Scott et al, 1985). This 
mechanism of pseudosubstrate inhibition rather than blocking the ATP pocket 
increases specificity for PKAC over other kinases. The ATP binding pocket is 
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  extremely conserved across kinases, whereas the catalytic site is more diverse 
(Murray, 2008). 
 
PKI cannot compete with PKAR for PKAC within the holoenzyme, but rather binds 
free PKAC (Herberg & Taylor, 1993). PKI proteins contain a nuclear export signal 
(Wen et al, 1995), which is hidden unless PKI is bound to PKAC (Dalton & Dewey, 
2006). PKI proteins are thus thought to be involved in shuttling nuclear PKAC back 
to the cytoplasm. PKAR subunits that are not bound to cAMP can then compete for 
PKAC in order to reform the holoenzyme (Herberg & Taylor, 1993).  
 
PDE7A1, a cAMP specific phosphodiesterase, also contains two PKAC 
pseudosubstrate sites in its N-terminus (Han et al, 2006). It thus inhibits PKAC 
directly via pseudosubstrate binding, and indirectly via hydrolysing cAMP. 
 
Two PKAC binding proteins are involved in NFkB signalling. IkB, a negative 
regulator of the NFkB pathway, binds PKAC directly and blocks ATP binding, thus 
inhibiting kinase activity (Zhong et al, 1997). AKIP1 (A-kinase interacting protein 1), 
which can bind the transcription factor p65 subunit of NFkB (Gao et al, 2008), can 
also bind PKAC in the A-helix at its N-terminus. This does not affect PKA activity, 
but AKIP1 contains a nuclear localisation signal and is thought to play a role in 
nuclear shuttling of PKAC (Sastri et al, 2005). p65 is also a PKA substrate and thus 
AKIP1 helps to mediate its phosphorylation, which enhances NFkB pathway 
activation.  
 
The G protein Gαo binds PKAC and prevents it from translocating to the nucleus. 
The binding mechanism is unknown, however Gαo does not affect PKAC activity 
(Ghil et al, 2006). The role of Gαo signalling is unclear. It belongs to the Gαi family, 
but does not seem to inhibit the adenyl cyclase. 
 
A dual role of RSK1 (p90 ribosomal S6 kinase-1) in PKA regulation has been 
proposed based on work from the Patel laboratory. Active RSK1 binds PKAC to 
promote PKAR binding and inactivation. In contrast, inactive RSK1 binds PKAR and 
displaces PKAC. RSK1 is thought to bind PKAR in the cytoplasm, and PKAC in the 
nucleus (Chaturvedi et al, 2006, 2009; Gao & Patel, 2009; Gao et al, 2010, 2012). 
 
Caveolin-1 is proposed to bind and inhibit PKAC, although the mechanism is not 
known (Razani et al, 1999). The binding site on PKAC has not been identified, but 
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  the scaffolding domain and C-terminal portion of Caveolin-1 can both mediate the 
interaction. How Caveolin-1 inhibits PKAC is unclear; the binding domains do not 
resemble substrates. Interestingly upon Caveolin-1 overexpression PKAC was seen 
to translocate from the cytosol to Caveolin-rich microdomains at the plasma 
membrane (Razani et al, 1999; Razani & Lisanti, 2001). 
 
1.4.2.4. Regulation of PKA protein levels 
PKAC and PKAR are encoded on different chromosomes, however their expression 
is thought to be co-regulated to result in approximately equal protein levels. This 
ensures optimal responsiveness of the kinase to cAMP. This has been shown 
across a wide variety of cells types (Hofmann et al, 1977). Compensatory 
mechanisms have been demonstrated in mice where knock out of either PKARIβ 
and PKARIIβ led to an increase in PKARIα levels (Amieux et al, 1997). Previous 
experiments in PKAC null cells showed that PKAR was much less stable and also 
synthesised to a lesser degree (Steinberg & Agard, 1981a). In contrast, when PKAC 
is exogenously overexpressed, a corresponding increase in PKAR levels could be 
seen (Uhler & McKnight, 1987). 
 
Conversely, degradation of PKAR has been shown to play a role in synaptic 
plasticity by causing persistent PKAC signalling (Sweatt & Kandel, 1989). PKAR 
degradation via the ubiquitin-proteasome system is thought to alter the R/C ratio 
and thus achieve continual and eventually autonomous PKAC activation, even in the 
presence of basal cAMP levels (Greenberg et al; Hegde et al, 1993; Chain et al, 
1995, 1999). Until recently the E3 ubiquitin ligase involved in this turnover was 
unknown. 
 
One of the more recent AKAPs to be discovered was Praja2, which is also a largely 
neuronal E3 ubiquitin ligase (Lignitto et al, 2011). Praja2 has dual specificity AKAP 
properties. It binds the D/D domain of both RI and RII subunits via an amphipathic 
helix located in its N-terminus. Interestingly it was identified as the E3 ligase that 
mediates the ubiquitylation and proteasomal degradation of the PKAR subunits 
(Lignitto et al, 2011). PKAC activation leads to Praja2 phosphorylation and 
enhanced E3 activity, causing ubiquitylation and degradation of PKAR, which in turn 
leads to more free and active PKAC. Praja2 thus mediates a positive feed forward 
loop. This was the first identification of an E3 ubiquitin ligase that regulates PKAR. 
There is currently no mechanism described for PKAC degradation, even though 
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  degradation of activated kinases is a common mechanism of their regulation (Lu & 
Hunter, 2009; Liu et al, 2012). However some studies in the literature provide hints 
that PKAC is degraded upon chronic stimulation (Hemmings, 1986; Armstrong et al, 
1995; Richardson et al, 1990). 
 
1.4.3. PKA substrates 
PKA is a serine/ threonine kinase, which phosphorylates substrates with the 
sequence R-R-X-S/T-Y, where X is variable and Y is a hydrophobic residue 
(Songyang et al, 1994). PKA phosphorylates a myriad of substrates with new 
targets constantly being identified (Shabb, 2001). Here I will outline a selection of 
these to highlight the diverse roles of PKA in a variety of cellular pathways. 
 
1.4.3.1. Nuclear substrates 
PKA mediates many of its long-term effects by modulating gene expression through 
regulation of transcription factors. CREB, cAMP response element binding protein, 
was the first transcription factor for which activity was shown to be regulated by 
phosphorylation (Gonzalez & Montminy, 1989). CREB becomes activated upon 
phosphorylation at Ser133 (Figure 1.9). Phospho-CREB (p-CREB) binds to 
palindromic CRE (cAMP response element) sequences within DNA (Montminy et al, 
1986; Comb et al, 1986; Short et al, 1986). In this activated state p-CREB can 
recruit transcriptional co-activators such as CBP (CREB binding protein) and p300. 
These proteins are acetyl tansferases and are also thought to interact with RNA 
polymerase II complexes (Kee et al, 1996; Vo & Goodman, 2001). Upon activation, 
PKAC translocates to the nucleus to phosphorylate CREB. CREB activity peaks 
after approximately 30 minutes of stimulation, at which point maximal amounts of 
active PKAC have accumulated in the nucleus. Activity is then attenuated via the 
action of the phosphatases PP-1 and PP-2 on Ser-133 (Hagiwara et al, 1992; 
Wadzinski et al, 1993).  
 
The CREB family contains two further transcription factors, CREM (CRE modulator) 
and ATF-1. CREM is highly expressed in neuroendocrine tissues, whereas CREB 
and ATF-1 are expressed ubiquitously. CREM proteins can also be alternatively 
spliced to produce ICER (inducible CRE repressor), which lacks an activation 
domain, and is thus a negative transcriptional regulator (Molina et al, 1993). 
Transient expression of ICER is induced by the binding of phosphorylated CREB 
family proteins to CRE elements. ICER then acts in a negative feedback loop to  
42
CRE CRE
CBP
R
R
C
C
R
R
C
C
CREB CREBX
cAMP
Cytoplasm
Nucleus
Figure 1.9 PKA mediated CREB activation
cAMP activation of PKA allows phosphorylation of CREB at Ser133. 
This mediates binding to cofactors, such as CREB binding protein 
(CBP) and allows the activation of transcription from CRE sequences. 
Adapted from (Altarejos & Montminy, 2011).
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  switch off other CRE genes, which is of particular importance for hormone secretion 
in the pituitary gland (Mazzucchelli & Sassone-Corsi, 1999). 
 
Although CREB is clearly regulated by PKA, this is not the only mechanism for its 
activation. It has been shown in recent years that phosphorylation of CREB family 
proteins can also be stimulated by a vast array of stimuli and multiple different 
kinases (Johannessen et al, 2004). 
 
PKA has many other nuclear substrates that can affect transcription. I have 
described above how p65, the NFkB subunit and transcription factor is also 
activated by PKA phosphorylation (Gao et al, 2008). PKA has also been shown to 
phosphorylate many different nuclear hormone receptors in order to mediate their 
transcriptional activity (Shao & Lazar, 1999). However, PKA does not just affect 
transcription factors. Histone H1 was the first PKA substrate for which the 
phosphorylation site was identified (Langan, 1969). This was initially found upon 
glucagon stimulation in liver cells, and was also later observed in mouse 
neuroblastoma cells (Ajiro et al, 1990). PKA was later shown to also phosphorylate 
Histone H3 (Wei et al, 1999; DeManno et al, 1999).  
 
Recently a role for PKA phosphorylation has been identified in the regulation of 
splicing (Kvissel et al, 2007). SFRS17A (splicing factor arginine/serine-rich 17A) 
was also recently found to be an AKAP that can target PKA to splicing factor 
compartments within the nucleus (Jarnaess et al, 2009). Whereas previous models 
hypothesised that only free activated PKAC translocates to the nucleus, it has 
recently been shown that functional holoenzyme complexes also exist in the nucleus 
(Sample et al, 2012). They hypothesised that cAMP produced at the plasma 
membrane would normally not be able to activate nuclear PKA holoenzymes due to 
cytosolic phosphodiesterase activity. Consequently, PKAC translocation from the 
activated cytoplasmic pool would normally be responsible for nuclear activity. 
However once a certain cAMP threshold is overcome, cAMP may directly activate 
this nuclear pool, leading to faster signalling kinetics. The soluble adenyl cyclase 
(sAC) has also been localised to the nucleus in some cells, and may play a role in 
nuclear PKA activation (Zippin et al, 2004). 
 
Through these nuclear substrates it becomes apparent how PKA can mediate long-
term effects and widely affect gene transcription. 
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  1.4.3.2. PKA in cell migration and Rho protein regulation 
PKA can both positively and negatively regulate cell migration, through the 
phosphorylation of a variety of proteins, including Integrins and Rho proteins, which 
I will discuss below (Howe, 2011). PKA activity during cell migration is spatially 
regulated and this is thought to be mediated by AKAP-Lbc (Howe et al, 2005; 
Paulucci-Holthauzen et al, 2009). AKAP-Lbc is, as the name suggests, an AKAP, 
however it is also a Rho GEF protein (Diviani et al, 2001, 2006). AKAP-Lbc GEF 
activity can be stimulated by activated Gα12 and is thought to play a role in stress 
fibre formation (Diviani et al, 2001). Phosphorylation of AKAP-Lbc by PKA mediates 
14-3-3 binding, which inhibits its GEF activity (Diviani et al, 2004; Jin et al, 2004). 
 
Integrins play an important role in cell migration as they mediate cell-extracellular 
matrix contacts (Harburger & Calderwood, 2009). PKA can phosphorylate α4 -
integrin at Ser988, which inhibits its interaction with Paxillin (Han et al, 2001). 
Dynamic paxillin binding to the cytoplasmic tail of α4-integrin is required for proper 
cell migration. Phosphorylated α4-integrin is spatially restricted to the leading edge 
of the migrating cell, in order to enhance lamellipodia formation there, and restrict 
formation elsewhere (Goldfinger et al, 2003). It was later shown that α4-integrins are 
actually non-canonical AKAPs which specifically bind the type I holoenzyme (Lim et 
al, 2007). Integrins are also hypothesised to activate PKA in response to mechanical 
stress, which is thought to be via integrin-mediated activation of Gαs (Lim et al, 
2008; Alenghat et al, 2009). 
 
Rac1 has been shown to be sequestered in AKAP complexes mediated by 
AKAP220 and WAVE1. AKAP220 anchors PKA close to cortical actin. In response 
to high calcium levels AKAP220 further recruits IQGAP2, a Ras-GAP-like 
scaffolding protein (Logue et al, 2011b, 2011a). PKA phosphorylation of IQGAP2 
then leads to recruitment of active Rac1 to influence actin remodelling. WAVE1, is 
an AKAP that mediates subcellular targeting of two different PKA complexes, one at 
the mitochondria and one on actin (Wong & Scott, 2004). WAVE1 is a member of 
the Wiskott-Aldrich syndrome protein (WASP) family of scaffolding proteins that 
coordinate actin reorganization (Machesky & Insall, 1998). Actin associated WAVE1 
binds Rac as well as SRGAP3/WRP, a WAVE-associated Rac-GAP, and the Arp2/3 
complex (Miki et al, 1998; Westphal et al, 2000; Soderling et al, 2002). 
 
Rac1 itself was also shown to act in an AKAP manner, by interacting with PKAR via 
an amphipathic helix in its C-terminus (Bachmann et al, 2013). Rac1 interacts 
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  preferentially with PKAR in the holoenzyme context, and dissociates from PKAR 
upon PKAC release. Rac1 is not thought to be a PKA substrate itself, however its 
downstream effector PAK (p21 activated kinase) is regulated by PKA 
phosphorylation (Howe & Juliano, 2000). 
 
PKA phosphorylation has been implicated in regulating the association of Rho and 
GDI proteins. GDI proteins extract the Rho proteins from the membrane competent 
signalling pool and thus binding leads to termination of signalling (Garcia-Mata et al, 
2011). Phosphorylation of GDI by PKA at Ser174 was shown to inhibit its interaction 
with RhoA (Qiao et al, 2008). Conversely PKA was also found to phosphorylate 
RhoA at Ser188 and Cdc42 at Ser185, in proximity of their lipid anchors causing 
enhanced GDI binding (Lang et al, 1996; Forget et al, 2002; Ellerbroek et al, 2003).  
 
Interestingly, Tkachenko and colleagues found that PKA governs a RhoA-RhoGDI 
protrusion-retraction pacemaker in migrating cells (Tkachenko et al, 2011). By using 
activity sensors for both proteins in live migrating cells, they found PKA and RhoA 
activation correlated both temporally and spatially. RhoA activation led to protrusion 
of the leading edge, where PKA activation closely followed. This activation was 
proposed to be via mechanical stimulation due to the formation of adhesions within 
the protrusion. PKA is then thought to phosphorylate RhoA at Ser188, and thus 
cause displacement of RhoA from the membrane via enhanced GDI binding. This 
leads to termination of protrusions and in turn adhesions, forming a self-inhibiting 
feedback loop. This is an intriguing new insight into how PKA activity is dynamically 
regulated at the leading edge. PKA inhibition via PKI significantly increases both 
duration and amplitude of the protrusions. This additional intersection of the Rho 
and PKA signalling pathways further supports the notion that this crosstalk is critical 
for controlled migration. 
 
Other cytoskeleton related AKAPs include Pericentrin and AKAP350, which are both 
targeted to the centrosome via PACT domains (Diviani et al, 2000; Gillingham & 
Munro, 2000), and MAP2, the first identified AKAP, which is localised to 
microtubules (Theurkauf & Vallee, 1982). Multiple AKAPs localise to the plasma 
membrane, including AKAPP79/150, Gravin and AKAP18. This is mediated via a 
basic region in AKAPP79/150 that binds phospholipids. Gravin requires 
myristolylation and phospholipid binding, whereas AKAP18 requires both 
myristoylation and palmitoylation for membrane association (Dell’Acqua et al, 1998; 
Trotter et al, 1999; Malbon et al, 2004). 
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  1.4.3.3. PKA phosphorylation in the Hedgehog signalling pathway 
PKA is emerging as a negative master regulator of the Hedgehog (Hh) signalling 
pathway in mammals (Figure 1.10) (Chen & Jiang, 2013). Hh signalling responses 
are mediated by the Gli transcription factors. There are three Gli proteins in 
mammals Gli1, Gli2 and Gli3. Gli2 and Gli3 respond first to signalling and induce the 
expression of Gli1, which amplifies the response (Dai et al, 1999). In the absence of 
a stimulus, Gli3, and to a lesser extent Gli2, undergo partial cleavage from 
transcriptional activators (GliA) into transcriptional repressors (GliR) (Tian et al, 
2005; Hui & Angers, 2011). Binding of Hh ligands to the twelve-transmembrane-
pass receptor Ptch1 relieves its suppression of the GPCR Smoothened (Smo) 
leading to the accumulation of transcriptionally active GliA.  
 
PKA initiates the multistep phosphorylation of a cluster of sites within Gli2/3 (Pan et 
al, 2009; Wang et al, 1999, 2000). PKA phosphorylation primes for further 
phosphorylation by GSK3 and CK1, generating a so-called phosphodegron (Tempé 
et al, 2006). This leads to recognition of Gli2 and Gli3 by the SCFβTRCP ubiquitin E3 
ligase complex (Tempé et al, 2006; Wang & Li, 2006). They are then subsequently 
ubiquitylated and partially cleaved by the proteasome, resulting in the loss of the 
transcriptional activation domain. PKA is often used as a priming kinase for the 
generation of phospho-degrons. Within the phosphorylated cluster, PKA directly 
phosphorylates six sites (termed p1-6) (Niewiadomski et al, 2014). Loss of 
phosphorylation at p1-4 is enough to inhibit GliR production. However loss of 
phosphorylation at all six sites is required for full GliA activity and nuclear 
accumulation. PKA thus not only mediates GilR formation but also inhibits the 
generation of GliA.  
 
Sufu is a negative regulator of the pathway that is thought to bind and sequester Gli 
proteins in the cytosol and promote their conversion into transcriptional repressors 
(Humke et al, 2010). Upon pathway activation by Hedgehog, the Gli proteins 
translocate to the tip of the primary cilium and dissociate from Sufu, before 
translocating to the nucleus to activate transcription (Tukachinsky et al, 2010). 
Activation of signalling also promotes the proteasomal degradation of Sufu (Yue et 
al, 2009). In an additional negative regulatory feedback loop PKA, and GSK3β, are 
thought to phosphorylate Sufu and thus stabilise it (Chen et al, 2011).  
 
PKA thus tonically suppresses Hh pathway activation, but how is PKA activated in 
this context? Recently an orphan GPCR was characterised, GPR161, which   
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Figure 1.10 PKA regulation of Gli repressor formation
In the absence of Hh ligand, Ptch represses Smo. PKA phosphorylates 
Gli2/3, initiating further phosphorylation by GSK3 and CK1. This leads to 
recognition of Gli2/3 by the SCF βTRCP E3 ligase complex, ubiquitylation 
and partial processing by the proteasome into a Gli repressor form (GliR). 
Shh binding to Ptch relieves its suppression of Smo and allows Gli activa-
tor formation (GliA). Adapted from (Niewiadomski et al, 2014)
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  localises specifically to cilia. GPR161 is thought to be constitutively basally active, 
and coupled to Gαs which thus leads to constant cAMP production (Mukhopadhyay 
et al, 2013). Interestingly Shh signalling leads to GPR161 internalisation and 
removal from the cilium, which would reduce cAMP levels and contribute to 
suppressing PKA signalling in the cilium (Mukhopadhyay et al, 2013; Pal et al, 
2016). Furthermore, upon stimulation, Smo has been proposed to couple to Gαi in 
order to inhibit adenyl cyclase activation (Ogden et al, 2008; Barzi et al, 2011; Riobo 
et al, 2006). 
 
Complete PKAC knockout mice arrest at E9 with complete ventralisation of the 
neural tube (Tuson et al, 2011). This phenotype is strikingly similar to null mutants of 
Ptch1 and Sufu, both negative regulators of the Hh pathway. This phenotype 
suggests that a primary function of PKA in the early embryo is to restrain Hh 
pathway activity.  
 
A role of PKA phosphorylation of the fly homologue of Gli, Ci, has long been 
proposed (Chen et al, 1998). Drosophila mutants that lack PKA catalytic activity also 
show a gain of Hh pathway activity (Chen et al, 1999). In the fly, PKA 
phosphorylation also leads to formation of a Ci repressor form (Dai et al, 1999). 
However, upon pathway activation in the fly, PKA has been proposed to switch 
substrates and instead phosphorylate and activate Smo (Ranieri et al, 2014). PKA is 
thus hypothesised to have a dual function in the fly Hh pathway, suppressing the 
pathway in the absence of Hh and supporting activation upon Hh stimulation. 
 
Hh is a classic morphogen and its diffusion creates a graded signal to control cell 
patterning and differentiation in various embryonic tissues (Jiang & Hui, 2008). Hh 
signalling also regulates stem cell maintenance in adult tissues (Beachy et al, 2004). 
This perhaps explains why aberrant Hh signalling is found in a variety of cancers 
(Teglund & Toftgård, 2010). Thus tight regulation of this pathway is critical. 
 
1.4.3.4. The role of PKA in water homeostasis 
The water channel aquaporin-2 (AQP2) is important in water homeostasis in the 
distal collecting duct cells of the kidney. The subcellular localisation of AQP2 is 
controlled by the hormone vasopressin and subsequent activation of PKA. In the 
absence of a stimulus, AQP2 is located on vesicles in the cytoplasm. Upon  
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Figure 1.11 PKA regulation of AQP2 trafficking 
In the proximal cells of the kidney, in the absence of stimulus AQP2 is located on 
vesicles in the cytoplasm. Vasopressin binding to its receptor V2R, leads to disso-
ciation of the heterotrimeric G proteins (α, β, γ), activation of the adenyl cyclase 
(AC), and subsequent cAMP production. Activated PKA then mediates the phos-
phorylation of AQP2 at Ser256 (p-AQP2), which directs its insertion into the apical 
membrane, in order to increase water reabsorption. Water can then leave the 
proximal cells through AQP3 and AQP4 located in the basolateral membrane.
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  vasopressin stimulation of the V2 receptor, which is located in the basolateral 
membrane, PKA is activated and phosphorylates AQP2 at Ser256 (Katsura et al, 
1997; Fushimi et al, 1997). This leads to translocation and insertion of AQP2 into 
the apical plasma membrane (Figure 1.11). As each AQP2 monomer forms an 
independent pore this leads to a significant increase in permeability and 
reabsorption of water from the urine. Reabsorbed water can then exit the principal 
cells via AQP3 and AQP4 that are located in the basolateral membrane (Nedvetsky 
et al, 2009). This PKA activity is thought to be AKAP dependent, as peptide 
disrupters of AKAP-PKAR D/D domain binding abolished this effect (Klussmann et 
al, 1999). A potential AKAP, described as a 90 kDa RII binding protein was 
identified on AQP2 vesicles (Jo et al, 2001). Another AKAP, AKAP11δ also 
colocalised together with AQP2 on vesicles, as well as with PDE4D (Stefan et al, 
2007). This suggests PKA is specifically targeted to AQP2 containing vesicles, 
ready to respond to vasopressin. PDE4D may keep local cAMP levels low under 
basal conditions in order to prevent aberrant trafficking and excessive water 
reabsorption. Precise regulation of this process is required, as aberrations are 
associated with disease. Excess water retention stimulated by abnormally high 
levels of vasopression can lead to chronic heart failure (Schrier, 2011). Loss of 
vasopressin secretion leads to central diabetes insipidus, whereas mutations in both 
AQP2 and the vasopressin V2 receptor can lead to nephrogenic diabetes insipidus 
(Deen & Knoers, 1998). 
 
1.4.4. PKA in disease 
Clearly perturbations of the PKA pathway can have vast implications, and not 
surprisingly lead to various diseases, some of which are already mentioned above. 
Here I will discuss a few examples of particular interest. 
 
1.4.4.1. PKA in diseases of the Endocrine System relating to Cushing’s 
Syndrome 
A recurring theme is the deregulation of PKA in cancers of endocrine origin, 
especially those of the HPA axis (hypothalamus-pituitary-adrenal gland). Stress 
leads to the release of corticotropin-releasing hormone (CRH) by the hypothalamus, 
which stimulates the pituitary gland to release adrenocorticotropic hormone (ACTH). 
ACTH binds its receptor at the adrenal gland, the melanocortin receptor 2 (MC2R). 
This leads to stimulation of the adenyl cyclase, cAMP production and thus activation 
of PKA (Ramachandran et al, 1987; Simpson & Waterman, 1988). PKA is thought to 
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  be involved in both short and long term responses in the regulation of 
steroidogenesis. In the short term PKA phosphorylates and stabilises the 
mitochondrial protein StAR (steroidogenic acute regulatory protein) (Arakane et al, 
1997; Clark et al, 2001). StAR then mediates the transport of cholesterol from the 
outer to the inner mitochondrial membrane, and thus regulates cortisol production 
(Epstein & Orme-Johnson, 1991; Clark et al, 1994; Artemenko et al, 2001; Manna et 
al, 2015). In the long term, PKA upregulates the transcription of genes involved in 
cortisol production (Simpson & Waterman, 1988). 
 
Overproduction of cortisol can lead to Cushing’s syndrome, characterised by 
metabolic aberrations including central obesity, myopathy, hypertension and 
osteoporosis (Hatipoglu, 2012). Cushing’s syndrome has a variety of causes, some 
of which I will detail below, all leading to excessive cortisol secretion. This can be 
due to adrenal tumours autonomously producing cortisol, or tumours producing 
ACTH or CRH (Lodish & Stratakis, 2016). Overproduction of cortisol due to pituitary 
tumours that secrete ACTH is classified as Cushing’s disease.  
 
Deregulated PKA signalling was first implicated in cortisol-producing tumours of the 
adrenal cortex in patients with McCune Albright Syndrome (Weinstein et al, 1991). 
This is a rare disease that occurs sporadically, characterised by multiple tumours of 
the endocrine system. Weinstein and colleagues identified mutations in the gene 
coding for the G protein GαS, GNAS, as the cause for this syndrome. These 
mutations caused constitutive activation of GαS, thus leading to increased adenyl 
cyclase activity and cAMP production. 
 
Carney Complex is another rare disorder that leads to multiple neoplasms including 
those of the adrenal and pituitary gland that can lead to Cushing’s syndrome 
(Correa et al, 2015). It can be both inherited and sporadic. Carney Complex is 
caused by a variety of mutations in PKARIα; over 120 have been identified so far 
(Salpea & Stratakis, 2014). Most of these lead to haplo-insufficiency of PKARIα and 
thus defects in PKA signalling (Kirschner et al, 2000; Correa et al, 2015). Some 
mutations have also been identified that inhibit PKAC binding (Greene et al, 2008). 
Both Carney Complex and McCune Albright Syndrome are ultimately caused by 
uncontrolled PKA signalling.  
 
Inactivating mutations in phosphodiesterases, PDE11A and PDE8B, were later 
identified in adrenal hyperplasia that also leads to Cushing’s syndrome (Horvath et 
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  al, 2006, 2008). Most recently mutation of PKAC itself have been identified in 
adrenal tumours that lead to Cushing’s syndrome (Beuschlein et al, 2014; Cao et al, 
2014; Goh et al, 2014; Sato et al, 2014). This mutation, L206R, is thought to inhibit 
PKAR binding (Cheung et al, 2015), again leading to uncontrolled PKA signalling. 
 
1.4.4.2. PKA in other cancers 
As in normal physiology PKA plays a variety of roles in a wide range of cancers 
(Sapio et al, 2014).  
 
Around the same time as the PKAC mutants were described in adrenal tumours, a 
fusion protein of PKAC was identified in fibrolamellar hepatocellular carcinoma (FL-
HCC) (Honeyman et al, 2014). PKAC is fused to the C-terminus of DNAJB1, a 
molecular chaperone. It was initially hypothesised that this fusion protein has lost 
the ability to bind PKAR, however, further studies showed that this was not the case 
(Cheung et al, 2015). This chimeric PKAC is thought to be overexpressed under the 
control of the DNAJB1 promoter and is also intrinsically more active, leading to 
enhanced signalling (Cheung et al, 2015).  
 
Increased PKAR1α expression has been observed in a wide variety of cancers, 
including colorectal, ovarian, breast, melanoma and cholangiocarcinoma (a cancer 
of the bile ducts) (Bradbury et al, 1994; McDaid et al, 1999; Miller, 2002; Mantovani 
et al, 2008; Loilome et al, 2011). This has led to the hypothesis that type II PKAR is 
preferentially expressed in non-proliferating tissues, and type I PKAR is transiently 
upregulated in proliferating cells, and constitutively upregulated in cancer (Cho-
Chung et al, 1995; Sapio et al, 2014). Type I PKAR binds cAMP with higher affinity 
than type II, and thus is thought to be able to activate PKA signalling in the presence 
of lower cAMP levels (Rannels et al, 1985; Robinson-Steiner et al, 1984). It has thus 
been speculated that ‘isozyme switching’ may be a potential strategy for cancer 
therapy (Cho-Chung & Nesterova, 2005). Overexpression of RIIβ led to growth 
arrest in colon cancer cells (Nesterova et al, 1996). Furthermore, treatment of cells 
with RIα antisense oligonucleotides caused a decrease in RIα levels, and led to 
stabilisation and increased RII levels. This led to differentiation in leukaemia cells, 
and induced growth arrest in a variety of epithelial cancer cell lines (Cho-Chung et 
al, 1999; Nesterova et al, 2000). A single subcutaneous injection of RIα antisense 
given to mice with colon carcinomas led to decreased RIα expression and a striking 
suppression of tumour growth for up to 14 days (Nesterova & Cho-Chung, 1995). 
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As mentioned above perturbation of Hh signalling has been found in a range of 
cancers. Given the role of PKA as a negative master regulator in this pathway, PKA 
has unsurprisingly been implicated as a tumour suppressor in both medulloblastoma 
and basal-cell carcinoma, two tumour-types that are driven by Hh signalling (He et 
al, 2014; Iglesias-Bartolome et al, 2015). 
 
PKA has most recently been implicated as a mediator of mesenchymal-epithelial 
transition (MET) in a variety of cancer cell lines. This is thought to be through 
phosphorylation and activation of the histone demethylase PHF2, which enhances 
the expression of epithelial genes (Pattabiraman et al, 2016). Importantly PKA-
induced MET made cells much more susceptible to chemotherapeutics, as well as 
causing a dramatic reduction in their potential to metastasise. This is thus a further 
mechanism by which PKA can convey tumour suppressive qualities, as the 
mesenchymal state is associated with increased tumourigenic potential. 
 
 
1.5. Project Summary 
Previous mass spectrometry data from a systematic screen, aimed at characterising 
Rho regulatory proteins, identified ARHGAP36 as a novel interacting partner of 
PKAC (Rocks and Pawson manuscript in preparation). The initial aim of this thesis 
was to confirm and characterise the interaction between ARHGAP36 and PKAC, 
and investigate a potential interplay between the Rho and PKA signalling pathways. 
In this thesis, I found that ARHGAP36 interacts with PKAC via a pseudosubstrate 
inhibition motif, akin to those found in the PKA regulatory subunits and the PKI 
proteins. Furthermore and unexpectedly, ARHGAP36 promotes polyubiquitylation of 
PKAC at a single lysine, K285. Surprisingly for a cytosolic protein, this mediates its 
degradation via the endolysosomal pathway. This bimodal antagonism of PKAC by 
ARHGAP36 results in a suppression of a wide variety of PKA signalling responses, 
including CREB activation and AQP2 trafficking. The ability of ARHGAP36 to inhibit 
PKAC and promote its degradation was independent of its Rho GAP domain.  
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  2.1. Molecular Biology 
2.1.1. Creator Reactions 
cDNAs for overexpression of ARHGAP36 were available as donor plasmids of the 
Creator system described previously from the Pawson Lab Toronto (Colwill et al, 
2006). The full-length sequence refers to human ARHGAP36 UniProt ID: Q6ZRI8-2. 
Subcloning into acceptor expression plasmids was then done by Creator Reaction 
as shown in Table 2.1. The reaction was pipetted at room temperature and 
incubated for 15 min before heat inactivation of the Cre enzyme for 10 min at 70 °C. 
After cooling the total reaction was transformed into DH5α and plated onto sucrose 
chloramphenicol plates. If possible three colonies were picked to be screened. 
Colonies were then grown overnight in approximately 5 ml LB media containing 
kanamycin. Purified DNA was digested at 37 °C for 1 h with the restriction enzymes 
AscI and PacI, to cut out the insert from the backbone. Resulting fragments were 
then assessed by agarose gel electrophoresis. Where necessary clones were 
sequenced by Source Bioscience with primers O19, O20 or RE.  
 
Component Amount 
Donor Plasmid 500 ng 
Acceptor Plasmid 500 ng 
BSA 1 µl 
Cre 10x Buffer 1 µl 
Cre Enzyme 0.5 µl 
Water Up to 10 µl 
Total 10 µl 
Table 2.1 Standard Creator Reaction 
 
Clone Number Acceptor Plasmid 
v180 Triple Flag  
v3531 Cerulean (CFP) 
v3534 Citrine (YFP) 
v3535 Cherry 
Table 2.2 Creator Acceptor Plasmids  
2.1.2. Gifted Plasmids 
Mouse PKAC-Venus YFP was provided by Manuela Zaccolo (Zaccolo & Pozzan, 
2002). Human PRKACA (GenBank: BC039846.1) was cloned into the Gateway 
system (Life Technologies). K285R mutants were generated by site directed 
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  mutagenesis. Human PRKAR1α (GenBank: BC036285) was cloned into the 
gateway system. Praja2, Stub1 and Huwe1 were also available as Gateway donors 
and cloned into the Gateway expression system. Cerulean CFP-PKI was kindly 
provided by Susan Taylor (University of California, San Diego). AKAR-4-NES and 
PKI-Cherry were provided by Jin Zhang (Johns Hopkins) and were described 
previously (Herbst et al, 2011). LAMP1-YFP was a gift from Lee Haynes (University 
of Liverpool). GFP-HRS was described previously (Urbé et al, 2003). GFP-Vps4 and 
the EQ mutant were a gift from Phil Woodman (Bishop & Woodman, 2000), GFP-
Rab5-Q79L was a gift from Volker Haucke (FMP, Berlin).  
 
2.1.3. Site-directed mutagenesis 
Subsequent mutation and deletion constructs of ARHGAP36 and PKAC were 
created by site-directed mutagenesis (QuikChange, Agilent Technologies) according 
to manufacturer’s guidelines using the Pfu polymerase. Following the reaction DNA 
was incubated with Dpn1, to digest methylated bacterial template DNA, leaving only 
unmethylated mutant DNA. Part of the reaction was then transformed into XL10 
Gold bacteria (Invitrogen). All primers were purchased from Sigma. 
 
ARHGAP36 Primer Sequence Template 
N F cttctgggatccaaaaggaagttaattaaccaggtaagttcc dC 
  R ggaacttacctggttaattaacttccttttggatcccagaag   
N1 F cggtcaggctgcgggcttaattaaccaggtaag dC 
  R cttacctggttaattaagcccgcagcctgaccg   
N2 F cttctgggatccaaaaggaagttaattaaccaggtaagttcc Iso3 
  R ggaacttacctggttaattaacttccttttggatcccagaag   
ARG F tcgccgtgggcgtcgattaattaaccaggtaag N2 
  R cttacctggttaattaatcgacgcccacggcga   
dARG F tcaggctgcgggcggtgcagtgtctg WT 
  R cagacactgcaccgcccgcagcctga   
dN F ccaggggcgcgccatgagtctcaatcc WT 
  R ggattgagactcatggcgcgcccctgg   
dC F gataactgggatgtcctcttcttaattaaccaggtaagttcc WT 
  R ggaacttacctggttaattaagaagaggacatcccagttatc   
GAP F gataactgggatgtcctcttcttaattaaccaggtaagttcc dN 
  R ggaacttacctggttaattaagaagaggacatcccagttatc   
dGAP F gggatccaaaaggaagcaggtgcctccccata WT 
  R tatggggaggcacctgcttccttttggatccc   
Linker F agacactgcaccggcgcgcccctg N2 
  R caggggcgcgccggtgcagtgtct   
RRV F tcagccagactatccacagaatctgcaccatcatccccacggcgagtg WT 
  R gggagttcactcgccgtggggatgatggtgcagattctgtggatagtc   
Iso3 (delN1) F ggggcgcgcccgtcgtcggg WT 
  R cccgacgacgggcgcgcccc   
Table 2.3 ARHGAP36 Mutagenesis Primers 
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PKAC F R 
K286R atcgttgaccccattcctgaggttcccaaagcg cgctttgggaacctcaggaatggggtcaacgat 
E127A ggtgggagaacatcgcgccaccagctaca tgtagctggtggcgcgatgttctcccacc 
E170A tcgatgagaagattcgcgggcttcaggtccc gggacctgaagcccgcgaatcttctcatcga 
E230A ggagtcctcatctacgcgatggctgctggttac gtaaccagcagccatcgcgtagatgaggactcc 
Table 2.4 PKAC Mutagenesis Primers  
 
2.1.4. 36i Cloning 
36i was amplified with the primers below and inserted into pmCherry-C1 (Clontech) 
with BsrGI and EcoRI, or into pmCherry-N1 (Clontech) with EcoRI and AgeI by 
ligation.  
 
 36i F R 
N1 gcgcggaattcgccaccatggagcccaccttgccccgg  cgcgcaccggtccgctcagctcagccagactatccac 
C1 gcgcgtgtacagcgagcccaccttgccccgg  cgcgcgaattcctacagctcagccagactatc  
Table 2.5 36i Primers  
 
2.1.5. LR Reaction 
Gateway donor constructs were cloned into Gateway expression vectors using the 
LR clonase II (Invitrogen) according to manufacturers guidelines.  
 
2.1.6. Transformation 
Unless otherwise indicated, 100 µl DH5α were briefly thawed on ice before addition 
of plasmid or reaction to be transformed. Bacteria were incubated for 30 min on ice, 
before heat shock at 42 °C for 45 s. Bacteria were cooled on ice for minimum 2 min 
before addition of 500 µl LB media and 20 mM Glucose. Bacteria were shaken for 1 
h at 37 °C before plating on LB agar plates with the required antibiotic, then left to 
form colonies overnight at 37 °C. 
 
2.1.7. Plasmid DNA Purification 
For minipreps single colonies were picked and grown in approximately 5 ml LB 
media in presence of the required selection antibiotic overnight at 37 °C shaking. 
DNA was purified from pelleted bacteria using the Zymogen Research ZR Plasmid 
Miniprep Classic kit (D4054), according to manufacturer’s instructions. When more 
DNA was required, midipreps were done from 100 ml bacterial culture, using the 
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  Invitrogen Midi kit (K210005). DNA concentrations were measured using a 
NanoDrop (PeqLab).  
 
2.1.8. Glycerol Stock 
Glycerol stocks were prepared from the same cultures as those for minipreps. 700 
µl bacteria in LB media was combined with 300 µl glycerol, thoroughly mixed and 
frozen at -80 °C. 
 
2.1.9. Sequencing  
When necessary clones were sequenced by Source Bioscience (Berlin). 
Sequencing 
Primers  Sequence Binds 
O19 TGCTCACATGTTCTTTCCTG All Creator- before insert- F 
O20 TGGATTTGTTCAGAACGCTC All Creator- after insert- R 
RE CGA AGT TAT GGC GCG AGG G Creator Expression- between tag and insert 
M13F TGT AAA ACG ACG GCC AGT Gateway 
M13R CAG GAA ACA GCT ATG ACC Gateway 
Table 2.6 Primers used for sequencing  
 
2.1.10. Agarose gel electrophoresis 
Agarose gels of 0.8-1 % were prepared by dissolving agarose in TAE (40 mM Tris, 
20 mM acetic acid, 1 mM Na2EDTA). DNA samples were loaded in Orange G 
loading buffer (50 % Glycerol, 25 mM EDTA, 0.5 % Orange G). After running in TAE 
buffer, gels were incubated in a 0.025 mg/ml Ethidium Bromide bath for 10 min 
before imaging in a Transilluminator. 
 
2.1.11. In situ hybridization 
Specific fragments of the Arhgap36 gene were amplified from whole mouse E12.5 
embryo cDNA using the following primers: GCATCTGTCAATGTTGTCCG and 
GGTGGCAAATTTGCCCTTCTTCC. The PCR product was then cloned into the 
pGEM-T Easy plasmid using T4 DNA ligase (Promega). In vitro transcription of the 
antisense probe was performed using the DIG-RNA labelling kit (Roche). Paraffin 
sections were rehydrated by successive incubations in decreasing concentrations of 
Ethanol before additional incubation in Xylol. Subsequently, the sections were post-
fixed in 4 % PFA for 20 min and incubated in a 10 µg/ml Proteinase K solution for 8 
min. The tissue was incubated with the RNA-probe overnight at 65 °C. Following 
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  successive washing with SSC/Formamide and MABT, the sections were incubated 
in blocking reagent (Roche) and goat serum. The sections were then incubated with 
an alkaline-phosphatase-coupled against digoxigenin (DIG, Roche). After further 
washing with MABT and NTMT, NBT/ BCIP Purple (Roche) was used as a 
chromogenic substrate for the alkaline phosphatase (Boehringer) in order to detect 
the RNA probe. The sections were then mounted with Roti-Histokitt II (Roth) and 
imaged on a Leica DMI 6000B inverted microscope.  
 
2.2. Cell Biology 
2.2.1. Cell Lines 
All cell lines were cultured at 37 °C with 5 % CO2, and split every 2-3 days at the 
indicated ratios. Cells were washed once with PBS (PAA) before incubation with 
Trypsin/EDTA (PAA) for the indicated times, followed by resuspension in the 
indicated media and replating. Penicillin/streptomycin (P/S) was purchased from 
PAA. All media were from Gibco. 
a. 
Cell Line Origin Species Media Additives 
MDCK Madin-Darby canine kidney II Dog MEM 10 % FBS, 1 % P/S 
HEK293T Human Embryonic Kidney Human DMEM 10 % FBS, 1 % P/S 
HeLa Cervical Cancer Human DMEM 10 % FBS, 1 % P/S 
NIH-3T3 Fibroblast Mouse DMEM 10 % FBS, 1 % P/S 
U2OS Osteocarcoma Human DMEM 10 % FBS, 1 % P/S 
MCD4 Collecting duct cells Mouse DMEM/F12 
10 % FBS, 10 µM 
dexamethasone 
NGP Neuroblastoma Human RPMI 10 % FBS, 1 % P/S 
SK-N-BE(2) Neuroblastoma Human DMEM/F12 10 % FBS, 1 % P/S 
b. 
Cell Line 
Splitting 
Density Trypsinisation Time DNA Transfection 
RNA 
Transfection 
MDCK 1:8 10-15 min Effectene - 
HEK293T 1:8 3-5 min PEI RNAiMAX 
HeLa 1:10 3-5 min PEI RNAiMAX 
NIH-3T3 1:10 3-5 min Lipofectamine 3000   
U2OS 1:5 3-5 min Lipofectamine 3000 - 
MCD4 1:4 3-5 min PEI   
NGP 1:3 3 min Lipofectamine 3000 RNAiMAX 
SK-N-BE(2) 1:5 3-5 min Lipofectamine 3000 RNAiMAX 
  
Table 2.7 Cell Lines  
The table shows the cell lines used within this thesis, how they were cultured and 
which reagents were used for transfection. 
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  2.2.2. DNA Transfection 
For live cell microscopy, cells were transfected the same day as they were seeded, 
a minimum of 3 h later, after cells had adhered. For immunofluorescence (IF) and 
other applications, cells were transfected the day after seeding, or for NGP cells two 
days after seeding. 
 
Effectene (Qiagen): DNA and Enhancer were incubated together in Buffer EC for 5 
min, before addition of Effectene for a further 10 min. The mixture was then 
vortexed for 10 s before adding to cells. Enhancer and Effectene were both vortexed 
before use, and used at a ratio of 3:1:1 (µl:µl:µg) with DNA. Medium on cells was 
changed to OptiMEM (Invitrogen) before transfection. 
 
PEI: DNA and PEI were incubated together in OptiMEM at a ratio of 1:3 (µg:µl) for 
15-60 min, before adding dropwise to cells. PEI (Polysciences Inc) was prepared by 
dissolving in water at 1 mg/ml pH 7 and sterile filtered before use. 
 
Lipofectamine 3000 (Thermo): DNA and p3000 reagent were added together in 
OptiMEM and combined with Lipofectamine in OptiMEM at a ratio of 1:2:3 (DNA 
(µg): p3000 (µl): Lipofectamine(µl)). The mixture was incubated for 5 min before 
adding dropwise to cells. Medium on cells was changed to OptiMEM before 
transfection. 
 
2.2.3. RNA Transfection 
HEK293T cells were transfected one day after seeding in the absence of 
penicillin/streptomycin using Lipofectamine RNAiMAX (Invitrogen) and 40 nM final 
concentration siRNA according to manufacturer’s guidelines. 48 h later cells were 
harvested. NGP cells were cultured for two days before transfection with 50 nM 
ARHGAP36 SMARTpool or individual oligos, also using Lipofectamine RNAiMAX. 
24 h later cells were harvested. All oligos were purchased from Dharmacon, except 
for HRS which was custom synthesised. 
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  Target Species No. Sequence 
Praja2 Human J-006916-08 GAAGCACCCUAAACCUUGA 
OTP 
 
J-006916-07 AGACUGCUCUGGCCCAUUU 
  
 
J-006916-06 GCAGGAGGGUAUCAGACAA 
    J-006916-05 GUUAGAUUCUGUACCAUUA 
Stub1 Human J-007201-10 UGGAAGAGUGCCAGCGAAA 
OTP 
 
J-007201-09 GAAGGAGGUUAUUGACGCA 
  
 
J-007201-08 GUGGAGGACUACUGAGGUU 
    J-007201-07 CGCUGGUGGCCGUGUAUUA 
Huwe1 Human J-007185-10 UAACAUCAAUUGUCCACUU 
OTP 
 
J-007185-09 GAGCCCAGAUGACUAAGUA 
  
 
J-007185-08 GCAGUUGGCGGCUUUCUUA 
    J-007185-07 GCUUUGGGCUGGCCUAAUA 
ARHGAP36  Human J-032590-12 GCGGGUCAGCUCCGAGAAA 
OTP 
 
J-032590-11 CCUCGGAGACGGACAUCGA 
  
 
J-032590-10 UAUGAGAUUUACCGGGAUU 
    J-032590-09 GCAUGCAGAGAGAGCGCUA 
HRS Human Sense GUCAACGACAAGAACCCACdTdT 
  Duplex Anti-sense dTdTCAGUUGCUGUUCUUGGGTG 
Table 2.8 siRNA sequences  
 
2.2.4. Virus Infection 
Cells were infected with lentiviruses produced previously in the Pawson lab 
containing shRNA in a pLKO.1 vector and a puromycin selection cassette. The 
stuffer control virus contains the pLKO.1 plasmid containing a 1.9 kb stuffer 
sequence in place of the shRNA cassette. 24 h after infection puromycin was added 
at 2 µg/ml for SK-N-BE(2) and 0.5 µg/ml for NGP. Cells were then expanded in the 
presence of puromycin. 
 
Virus Number shRNA Sequence 
A8 GATGACAATCAGAATGTGCAT 
A9 GCTGTATCACACAAGACATTT 
A10 CACACAAGACATTTGGCATTA 
G11 GCAGAGATGTTTCTGTGTCAT 
G12 CAACCGTATGACTTCCACTAA 
Table 2.9 ARHGAP36 targeting shRNA sequences  
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  2.2.5. Antibodies and Chemicals  
 
Chemicals Target Source Vehicle Final Concentration 
Bafilomycin Lysosome Cayman DMSO 100 nM 
Leupeptin Lysosome US Biological Water 500 µM 
Epoxomicin Proteasome Cayman DMSO Hek: 50 nM; MDCK: 100 nM 
Cycloheximide Protein Synthesis Calbiochem DMSO 
Hek: 50 µg/ml; 
MDCK: 1 µg/ml 
Forskolin Adenyl Cyclase Cayman EtOH 10 µM 
IBMX Phosphodiesterases Cayman EtOH 100 µM 
SAG Hh Pathway Enzo Water 0.2 µM 
PKI PKAC Santa Cruz DMSO 10 µM 
Table 2.10 Inhibitors used within this thesis  
 
 
Source Species Verified IF WB IP Order Number 
Atlas Rabbit Y 1:200 1:500 ~0.5 µg/ 1 mg protein HPA002064 
Thermo Rabbit Y 1:200 1:500 ~1 µg/1 mg protein PA5-31619 
Sigma Rabbit - 1:100 1:500 - SAB2102046 
Millipore Rabbit - 1:100 1:500 - 07-2142 
Abgent Rabbit - 1:100 1:500 - AP16204b 
Table 2.11 ARHGAP36 Antibodies  
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  Antibody Species Source Clone/Order Number IF WB IP 
EEA1 Rabbit CST 3288 1:100 - - 
Rab7 Rabbit CST 9367 1:100 - - 
GAPDH Rabbit CST 2118 - 1:10,000 - 
GFP Rabbit AbCam ab290 1:1000 1:10,000 0.5 µl 
GFP Chicken AbCam ab13970 1:1000 - - 
Flag Mouse Sigma M2 1:500 1:5,000 - 
His Mouse Sigma H1029 - 1:500 1 µl 
Ubiquitin Mouse Covance P4G7 - 1:500 - 
PKAC Mouse BD 610981 1:200 1:1000 - 
PKAC Rabbit CST 4782 1:200 1:1000 - 
pCREB Rabbit CST 9198 1:200 1:500 - 
pSubstrate Rabbit CST 9624 - 1:1000 1 µl 
RIa Mouse BD 610610 1:200 1:1000 - 
RIb Sheep R&D AF4177 - 1:500   
RIIa Rabbit Santa Cruz sc-909 1:200 - - 
RIIa Mouse BD 612243 1:200 1:1000   
RIIb Rabbit Santa Cruz sc-25424 1:200 - - 
RIIb Mouse BD 610626 1:200 1:1000   
AQP2 Rabbit Enno Klussmann H27 1:1000 - - 
ZO-1 Rat Santa Cruz sc33725 1:1000 - - 
HRS Rabbit Sylvie Urbe 958/3 1:500 1:1000 - 
AMSH Rabbit Sylvie Urbe 850/3 1:500 1:500 - 
Stub1 Rabbit CST 2080 - 1:1000 - 
Praja2 Rabbit Bethyl A302-991A - 1:1000 - 
GST Mouse CST 26H1 - 1:5000 - 
Acetylated 
Tubulin Mouse Sigma T6793 1:1000 - - 
Polaris Goat Acris AP16448PU-N 1:100 - - 
Tubulin Mouse Sigma DM1a, T6199 1:1000 1:10,000 - 
β-catenin Mouse BD 610153 - 1:5,000 - 
Vinculin Mouse Sigma  V9264 1:2000 - - 
Phalloidin-594 - Biotium CF594 1:200 - - 
Cell Tracker-
647 - 
Molecular 
Probes  C34565 250 nM  - - 
Table 2.12 Primary Antibodies  
 
Alexa Fluor secondary antibodies for immunofluorescence were purchased from 
Molecular probes and used at 1:1000. 488, 555 and 647 conjugates were used. All 
HRP coupled antibodies for western blot were purchased from Biorad.   
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  2.3. Microscopy 
2.3.1. Immunofluorescence  
Cells seeded on glass coverslips, were washed once with warm PBS containing 
calcium and magnesium (PBS++), before fixing with 4 % PFA in PBS for 10 min. 
Cells were washed 2 x 5 min with PBS between every further step. Cells were then 
permeabilised with 0.2 % Triton X-100/ 100 mM glycine in PBS for 10 min, and 
blocked for a minimum of 20 min in 3 % BSA in PBS. Primary antibodies were 
incubated in blocking solution for minimum 1 h at room temperature or at 4 °C over 
night. Alexa Fluor secondary antibodies were incubated for 30 min, also in blocking 
solution. Coverslips were mounted using ProLong Gold (Invitrogen). For 
experiments with Cell Tracker 647, cells were washed with PBS and incubated for 
30 min with 250 nM Cell Tracker in serum free media, before fixing as normal. 
 
2.3.2. Live Cell Imaging 
Cells were seeded on MatTek dishes and transfected later the same day after 
having time to adhere. Transfected cells were imaged the following day. 
 
2.3.3. Fluorescence microscopy 
Confocal laser scanning microscopy was used for both live and fixed cells, and 
performed on a Fluoview 1000 confocal laser scanning microscope (Olympus) 
equipped with a UPLSAPO 60X/1.3 NA silicon immersion oil immersion lens. 
Images were taken with the following excitation (Ex) and emission (Em) settings: 
Hoechst Ex: 405 nm diode laser (50 mW) Em: 425-475 nm; mCerulean Ex: 440 nm 
diode laser (25 mW) Em: 460-500 nm; GFP, AlexaFluor488 Ex: Multi-Line Argon 
laser 488 nm (40 mW) Em: 500-545 nm; mCitrine, Venus Ex: Multi-Line Argon laser 
515 nm (40 mW) Em: 530-545 nm; AlexaFluor555 Ex: 559 nm diode laser (20 mW) 
Em: 570-625 nm; mCherry Ex: 559 nm diode laser (20 mW) Em: 575-675 nm; 
AlexaFluor647 Ex: 635 nm diode laser (20 mW) Em: 655-755 nm. 
 
2.3.4. AKAR FRET (with Markus Müller) 
1.3 x 105 HEK293T cells were seeded per well on poly-L-lysine (0.01 %, Sigma) 
coated 12 well plates. The following day cells were transfected with 650 ng AKAR4-
NES FRET sensor together with 150 ng Cherry tagged ARHGAP36 constructs or 
control. After 24 h transfection, cells were serum starved for 5 h, treated with 10 µM 
Forskolin and 100 µM IBMX for 30 min and subsequently imaged. Intensity-based 
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  FRET ratio-imaging experiments were then performed on an inverted 
epifluorescence IX81 microscope (Olympus) equipped with a MT20 xenon-arc 
burner (Olympus) and an UPLSAPO air 10x/0.4 NA objective controlled by 
xcellence software (Olympus). Images were acquired with a Hamamatsu ImagEM 
Enhanced EM-CCD camera at a 16-bit depth. Donor and FRET-acceptor images 
were acquired with the following settings: 430/25 (excitation), zt442RDC (dichroic 
mirror) and emission changing between 483/32 (donor-channel) and 542/27 (FRET-
acceptor-channel) using a filter wheel. Images were analysed with ImageJ. Images 
were background corrected and regions of interest were defined by AKAR4-Venus 
fluorescence channel. Average intensities of acceptor channel were divided by 
donor channel to calculate FRET efficiency. 
 
2.3.5. Image Analysis (with Markus Müller) 
Line scans to determine fluorescence intensity profiles were analysed using ImageJ 
software. Plot Profile analysis was used to create a graph of pixel intensity plotted 
against the distance along the line. To reduce noise, pixel intensity was averaged on 
a line width of 10 pixels. Intensity was then normalized to the lowest and the highest 
intensity within the selection. For analysis of protein level ratios of ARHGAP36 and 
PKAC in immunofluorescence images of NGP cells, automated cell segmentation 
was performed with CellProfiler software (Kamentsky et al, 2011) based on DAPI, 
CellTracker Deep Red and ARHGAP36 images. Average PKAC and ARHGAP36 
intensities were measured in each cell outline. Each single cell intensity was 
normalised to the median intensity of all cells in each image. Pearson’s sample 
correlation analysis was performed in OriginPro (OriginLab). 
 
2.3.6. Cilia Formation 
NIH-3T3 cells were seeded on coverslips, the following day they were starved for 48 
h in serum free medium. Cells were transfected for the final 24 h before fixing. 
MDCK cells seeded on coverslips were grown for up to nine days in complete 
medium, and the media changed every day. Cells were then transfected for the final 
24 h before fixing. 
 
 
66
	  2.4. Biochemistry 
2.4.1. Lysis  
As HEK293T cells easily detach they were harvested by merely pipetting up and 
down in PBS++ on ice. Cells were then pelleted by spinning at 400 RCF for 5 min at 
4˚C. Unless otherwise stated HEK293T cell pellets were lysed in NP40 (1 % NP40, 
50 mM Tris-HCL pH 8, 150 mM NaCl,), with complete protease inhibitor cocktail 
(Roche) and 10 µM N-Ethylmaleimide (NEM, Sigma) for 20 min on ice. NGP cells 
were lysed directly in RIPA (50 mM Tris pH 7.4, 150 mM NaCl, 0.1 % SDS, 1 % 
NP40, 0.5 % Sodium deoxycholate) supplemented with complete protease inhibitor 
cocktail (Roche), 10 µM NEM. For Forskolin/IBMX stimulation experiments lysis 
buffer was also supplemented with PhosSTOP (Roche).  All other cell lines were 
also lysed directly in RIPA. Lysates were then cleared by spinning at 18,000 RCF 
for 5 min at 4 ˚C. Cleared lysates were then transferred to new eppendorf tubes. 
Protein concentration was measured using the Precision Red Protein Assay 
(Cytoskeleton) according to manufacturers instructions. Absorbance was measured 
at 600nm.  
 
2.4.2. Immunoprecipitation  
HEK293T cells were transfected when 80 % confluent and harvested as above the 
following day. For Ubiquitin immunoprecipitations (IPs), His-Ubiquitin was always 
co-transfected for improved detection at the same ratio as the substrate protein, with 
less ARHGAP36. For a 10cm plate specifically 5:5:3 µg ratio of 
PKA:Ubiquitin:ARHGAP36 was used. Cleared lysates were added to either Flag-M2 
affinity gel (Sigma), or Protein G Sepharose beads (Sigma) coupled with anti-GFP 
(ab290, Abcam) or anti-His (H1029, Sigma). After minimum 1 h rotation at 4 ˚C, 
beads were washed three times in lysis buffer and eluted with 2x Sample Buffer. To 
try to avoid antibodies becoming uncoupled from the beads, samples were 
incubated first at 37 °C for 20 min, then the supernatant was separated from the 
beads and boiled. Lysate samples were always saved and run together with the 
eluates to check for expression levels. 
 
For endogenous ARHGAP36 IP NGP cells directly lysed in RIPA supplemented with 
EDTA-free complete protease inhibitor cocktail (Roche), 10 µM NEM, 5 mM MgCl2 
and 1 mM ADP were subjected to protein assay before IP. 4.5 mg protein was 
incubated for 1 h at 4 ˚C with 4 µg ARHGAP36 Thermo antibody or IgG control. 
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  Beads were then added for 30 min, washed three times in lysis buffer and eluted 
with 2x Sample Buffer. 
 
2.4.3. UbiCREST  
The assay kit was purchased from Boston Biochem and the experiment carried out 
according to manufacturer’s guidelines and as described previously (Hospenthal et 
al, 2015; Mevissen et al, 2013). Specifically, HEK293T cells were transiently 
transfected with PKAC-YFP, Flag-ARHGAP36 and His-Ubiquitin as for Ubiquitin IPs. 
Cells were lysed in the presence of 10 µM NEM. Lysates were subjected to one 
single GFP IP, which after washing, was then split and incubated with the DUBs for 
45 min at 37 °C. Eluates were run on 12 % SDS-PAGE gels, and membranes 
probed with GFP and Ubiquitin antibodies. 
 
2.4.4. Western Blotting 
Boiled samples were separated on SDS-PAGE gels of varying percentage with a 4 
% stacking gel. Gels were run first at 80 V then at up to 200 V until proteins were 
sufficiently separated, in SDS Running Buffer (100 mM Tris, 100 mM Hepes, 0.1 % 
SDS). Gels were then transferred onto 0.45 µm Nitrocellulose (Amersham) using the 
Wet Blot System (BioRad) for 90 min at 100 V in Wet Blot Transfer Buffer (25 mM 
Tris, 190 mM Glycine, 20 % Methanol). Membranes were then incubated with 
Ponceau Red to determine transfer efficiency. After washing with TBST (50mM Tris, 
150mM NaCl, 0.01% Tween20), membranes were blocked with 5 % Milk Powder in 
TBST for approximately 1 h, before incubating with the primary antibody overnight at 
4 °C. For phospho antibodies 1 % BSA/TBST was used for blocking. Membranes 
were then washed 3 x 5 min in TBST before incubation with HRP-coupled 
secondary antibodies for 1 h at RT. After washing 3 x 5 min in TBST membranes 
were then incubated with the LumiGlo Peroxide Substrate (CST) for 1 min. Films 
were exposed for varying times before developing. 
 
2.4.5. Peptide Spots  
Peptide spots were produced by automatic SPOT synthesis on Whatman 50 
cellulose membranes using Fmoc (9-fluorenylmethyloxycarbonyl) chemistry with the 
AutoSpot-Robot ResPep-SL (Intavis Bioanalytical Instruments) as previously 
described (Hundsrucker et al, 2010). Fmoc-protected amino acids and derivatized 
cellulose-membranes (amino-modified acid-stable cellulose membrane with PEG-
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  spacer) were purchased from Intavis. Membranes were activated for 1 min in 
MeOH, washed 3 x 10 min in TBST followed by blocking for minimum 2 h in 3 % 
filtered BSA. Membranes were then incubated with 0.1 µg/µl GST-PKAC (Biovision) 
overnight at 4 °C. The next day membranes were washed 3 x 10 min in TBST, 
before primary antibody incubation with α-GST, for 2 h at RT. Membranes were then 
again washed before secondary antibody incubation for 1 h at RT, followed by final 
washing and developing as for western blotting. 
 
2.4.6. Peptide Synthesis (Rudolf Volkmer) 
36i and the corresponding scrambled control peptides were synthesised on a 433A 
peptide synthesiser (Applied Biosystems) on Rapp resin columns (Rapp Polymere, 
Tuebingen, Germany) using Fmoc (N-(9-fluorenyl)methoxycarbonyl) chemistry. The 
peptides were purified and analysed by high performance liquid chromatography on 
Polyencap A300 columns (Bischoff, Leonberg, Germany) and electrospray mass 
spectrometry (TSQ 700, Finnigan MAT, Bremen, Germany). The sequences of the 
peptides are: 
36i:   E-P-T-L-P-R-E-F-T-R-R-G-R-R-G-A-V-S-V-D-S-L-A-E-L 
Scrambled:  V-R-R-F-P-T-R-A-E-E-T-S-L-E-G-A-G-R-S-R-V-L-L-P-D 
 
2.4.7. PepTag Assay (with Carolin Barth) 
In order to assess PKA activity the Peptag Assay (Promega) was used as described 
previously (Christian et al, 2011). A1 Peptide (L-R-R-A-S-L-G) was incubated with or 
without 25 ng recombinant PKACα (Biovision) together with 10 µM scrambled, 36i or 
PKI peptides for 45 min shaking at 30 °C.  The separation of phosphorylated and 
non-phosphorylated peptide was achieved by agarose gel (0.8 %) electrophoresis. 
PKI (5-24) peptide was purchased from Santa Cruz, the sequence is: 
TTYADFIASGRTGRRNAIHD. 36i and scrambled peptides were synthesised as 
described above.	  
2.5. Mass Spectrometry 
2.5.1. Ubiquitin site identification (with Erik McShane) 
For ubiquitin site identification HEK293T cells were cultured in SILAC DMEM (Life 
Technologies) containing 1% penicillin/streptomycin, and 10% dialysed FBS 
(Sigma-­‐Aldrich) containing either heavy (Lys8 and Arg10, Cambridge isotope 
laboratories) or light (Lys0 and Arg0, Sigma-Aldrich) versions of amino acids, for a 
minimum five passages before being transiently transfected with PEI (Ong et al, 
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  2002). Cells were harvested after 24 h transfection, lysed by sonicating in RIPA 
buffer (50 mM Tris HCl, pH 7.4, 150 mM NaCl, 0.25 % Na-deoxycholate, 1 mM 
EDTA) containing 0.1 % SDS, supplemented with NEM, DNAse and complete 
protease inhibitor cocktail (Roche). Lysates were subjected to IP using Flag-M2 
affinity gel (Sigma). Heavy and light corresponding samples were mixed before the 
last washing step. 
 
Proteins eluted in Guanidine-HCl were precipitated in ethanol over night at 4 °C as 
previously described (Sury et al, 2015). Proteins were spun down and ethanol 
decanted. Protein pellet was resuspended in 6 M urea and 2 M thiourea in 10 mM 
HEPES (pH 8). Proteins were denatured using DTT followed by alkylation of 
cysteines by 2-chloroacetamide (Nielsen et al, 2008). Proteins were digested by 
endoproteinase LysC and then diluted in 50 mM Ammonium bicarbonate (pH 8) in 
water before being further digested by trypsin over night at room temperature. 
Resulting peptide solution was desalted on stage tips by washing in 5 % acetonitrile 
and 0.1 % formic acid (Rappsilber et al, 2003). Samples were eluted in 80 % 
acetonitrile and 0.1 % formic acid and vacuum dried before being diluted in 5 % 
acetonitrile and 0.1 % formic acid. The peptides were separated on a 15 cm column 
packed in house with ReproSil-Pur 120 C18-AQ 3 µm resin (Dr. Maisch GmbH), 
using a 1 h linear gradient of increasing acetonitrile concentration with a flow rate of 
250 nl/ min on a high pressure liquid chromatography (HPLC) system 
(ThermoScientific). Separated peptides were ionized using an electrospray 
ionization source (ThermoScientific) and analysed on Q Exactive mass 
spectrometer (ThermoScientific). The Orbitrap resolution was set to 70,000 (target 
value 3,000,000; maximum injection time of 20 ms) for full scans and 17,500 
(maximum injection time 60 ms; target value 1,000,000) for MS/MS spectra. The 
system was run in a data dependent mode selecting the top 10 most intense ions for 
higher energy collision induced dissociation.   
 
Raw files were analysed using the MaxQuant software 1.5.1.1 (Cox & Mann, 2008) 
using the default setting but with ‘Requantify’ and ‘match between runs’ activated. 
Lys8 and Arg10 were set as the heavy label. Ubiquitin leaves a signature GlyGly 
modification of Lysines (+114.0429 Da) after tryptic digestion. The GlyGly(K) 
modification, acetylation of protein N-termini and oxidation of methionine were set 
as variable modifications. C-terminal carbamidomethylation was set as a fixed 
modification. Trypsin/P was set as protease for the in silico digest of the Human 
Uniprot database (2014-01) in addition to a data base containing common 
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  contaminants. The false discovery rate was set to 1 % both at the peptide and 
protein level and was estimated by in parallel matching the MS/MS spectra against 
a database contain the reversed sequences of the Uniprot database (Cox & Mann, 
2008). 
 
Plotting of the SILAC ratios was done using R version 2.15.1 (R Foundation for 
Statistical Computing, Vienna, Austria). Spectra were visualized using the 
MaxQuant viewer and figures were modified in Illustrator (Adobe). 
 
2.5.2. Selected Reaction Monitoring (with Patrick Beaudette) 
For Selected Reaction Monitoring (SRM) chain linkage identification, 1x 15 cm dish 
of HEK293T cells were used for each condition. Cells were lysed with NP40, and 
subjected to IP using GFP-Trap Beads (Chromotek) due to their ability to withstand 
harsh washing conditions, in order to elute only the GFP tagged protein itself. After 
1 h rotating at 4 °C, beads were washed with 2 M Guanidine-HCl followed by water, 
then eluted by boiling in 2x SDS sample buffer. Eluates were run briefly on an SDS-
PAGE gel followed by an in-gel digestion with trypsin. After a solid-phase extraction 
and desalting, peptides were eluted, lyophilized and reconstituted with a 0.1 % 
formic acid/ 3 % ACN buffer containing 100 fmol/µl of heavy tryptic peptide 
standards corresponding to all the different polyubiquitin linkage types (Mirzaei et al, 
2010). Peptides were separated on a reversed-phase column (20 cm length, 75 µm 
ID, 3 µm Dr. Maisch C18) with a gradient from 3 to 36 % ACN in 38 min and SRM 
measurements performed using a Q-Trap 6500 (AB Sciex). The top two most 
intense transitions were selected and their peaks integrated with MultiQuant 3.0 
software (AB Sciex). In parallel, the samples were measured in data-dependent 
acquisition mode using an Orbitrap Q-Exactive instrument (Thermo) with an on-line 
chromatography equivalent to what was described for the SRM analysis. The raw 
files were analysed with MaxQuant 1.5.2.8 and the signal intensity for PKAC used to 
normalize the SRM-MS data to account for variation between the IPs. 
 
2.5.3.  Identification of Stub1 as an ARHGAP36 interactor (with Erik McShane) 
HEK293T cells transfected with YFP-ARHGAP36, were lysed with NP40 and 
subjected to regular GFP IP. Eluates were then separated by SDS-PAGE. Proteins 
in the SDS-PAGE gel were fixed by incubation in 50 % methanol and 10 % acetic 
acid solution. The gel was then stained with Coomassie blue using the Novex colloid 
blue stain Kit (Thermo Scientific) following the manufacturer’s instructions. After the 
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  gel was de-stained overnight, the unidentified band at approximately 35 kDa was cut 
out, then further cut into smaller pieces, and transferred to an Eppendorf tube. 
Proteins were then reduced, alkylated and digested “in-gel” as described previously 
(Shevchenko et al, 2007). In brief, gel pieces were washed by switching between 50 
% ethanol in 50 mM ammoniumbicarbonate (ABC buffer) solution or just ABC buffer. 
Gel pieces were fully dehydrated in 100 % ethanol and then speed vacced. 10 mM 
DTT in ABC was then added and incubated at 56 °C for 1 h to reduce the proteins. 
After decanting the DTT solution, 55 mM iodoacetamide in ABC buffer was added to 
block free sulfhydryl groups. After 45 min the gel pieces were washed in ABC buffer 
before being dehydrated as described above. The proteins were digested by 
incubating the gel pieces with trypsin at 37 °C overnight. Peptides were eluted from 
the gel by sequentially adding 3 % trifluoracetic acid and 30 % acetonitrile followed 
by 100 % acetonitrile. The resulting peptide solution was vacuum dried to get rid of 
organic solvents before peptides were stored on StageTips as described above in 
section 2.5.1. 
 
2.5.4. Global protein abundance measurements (iBAQ, with Patrick Beaudette 
and Erik McShane) 
For iBAQ, NGP cells were harvested, pelleted and flash-frozen prior to precipitation 
of proteins with equal volumes of chloroform, methanol and water (Wessel & 
Flügge, 1984). Proteins were solubilized in 6 M urea/2 M thiourea buffer containing 
10 mM HEPES and treated with benzonase to digest DNA and reduce viscosity. 50 
µg lysate was subjected to reduction with TCEP (tris(2-carboxyethyl)phosphine) and 
alkylation with CAA (2-chloroacetamide) before digestion with trypsin. Peptides were 
extracted and desalted with a C18 StageTip prior to elution and reconstitution in 3 % 
ACN/0.1 % formic acid, followed by separation on a reversed-phase column (20 cm 
length, 75 µm ID, 3 µm Dr. Maisch C18) with a gradient from 5 to 45 % ACN in 120 
min, while MS and MS/MS spectra were acquired in data-dependent mode on a Q-
Exactive Plus interment (Thermo).  Raw data files were then analysed with 
MaxQuant 1.5.2.8.  
 
In order to calculate protein abundances we applied the ‘intensity based absolute 
quantification’ algorithm [iBAQ] (Schwanhäusser et al, 2011). In short, we first 
calculated the number of theoretically observable peptides per protein by in silico 
trypsin-digesting the Uniprot database. We then divided the protein intensities by the 
theoretical observable peptide count.  
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2.6. Statistics 
An unpaired Student’s T-test was used to evaluate statistical significance were 
required. Values are expressed as the mean ± s.e.m or s.d as indicated. 
Significance was set at the 95 % confidence level and ranked as * p<0.05, ** 
p<0.01, *** p<0.001. 
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   ARHGAP36 is a novel PKAC binding Chapter 3.
protein and pseudosubstrate inhibitor  
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  3.1. Introduction 
The starting point for my PhD thesis was a finding from a systematic screen carried 
out by my supervisor Oliver Rocks in the laboratory of Tony Pawson (Rocks and 
Pawson, manuscript in preparation). This screen set out to characterise the 
regulatory proteins of the Rho family GTPases. The interactome and localisation of 
all GAP and GEF proteins was analysed by mass spectrometry and imaging 
respectively. Proteins of significant interest were then selected for further extensive 
characterisation. One such protein was ARHGAP36, a novel GAP protein. Flag-
tagged ARHGAP36 was found to interact with several proteins involved in PKA 
signalling, including the catalytic subunits of the kinase itself (PKACα and PKACβ). 
This alone is interesting: control of this pathway is mostly mediated through the 
regulatory subunits (which were not identified in the interactome) with few proteins 
binding directly to the catalytic subunits themselves. Rho GTPases and their 
regulatory proteins are known to be regulated by PKA phosphorylation (Tkachenko 
et al, 2011). In addition, many AKAP proteins have functions related to the 
cytoskeleton, and some of them are Rho related signalling proteins themselves 
(Klussmann et al, 2001; Wong & Scott, 2004). I was thus initially interested in the 
crosstalk of the Rho and PKA signalling pathways. In this chapter I aim to discuss 
the following questions: 
 
• What is known about ARHGAP36? 
• Do ARHGAP36 and PKAC interact? 
• How do ARHGAP36 and PKAC interact? 
• What is the nature of the interaction? 
 
3.2. Results 
3.2.1. ARHGAP36 Characterisation 
ARHGAP36 is a relatively small GAP protein. Uniprot describes five isoforms, 
ranging in size between 46 and 61 kDa. These isoforms vary only in the very N-
terminus and all share a Rho GAP domain and an arginine rich region (Figure. 
3.1a). Isoform 1 contains an additional signal peptide, and is described in NCBI as a 
precursor. SignalP confirms the presence of a signal peptide and cleavage site 
(Petersen et al, 2011). ARHGAP36 is located between 131,058,242-131,089,883 on 
the forward strand of the X chromosome. ENSEMBL corroborates the existence of 
isoforms 1-4 at the transcript level (Figure 3.1b).  
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516aaisoform2 1-32: MGGCIPFLKAARALCPRIMPPLLLLSAFIFLV → MRho-GAPArg GAP 58.3 kDa
411aaisoform3 1-136: MissingRho-GAPArg GAP 46.2 kDa
535aaisoform4 1-31: MGGCIPFLKAARALCPRIMPPLLLLSAFIFL → MAWILDCLFASAFEPRPRRRho-GAPArg GAP 60.6 kDa
499aaisoform5 1-48: MissingRho-GAPArg GAP 55.6 kDa
547aaisoform1 Rho-GAPArg GAP canonical sequence61.7 kDa
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Figure 3.1 ARHGAP36 has five predicted isoforms Uniprot describes five ARHGAP36 isoforms, Q6ZR18 1-5, depicted in (a), four out of the 
five sequences are corroborated at the transcript level in Ensmbl and shown in the graphic in (b) created using Fancy Gene.
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  Upon overexpression, isoform 1 localised on cytoplasmic punctae, whilst Isoform 2 
and the shortest isoform, 3, localised mostly to the plasma membrane in MDCK 
cells, as well as to some discrete cytoplasmic structures (Figure 3.2a). In hindsight, 
N-terminal tagging may have blocked cleavage of the signal peptide of Isoform 1, 
and C-terminally tagged constructs should have been tested for this isoform. 
However, as Rho GTPases signal from membranes, I focused on the interesting 
plasma membrane localisation of Isoform 2 and 3, which may be of functional 
relevance. I therefore set out to map the determinants for membrane localisation. I 
refer to isoform 2 of ARHGAP36 from here on, unless otherwise indicated. 
 
3.2.1.1. ARHGAP36 membrane localisation is encoded by the arginine-rich 
region 
I next generated a panel of ARHGAP36 expression constructs in order to delete 
discrete sections or to express them in isolation. All truncations were N-terminally 
tagged with either a CFP or YFP fluorophore. Interestingly deletion of the GAP 
domain had no effect on ARHGAP36 localisation, whereas the GAP domain alone 
appeared cytosolic (Figure 3.2b). Deletion of the N-terminus of ARHGAP36 
rendered the protein cytosolic, whereas deletion of the C-terminus had no effect. 
Expression of the N-terminus alone was sufficient to localise ARHGAP36. The 
localisation requirements could be further pinpointed to the 36 amino acid arginine 
rich region. Expression of this region alone, ARHGAP36-ARG, or any construct 
containing it, resulted in localisation at the plasma membrane. Deletion of the 
arginine rich region in the context of the full-length protein was sufficient to render 
the protein cytosolic. Note the shorter expression constructs are not excluded from 
the nucleus.  
 
3.2.1.2. ARHGAP36 localisation does not depend on the GAP domain 
It was intriguing that the GAP domain did not contribute to ARHGAP36 membrane 
localisation. Overexpression of an active GAP protein may be expected to have an 
effect on the cytoskeleton due to perturbation of Rho GTPase activity. I therefore 
overexpressed ARHGAP36 and looked at effects on actin, microtubules and focal 
adhesions, visualised by phalloidin, tubulin and vinculin respectively. I saw no 
obvious effect on any of these markers in cells overexpressing YFP-ARHGAP36 
(Figure 3.3). GAP proteins usually have a conserved ‘arginine finger’ which confers 
catalytic activity (Rittinger et al, 1997; Cherfils & Zeghouf, 2013), however 
ARHGAP36 has a threonine in place of this arginine (isoform 2: position 227).  
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Figure 3.2 ARHGAP36 localises to the plasma membrane  (a) Confocal live cell imaging micrographs of MDCK cells transiently transfected with 
CFP- or YFP- tagged ARGAP36 isoforms. Scale Bars: 10 µm. (b) As in (a) except cells transiently transfected with CFP- or YFP- tagged 
ARHGAP36 truncations based on Isoform 2. A comparison to Isoform 2 is shown, with construct boundaries indicated. Dashed line indicates 
deleted regions. All images are representative of both the CFP- and YFP- tagged forms, from three similar experiments.
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dGAP 1-194/396-516 Y
GAP 195-395 N
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dC 1-395 Y
dARG 1-117/155-516 N
ARG 118-154 Y
N 1-194 Y
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YFP-ARHGAP36 Phalloidin Tubulin Merge
Vinculin
Figure 3.3 ARHGAP36 overexpression does not obviously affect the 
cytoskeleton. MDCK cells were transfected with YFP-ARHGAP36, then 
fixed the following day and subjected to immunofluorescence using 
antibodies against GFP, tubulin or vinculin, as well as Phalloidin-555. 
YFP-ARHGAP36 Phalloidin Merge
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  Together with the lack of effect on the cytoskeleton, this led me to hypothesise that 
ARHGAP36 may not be an active GAP protein. Indeed, ARHGAP36 showed no 
activity toward RhoA, Cdc42 and Rac1, in an ongoing specificity screen using FRET 
activity sensors for these three GTPases (unpublished observation Markus Müller). 
However, specificity for one of the lesser-studied GTPases could not be ruled out. 
 
3.2.1.3. ARHGAP36 localises to primary cilia 
In 2014, a study by Rack and colleagues reported that ARHGAP36 overexpression 
caused massive Hh pathway activation (Rack et al, 2014). This activation was 
independent of Smoothened, and proposed to occur at the level of the Gli 
transcription factors, however, the mechanism by which ARHGAP36 achieved this 
was unclear. They also reported that ARHGAP36 localised to the primary cilium. 
Shh signalling requires a primary cilium: this organelle harbours the receptor Ptch 
and Gli proteins can be seen to translocate to the tip of the primary cilium upon 
pathway activation. Rack and colleagues showed that the N-terminus of mouse 
ARHGAP36, as well as human ARHGAP36-Iso3 localised at primary cilia in NIH-
3T3 cells. I wanted to see whether I could confirm this result and if so, explore 
whether cilia localisation properties are the same as those required for membrane 
localisation. I thus established cilia formation protocols in both NIH-3T3 and MDCK 
cells. Most cells are capable of forming primary cilia upon growth arrest. For cilium 
formation in NIH-3T3 cells, I simply serum-starved the cells for 48 hours. In order to 
induce cilium formation in MDCK cells, I cultured the cells for up to 9 days in full 
media and changed the media daily. These cells are epithelial and must first 
polarize before they can form a cilium. Once the cells form a complete tightly 
packed epithelium, they start to become taller, differentiate basolateral and apical 
membrane domains, and form primary cilia. I identified cilia by immunostaining for 
acetylated Tubulin and Polaris (Ift88- Intraflagellar transport protein 88 homolog). 
Cilia formation was much more reproducible and showed higher penetrance in 
MDCK cells, with almost 100% of cells displaying cilia, and these were much longer 
and more identifiable than in NIH-3T3 cells. This is in agreement with published 
findings by others (Ott & Lippincott-Schwartz, 2012). In MDCK cells locating the 
cilium was obvious merely based on the acetylated tubulin stain, with no need for 
the Polaris co-stain. In these cells I could see clear localisation of both Isoform 2 
and 3 at the primary cilium (Figure 3.4). As a negative control I used YFP to ensure 
the fluorophore or GFP staining did not by itself confer ciliary localisation.   
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Figure 3.4 ARHGAP36 localises to primary cilia
MDCK cells were cultured on coverslips for seven days before transfection with the indicated constructs and fixation the 
following day. Cells were subjected to immunofluorescence with antibodies against GFP and acetylated tubulin. Scale bars: 
5 μm. All constructs that localise to the plasma membrane also localise to cilia.
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Figure 3.5 The arginine rich region is sufficient to target ARHGAP36 to the 
primary cilium NIH-3T3 cells were starved for 48 hours before fixing. 24 hours prior 
to fixation cells were transfected with the indicated constructs. Cells were subjected 
to immunofluorescence using antibodies against GFP, acetylated tubulin and polaris. 
Scale bars: 10 μm.    
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  ARHGAP36-dN was unable to localise to the primary cilium, whereas the N-
terminus alone was sufficient for localisation. I further mapped the localisation 
requirements to the ARG rich region, the same 36 amino acids that are required for 
membrane localisation (see Figure 3.2b).  
 
NIH-3T3 cells have much more cytoplasmic acetylated tubulin, making it more 
difficult to identify the cilium. The Polaris staining was very weak and gave high 
background in these cells. In addition, the combination of transfected, ciliated cells 
was low, despite optimisation attempts. Transfecting ciliated cells is generally 
difficult, as in order to form cilia the cells need to differentiate and stop dividing, 
whereas many transfection reagents require cells to divide to ensure good 
expression. These cells are also notoriously difficult to transfect in the first place. I 
was able to show that ARHGAP36-ARG as well as the larger fragment 
encompassing the ARG region, ARHGAP36-N2, localised to the primary cilium 
(Figure 3.5). It is likely that full-length protein does localise to cilia, as in MDCK cells 
(Figure 3.4), however in NIH-3T3 cells only the shorter, more easily transfected 
constructs could be visualised there. Note that Rack and colleagues also only 
showed Isoform 3, the shortest variant, to localise on primary cilia in NIH3T3 cells 
(Rack et al, 2014). 
 
Three different ARHGAP36 antibodies I was testing at the time also localised 
strikingly to the primary cilia. However, these antibodies had not yet been verified by 
knock down and it is also not clear whether ARHGAP36 is expressed in MDCK 
cells. It would be interesting to check whether ARHGAP36 is upregulated upon cilia 
formation and whether knocking down endogenous ARHGAP36 has an effect on 
cilium formation itself.  
 
3.2.2. The ARHGAP36 interactome indicates a role in PKA signalling 
Our interest in characterising ARHGAP36 stems from prior interactome data (Rocks 
& Pawson, manuscript in preparation). In that previous study, Flag-ARHGAP36 was 
overexpressed in HEK293T cells and interacting partners were identified by 
immunoprecipitation and subsequent mass spectrometry. Interestingly the PKA 
catalytic subunits, PKACα and PKACβ, were among the strongest hits. Other 
interactors identified were Praja2, the E3 ubiquitin ligase recently found to be an 
AKAP, which mediates ubiquitylation and proteasomal degradation of PKAR 
(Lignitto et al, 2011). Two other E3 ubiquitin ligases, Stub1 and Huwe1, were also 
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  identified. I wanted to first confirm the interaction with PKAC, and then establish the 
nature of this interaction. 
 
3.2.2.1. ARHGAP36 interacts with PKAC 
In order to first confirm the interaction of ARHGAP36 with PKAC I performed co-
immunoprecipitation (IP) experiments. I transiently overexpressed Flag-tagged 
ARHGAP36, or Flag-Cherry as a control, together with PKAC-YFP, in HEK293T 
cells for 24 hours. I then pulled down the Flag-tagged proteins using Flag-coupled 
beads and looked for interacting PKAC-YFP by western blotting. PKAC-YFP 
interacted strongly and specifically with Flag-ARHGAP36 (Figure 3.6a). I then 
wanted to know if ARHGAP36 could interact with endogenous PKAC. I pulled down 
overexpressed YFP-tagged ARHGAP36 or YFP-Cherry as a control from singly 
transfected HEK293T cells. Endogenous PKAC also interacted strongly and 
specifically with YFP-ARHGAP36 (Figure 3.6b).  
 
3.2.2.2. ARHGAP36 relocalises PKAC 
In MDCK cells PKAC-YFP is mostly cytosolic, with some Golgi localisation, 
presumably due to AKAP recruitment of PKA holoenzymes (Skroblin et al, 2010). In 
addition some aggregates can be seen that most likely result from overexpression 
(Figure 3.7a). Upon coexpression with ARHGAP36, PKAC is recruited and 
completely relocalises to the plasma membrane and to vesicles (Figure 3.7b).  
 
3.2.2.3. Just 77 amino acids are required to recruit PKAC 
I then wanted to map the determinants required for ARHGA36 recruitment of PKAC. 
To this end I utilised my mutation and deletion constructs previously designed to 
map ARHGAP36 localisation. Isoform 3, the shortest ARHGAP36 isoform, could 
also recruit PKAC (Figure 3.8). Deletion of the GAP domain had no effect on the 
ability of ARHGAP36 to recruit PKAC. Deletion of the N-terminus abolished the 
interaction, whereas the N-terminus alone was sufficient to recruit PKAC. From 
these imaging experiments it could not be ruled out that ARHGAP36 and PKAC 
interact in the cytosol, however IP experiments confirmed that the interaction site 
correlates with the ARHGAP36 membrane localisation determinants and lies within 
the N-terminus. PKAC-YFP did not interact with Flag-dN, whereas Flag-N did 
(Figure 3.9). ARGAP36-N2, encompassing just 77 amino acids, was sufficient to   
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Figure 3.6 ARHGAP36 interacts with PKAC (a) HEK293T cells were trans-
fected with PKAC-YFP and Flag-ARHGAP36 or a Flag-Cherry control. 
Lysates were subjected to IP using a Flag antibody, and immunoblotted with 
GFP or Flag antibodies. Blots representative of three similar experiments. (b) 
HEK293T cells were transfected with YFP-ARHGAP36 or a YFP-Cherry 
control. Lysates were subjected to IP using a GFP antibody, and immunoblot-
ted with GFP or PKAC antibodies. Blots representative of three similar experi-
ments.
Figure 3.7 ARHGAP36 recruits PKAC to the plasma membrane and vesi-
cles (a) MDCK cells transfected with PKAC-YFP or Flag-ARHGAP36, were 
fixed and stained with GFP or Flag antibodies. Images were collected by 
confocal microscopy. Scale bars: 10µM (b) As in (a) except cells were trasn-
fected with PKAC-YFP and Flag-ARHGAP36 together. Images representa-
tive of three independent experiments.
PKAC-YFPARHGAP36a.
b.
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Figure 3.8 Just 77 amino acids are required to recruit PKAC. Confocal live micrographs of MDCK cells transiently transfected with CFP-
tagged ARGAP36 truncations together with PKAC-YFP. Images representative of three independent experiments. Scale Bars: 10 µm. All trunca-
tions are based on isoform 2 and are depicted below. 
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  recruit PKAC (Figure 3.8). ARHGAP36-ARG was the only truncation that localised 
to membranes as the full-length ARHGAP36 but was unable to recruit PKAC.  
 
3.2.2.4. ARHGAP36 contains an N-terminal pseudosubstrate domain 
To further pinpoint the interaction site I used peptide-spotting experiments. 25 amino 
acid peptide spots were synthesised, with each spot shifted by five amino acids to 
provide overlap for the entire ARHGAP36 sequence. The spots were then incubated 
with purified GST-PKAC and interaction detected using a GST antibody as for 
western blotting (Figure 3.10a). One spot, B12, interacted most strongly. This spot 
spans part of the arginine rich region and the following ‘linker’ region, so called as it 
joins the arginine rich region to the GAP domain. This fits with my previous findings, 
as this sequence is located in the middle of ARHGAP36-N2, the minimal construct 
that could recruit PKAC. Further amino acid scanning experiments were performed, 
where each amino acid from the positive spot was in turn mutated to alanine or 
aspartic acid (Figure 3.10b). This revealed the requirement of two arginines, R153 
and R154 for PKAC binding. The surrounding sequence (RRGAV) resembles that of 
the consensus motif (R-R-X-S/(A/G)-Y) for PKAC substrates/inhibitors found in the 
PKAR and PKI proteins. X is variable, Y a hydrophobic residue and S/(A/G) the 
phosphorylation/pseudophosphorylation site, respectively (Kemp et al, 1976; Taylor 
et al, 2012). This region of ARHGAP36 aligns perfectly with the pseudosubstrate 
inhibitor sites within PKAR and PKI (Figure 3.10c). I thus mutated three amino acids 
corresponding to R94, R95, V98 in PKAR, which had been shown to dock into the 
active site of PKAC (Buechler et al, 1993; Zhang et al, 2012)(Figure 3.11), to 
aspartic acid R153D/R154D/V157D (ARHGAP36-RRV). This mutation had no effect 
on ARHGAP36 localisation, however ARHGAP36-RRV could no longer recruit 
PKAC to membranes (Figure 3.12a). IP experiments confirmed that ARHGAP36-
RRV could no longer interact with endogenous PKAC either (Figure 3.12b). Further 
analysis of the structure of PKAC in complex with PKAR, revealed three amino 
acids in the active site cleft of PKAC, critical for the interaction (Kim et al, 2005) 
(Figure 3.11). Mutation of these three amino acids E127A/E170A/E230A (PKAC-
EEE) was enough to abolish PKAC recruitment by ARHGAP36 (Figure 3.12c). I thus 
identified point mutations on both proteins that abolish their interaction. 
 
3.2.2.5. ARHGAP36 inhibits PKAC activity 
As ARHGAP36 binds PKAC via a pseudosubstrate site, in the same manner as 
PKAR and the PKI proteins, I next asked if ARHGAP36 also inhibits PKAC. With   
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Figure 3.10 ARHGAP36 contains a PKA pseudosubstrate motif (a) Immobilised 
peptide ‘spots’. Overlapping 25-mer peptides each shifted along by five amino acids 
in the entire ARHGAP36 sequence, were probed for interaction with GST-PKAC and 
immunoblotted using a GST antibody. The sequence of the spot with strongest inter-
action is shown. (b) Alanine and Aspartate scans of the spot indicated in (a) were 
treated the same as in (a). Asterisk indicates the control spot with the original 
sequence. (c) Alignment of human ARHGAP36 with the human isoforms of PRKAR 
and PKI revealing its pseudosubstrate motif RRxAY. 
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Figure 3.11 The PKA holoenzyme structure reveals critical residues 
for the pseudosubstrate interaction. Structure of the PKAC-PKARIIβ 
complex (in blue, sand, pdb 3TNP.pdb)(Zhang et al, 2012). The pseudo-
substrate motif of the regulatory subunit is coloured in pink. The inset 
shows the three residues in the pseudosubstrate sequence (R94, R95, 
V98) that were mutated in the corresponding ARHGAP36 sequence, 
together with selected contacts in the catalytic subunit. Figure created 
by Oliver Daumke (MDC).
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Figure 3.12 Point mutations on both proteins can abolish the interaction of 
ARHGAP36 and PKAC (a) Confocal live micrographs of MDCK cells coex-
pressing CFP-ARHGAP36-RRV and PKAC-YFP. Images representative of 
three similar experiments. (b) HEK293T cells were transfected with CFP-
ARHGAP36, the RRV mutant or a CFP-Cherry control. Lysates were immuno-
precipitated using a GFP antibody, and immunoblotted with GFP or PKAC 
antibodies. (c) Confocal live micrographs of MDCK cells expressing PKAC-
YFP-EEE alone or together with CFP-ARHGAP36. Images representative of 
three similar experiments. Scale bars: 10 μm throughout.
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  help from Carolin Barth (AG Rocks, MDC), we first used an in vitro assay, which 
assesses the ability of purified PKAC to phosphorylate a substrate peptide (L-R-R-
A-S-L-G). The peptide is then separated on an agarose gel, simply by its charge, as 
upon phosphorylation, modified residues become negatively charged. In the 
absence of purified PKAC, all the peptide is non-phosphorylated, whereas in the 
presence it is all phosphorylated. A scrambled peptide had no effect on 
phosphorylation, whereas the PKI (5-24) peptide could significantly inhibit 
phosphorylation. We then tested ‘36i’, a 25 amino acid peptide comprising the 
pseudosubstrate motif, based on spot B12 from the peptide spot experiments. 36i 
could also significantly inhibit substrate phosphorylation (Figure 3.13a). I would of 
course have liked to do this experiment with full-length purified ARHGAP36, 
however my attempts to purify ARHGAP36 were unsuccessful as the protein was 
always insoluble.  
 
I next wanted to know if full-length ARHGAP36 could inhibit PKAC in vivo. For this I 
used the AKAR4-NES FRET sensor. This is made up of cerulean and venus based 
(cpVE172) fluorophores, with a substrate site (LRRATLVD) and a FHA1 phospho-
binding domain in between (Herbst et al, 2011; Depry et al, 2011) (Figure 3.13b). So 
when the substrate site is phosphorylated the FHA1 domain can bind and FRET can 
occur between the two fluorophores, which are brought closer together. There is 
also an additional nuclear export signal (NES), to ensure the sensor remains in the 
cytosol. I first attempted to measure the FRET efficiency of single cells before and 
after stimulation with forskolin, in order to see whether the sensor worked. However 
our microscopy set up at the time did not allow for constant perfusion of liquid, and 
therefore I had problems with losing focus upon addition of stimulants. Together with 
Markus Müller (AG Rocks, MDC) we then tried these experiments on a larger scale, 
assessing many stimulated cells at one time-point then comparing between 
conditions. We co-expressed mCherry tagged ARHGAP36 variants, or mCherry 
itself as a control, so that we could always normalise FRET measurements to the 
expression level of the constructs. Full-length ARHGAP36 and ARHGAP36-N2 
could significantly reduce FRET activity, whereas ARHGAP36-RRV and 
ARHGAP36-dN had no effect (Figure 3.13c & d).  Overexpressing constructs 
encoding 36i or full-length PKI also significantly reduced FRET activity. Together 
these experiments show that ARHGAP36 interacts directly with PKAC and inhibits 
its kinase activity via a pseudosubstrate domain.  
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Figure 3.13  ARHGAP36 inhibits PKAC in vitro and in vivo (a) Recombinant PKAC
α (25 ng) was incubated with 10 μM scrambled, 36i or PKI peptide, and its activity 
determined by its ability to phosphorylate the substrate peptide PepTag A1. Phospho-
rylated and non-phosphorylated peptide were separated by agarose electrophoresis, 
and densitometrically analysed. Representative gel shown. Recombinant PKACα 
activity is shown as the ratio of phosphorylated to non-phosphorylated peptide (mean 
of eight repeats +/- SEM, *** p<0.001 versus all three controls). Figure contributed 
by Carolin Barth. (b) Representation of AKAR4-NES FRET sensor (Herbst et al, 
2011). (c) AKAR4-NES FRET sensor was expressed together with the indicated 
mCherry tagged constructs. Cells were serum starved for five hours, treated with 10 
µM Forskolin and 100 µM IBMX for 30 min and subsequently imaged. Mean FRET 
emission ratio (acceptor/donor intensity) of three independent experiments normal-
ised to control +/- s.d.  *** p<0.001, n.s. not significant versus control and RRV (d) 
Representative images of HEK293T cells expressing  AKAR4-NES FRET sensor 
together with the indicated mCherry tagged constructs. Cells were treated as in (c). 
Shown are YFP intensity images and pseudocoloured FRET ratio images 
(acceptor/donor intensity) reflecting the relative PKA activity levels. The histograms 
show the pixel distribution within the FRET emission ratio images. Scale bars: 100 
µm. Panels c-d contributed by Markus Müller.  
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  3.3. Discussion 
Main Chapter Findings 
• ARHGAP36 localises to the plasma membrane and the primary cilium via 
its arginine rich region.  
• ARHGAP36 binds PKAC directly via a pseudosubstrate site, recruiting it 
to the plasma membrane  
• ARHGAP36 inhibits PKAC activity in vitro and in vivo.  
 
3.3.1. Non GAP functions of other GAP proteins 
GEF and GAPs are diverse multidomain proteins that have numerous roles outside 
of regulating GTPase activity. ARHGAP36 may not be an active GAP protein. Other 
GAP proteins have already been shown to have functions independent of their GAP 
activity, even if they are still active. Overexpression of the GAP protein N-Chimaerin 
leads to lamellipodia and filopodia formation. Although this was shown to depend on 
Cdc42 and Rac1 activity, N-chimearin mutants lacking GAP activity could still cause 
the cellular phenotype (Kozma et al, 1996). Recently it was shown that ARHGAP30 
regulates p53 acetylation in a Rho independent manner (Wang et al, 2014). 
Catalytic mutants still had the same effects. The shorter ARHGAP30 isoform could 
not affect p53 acetylation, pointing to a role of the Glutamine-rich domain contained 
only in the longer-isoform. The other domains of Rho proteins are thus important in 
mediating protein-protein interactions and thus their diverse roles. ARHGAP11A 
binds p53 and surprisingly this is actually via the GAP domain (Xu et al, 2013). 
ARHGAP11A promoted p53 function upon DNA damage, and there was no effect of 
mutating the catalytic arginine, showing the effect to be independent of Rho GTPase 
activation. Another Rho GAP family protein, OCRL, contains many other domains 
critical for its function, and mutation of this protein leads to Lowe syndrome and 
Dent disease (Mehta et al, 2014). OCRL is an inositol 5-phosphatase, and binding 
of a C-terminal ASH domain to Rab GTPases mediates its subcellular localisation 
and stimulates its phosphatase activity (Hyvola et al, 2006). Its GAP domain is 
actually catalytically inactive, however it is still thought to mediate binding to Rac1 
and Cdc42 and rather act as an effector (Faucherre et al, 2003). Taken together this 
suggests that the GAP domain itself can also have functions independent of 
catalytic activity. The scaffolding roles of GAP proteins, even in context of GAP 
activity, contribute massively to their functions (Okada et al, 2011).  
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  3.3.2. ARHGAP36 is a novel PKAC inhibitory protein 
ARHGAP36 further extends the PKA regulatory repertoire. Regulation of this 
signalling pathway is mostly centred around PKAR, with much emphasis in the field 
on the role of AKAPs. ARHGAP36 interacts directly with PKAC via a 
pseudosubstrate motif that binds in the same manner as PKAR and the PKI proteins 
to the PKAC catalytic site. I thus conclude that binding would be at least in parts 
competitive. ARHGAP36 should thus be able to uncouple PKAC from upstream 
control via PKAR.  
 
ARHGAP36 could act as a tonic suppressor of PKA to greatly reduce the sensitivity 
of certain cells to cAMP-releasing stimuli. It might also oppose basal PKA activity, 
particularly in situations with stoichiometric excess of free PKAC. Compensatory 
mechanisms have long been suggested to balance the relative expression levels of 
PKAR and PKAC, so that proper responsiveness of the PKA holoenzyme to cAMP 
is maintained (Hofmann et al, 1977; Amieux et al, 1997). ARHGAP36 may 
contribute to such a mechanism by providing additional buffering capacity.  
 
3.3.3. Other pseudosubstrate Inhibitors of PKAC 
Isothermal titration calorimetry (ITC) experiments performed by Stephan Grunwald 
(AG Daumke, MDC) also support that ARHGAP36 inhibits PKAC in a similar 
manner to the PKI proteins. He found similar high nanomolar binding constants for 
both 36i and PKI (5-24) peptides for purified His-PKAC. Most protein kinase 
inhibitors bind the ATP-binding site, and thus specificity is a problem (Murray, 2008). 
PKI and 36i block substrate binding and therefore are much more specific to PKA. I 
have thus identified a new pseudosubstrate peptide inhibitor which can be used to 
inhibit PKA in vitro, and possibly also in vivo. 
 
It would be interesting to repeat these ITC experiments with full-length ARHGAP36 
protein, and with a series of mutants, to establish if other parts of the protein can 
contribute to binding of PKAC. For PKI a phenylalanine located N-terminally to the 
pseudosubstrate motif contributes to binding affinity (Glass et al, 1989). 
Interestingly, the peptide spotting experiments did identify a possible role for F148 in 
PKAC binding (Figure 3.10b).  
 
The PKI proteins have been implicated in nuclear export of PKAC (Fantozzi et al, 
1992, 1994). They contain a nuclear export signal (NES) (Wen et al, 1995), 
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  however, this is thought to be masked unless they are bound to PKAC (Dalton & 
Dewey, 2006). They can freely diffuse between the nucleus and cytoplasm, and 
upon binding active PKAC in the nucleus, the NES is uncovered and PKAC is 
translocated back to the cytoplasm. This is thought to then promote holoenzyme 
reformation. PKI thus participates in regulating the transcriptional response of PKA 
in the nucleus. ARHGAP36 is specifically targeted to the plasma membrane via its 
arginine rich region and can also recruit PKAC there. I would therefore hypothesise 
that ARHGAP36 rather regulates PKA activity at the plasma membrane. Similar to 
the role of PKI in the nucleus, ARHGAP36 could bind recently activated PKAC to 
ensure its timely inactivation in dynamic signalling events. ARHGAP36 would thus 
contribute to resetting the PKA pathway. 
 
PKI is a rather small protein of only 75 amino acids. By comparison ARHGAP36 is 
much larger and thus the possibilities for protein-protein interaction and further 
functions are increased. The ARHGAP36 interactome contained many more 
interesting proteins. Although ARHGAP36 is not a canonical AKAP, as it interacts 
with PKAC rather than PKAR, it may still act as a scaffold to recruit other proteins 
that could further modulate PKA signalling. 
 
The only other pseudosubstrate inhibitor of PKAC is PDE7A1, which actually 
contains two pseudosubstrate sites within its N-terminus (Han et al, 2006). It is also 
a phosphodiesterase, so can further regulate PKA activity by degrading cAMP.  
 
3.3.4. ARHGAP36 in Hedgehog signalling and Medulloblastoma 
Overexpressed ARHGAP36 has been shown to activate the Hh signalling pathway 
(Rack et al, 2014). Rack et al claimed that different parts of the protein had 
differential effects. Whereas the full-length protein activates Hh signalling, the N-
terminus had an inhibitory effect on Gli activation. However they could not explain 
how either effect occurs. They did report that overexpressed full-length ARGAP36 
could interact with overexpressed Sufu. Sufu is a negative regulator of Hh signalling, 
thought to bind the Gli proteins, and promote repressor formation. They did not 
explore how ARHGAP36 binds to Sufu or discuss how this could contribute to the 
observed effects on signalling. One theory would be that ARHGAP36 sequesters 
Sufu away from the Gli proteins, in order to promote their conversion into 
transcriptionally active forms.  
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  In the absence of a Hh stimulus, the Gli proteins are ubiquitylated and, particularly in 
the case of Gli3, undergo partial proteolysis into repressor forms. This cleavage 
process is carefully regulated by multi-step phosphorylation by various kinases. PKA 
has been shown to directly phosphorylate the Gli proteins, in a priming event 
leading to further phosphorylation by GSK3β and CK1. This leads to βTRCP binding 
and subsequent ubiquitylation by the SCF E3 ligase complex, this mediates their 
partial cleavage into transcriptional repressors. PKA is thought to be a negative 
master regulator of the pathway. PKA knock out mice even phenocopy Ptch1 and 
Sufu knock outs in the developing embryo (Tuson et al, 2011). We thus 
hypothesised that ARHGAP36 mediates its effects via its inhibitory role on PKA. 
Maciej Czajkowski (AG Rocks) could show an increase in Gli transcript levels upon 
ARHGAP36 overexpression, as well as with ARHGAP36-N2, the minimal construct 
that binds and targets PKAC. More importantly ARHGAP36-RRV could no longer 
mediate an increase in Gli1 transcript levels. Therefore if the ARHGAP36 
pseudosubstrate domain is mutated, and it can no longer bind and inhibit PKAC, it 
can no longer lead to Hh activation. 
 
Rack et al also reported that ARHGAP36 was upregulated in medulloblastoma, the 
most common brain tumour in childhood. This disease is frequently associated with 
abnormal Hh signalling (Teglund & Toftgård, 2010). Medulloblastomas are normally 
split into four subtypes, with Type 2 being classified by upregulated Hh signalling 
(Kool et al, 2012). However ARHGAP36 was upregulated within subtypes 3 & 4, and 
its expression did not correlate with Gli1 or Ptch1 levels (Rack et al, 2014). They 
could show that isoforms 2, 3 and 5 were those found to be upregulated. This 
argues that these are the physiological (or pathophysiological) relevant isoforms. I 
have shown here that isoforms 2 and 3 bind PKAC. Isoform 5 is an intermediate 
version, its N-terminus starting between Isoforms 2 and 3. It contains no extra or 
different domains, and contains the pseudosubstrate motif, I would thus also expect 
isoform 5 to bind and inhibit PKAC. ARHGAP36 inhibition of PKAC thus provides a 
simple rationale for how Gli activation is achieved, and provides a mechanism by 
which ARHGAP36 could promote medulloblastoma formation. ARHGAP36 could 
also oppose PKAC in further disease contexts.  
 
Unfortunately medulloblastoma cell lines are not thought to well represent the 
disease, otherwise this would have been an obvious choice to explore the role of 
endogenous ARHGAP36 on PKAC. 
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  4.1. Introduction 	  
I consistently observed a dramatic decrease in PKAC protein levels upon 
overexpression of ARHGAP36. Loss of PKAC could be caused by either an effect at 
the transcriptional or post-translational level. However, I also observed a reduction 
of the over-expressed form, which is not under the control of the endogenous PKAC 
promoter. This points towards a post-translational regulatory mechanism such as 
degradation. The regulatory subunits are known to be degraded by the proteasome 
upon ubiquitylation by the E3-ligase Praja2 (Lignitto et al, 2011). Many activated 
kinases are ubiquitylated and degraded (Lu & Hunter, 2009; Liu et al, 2012), 
however thus far there is no known mechanism for ubiquitin-mediated PKAC 
degradation. In this chapter I aim to discuss the following questions: 
 
• Does ARHGAP36 affect PKAC stability? 
• How is PKAC degraded? 
• Is PKAC ubiquitylated? 
• What other proteins are involved? 
 
4.2. Results 
4.2.1. ARHGAP36 causes depletion of PKAC 
Overexpression of ARHGAP36 in MDCK cells results in a striking loss of 
endogenous PKAC (Figure 4.1a, compare ARHGAP36 overexpressing cells with 
surrounding untransfected cells). In order to visualise an intermediate stage that 
may inform on the mechanism by which PKAC is degraded, I fixed cells after eight 
and 24 hours of transfection and monitored endogenous PKAC. At the eight hour 
timepoint, PKAC was concentrated on vesicles that colocalised with ARHGAP36, 
whilst it was completely lost after 24 hours of ARHGAP36 expression in the majority 
of transfected cells (Figure 4.1b).  Overexpression of YFP had no effect on PKAC at 
either time-point. At first it was difficult to see this decrease in PKAC levels by 
western blotting, as only a small percentage of cells were transfected with 
ARHGAP36, but the entire cell population is assessed.  Transfection efficiency thus 
had to be optimised first. HEK293T cells were used as they have the SV40 large T 
antigen for enhanced replication of DNA plasmids. Transfection of cells with PEI at 
high confluency (around 80%), resulted in transfection efficiency close to 100%. I 
always used YFP-tagged ARHGAP36 constructs, so efficiency could be easily 
judged by fluorescence microscopy before harvesting, and also later by western  
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   blotting using an anti-GFP antibody. Once thus optimised, endogenous PKAC 
levels could also be seen by western blot (Figure 4.1c).   
 
4.2.2. ARHGAP36 has no effect on PKAR 
As most regulation of PKA signalling is mediated through PKAR, I first wanted to 
investigate if this effect on PKAC was secondary to an effect on PKAR. I performed 
the same experiments as for PKAC, overexpressing ARHGAP36 and assessing 
PKAR levels by IF in MDCK and by WB in HEK293T. ARHGAP36 had no effect on 
any PKAR subunit tested, either by IF or by WB (Figure 4.2a & b).  
 
4.2.3. Pseudosubstrate binding is required but not sufficient to promote PKAC 
downregulation 
I next hypothesised that degradation of PKAC may require binding of any 
pseudosubstrate, promoting its dissociation from the regulatory subunits and 
release from the protective holoenzyme setting. It is known that some components 
of protein complexes are much less stable in isolation. For example, ribosomal 
proteins are synthesised at a high rate and accumulate in the nucleus to allow for 
ready assembly of ribosomes when required. However most of these proteins do not 
become incorporated into the ribosome and any free ribosomal proteins are quickly 
degraded via the proteasome, in order to prevent over accumulation. Ribosomal 
proteins that do assemble into ribosomes become stable as components of the 
complex and have a much longer half-life (Lam et al, 2007). This is also true for 
subunits of the T Cell Antigen Receptor (TCR) that contain hydrophobic sequences 
recognised for degradation in the endoplasmic reticulum unless they are bound by 
other members of the complex (Bonifacino et al, 1990). It has also been shown for 
PKAR that RIα half live increases from three to 14 hours upon incorporation into the 
holoenzyme (Amieux et al, 1997). I thus overexpressed PKI, which binds PKAC in 
the same manner as ARHGAP36 in the substrate binding pocket, and assessed 
PKAC levels. Both N and C terminally tagged constructs were tested, as it is 
possible that the fluorophore could mask the pseudosubstrate site in this small 
protein. Neither N nor C terminally tagged PKI had an effect on PKAC levels (Figure 
4.3a), arguing that down regulation of PKAC is a specific property of ARHGAP36. 
36i expression, just 25aa comprising the ARHGAP36 pseudosubstrate motif, was 
equally unable to promote PKAC degradation (Figure 4.3b). I then questioned 
whether ARHGAP36 pseudosubstrate binding was even necessary to mediate 
PKAC-degradation. Perhaps binding of a secondary protein via a different site is   
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  enough to catalyse this. However the RRV pseudosubstrate mutant, which varies 
from the WT ARHGAP36 by only three amino acids, could no longer cause 
degradation of PKAC (Figure 4.3c). This suggests a direct interaction via the 
pseudosubstrate domain is required but not sufficient to promote downregulation of 
PKAC. 
 
4.2.4. ARHGAP36-N2, encompassing just 77 amino acids, can mediate PKAC 
degradation 
I next set out to map the determinants in ARHGAP36 that are necessary and 
sufficient to promote downregulation of PKAC. ARHGAP36-N was able to promote 
down regulation of PKAC, and surprisingly so could ARHGAP36-N2, just 77 amino 
acids containing the pseudosubstrate domain. Otherwise all constructs that interact 
with PKAC could also cause its degradation (Figure 4.4, ARHGAP36-Iso3, -dGAP, -
dC). This supports the fact that pseudosubstrate binding is absolutely required for 
degradation. ARHGAP36-ARG (aa118-154), which contains the two critical 
arginines but not the rest of the pseudosubstrate motif (153-RRGAV-157), can no 
longer cause PKAC degradation, despite the fact that it still localises similarly to full-
length ARHGAP36. 
 
4.2.5. ARHGAP36 induced PKAC degradation is rescued by lysosomal 
inhibitors 
Most cytosolic proteins are degraded via the proteasome, therefore I tried to rescue 
PKAC degradation using proteasomal inhibitors such as MG132 and epoxomicin, 
but to no avail. The transient endosome-like vesicular PKAC staining observed prior 
to its degradation also pointed to a different mechanism. I next wanted to test the 
hypothesis that PKAC degradation occurs via the endolysosomal pathway, using 
inhibitors of the vacuolar ATPase that is responsible for lysosomal acidification and 
activation of lysosomal enzymes (Yoshimori et al, 1991). However, this was far from 
straight forward.  In order to trigger PKAC degradation, I first needed to overexpress 
ARHGAP36, but as degradation is quite rapid, it was important to optimise the time 
window for treatment with inhibitors. I first tried transfecting and treating at the same 
time, however the proteasomal inhibitor MG132 and bafilomycin	   interfered with 
expression. The PEI transfection reagent works by allowing complexed DNA to bind 
membranes, be endocytosed and subsequently released into the cytoplasm 
(Boussif et al 1995). Bafilomycin has previously been shown to interfere with the 
progress of endocytosed material from early to late endosomes (Clague et al, 1994)   
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  and may affect the release of DNA into the cytosol. Therefore I first had to wait after 
transfection to allow for proper ARHGAP36 expression, before an additional 
incubation with and without inhibitors. The second problem I encountered was that 
cells start to express ARHGAP36 at any point after transfection, thus after longer 
expression the ARHGAP36 transfected cells show quite heterogenous PKAC levels 
and localisation. By immunofluorescence microscopy, cells just starting to express 
ARHGAP36 present with the intermediate PKAC phenotype, which is also what a 
rescue may look like. In order to alleviate this confusing effect, I combined inhibitor 
treatment with cycloheximide (CHX), to also inhibit new protein synthesis. Cells can 
then no longer start to express ARHGAP36 during the inhibitor treatment, and are 
somewhat synchronised. PKAC levels should then be completely depleted in all 
ARHGAP36 transfected cells treated with CHX, therefore making the effect of 
inhibitors more obvious in comparison.   	  
I co-overexpressed PKAC-Flag with YFP-cherry or YFP-ARHGAP36 in HEK293T 
cells for 12 hours. The following day I pre-treated the cells with epoxomicin or 
bafilomycin for 30 minutes prior to addition of CHX for a further six hours. In the 
absence of ARHGAP36 there was no effect of epoxomicin, bafilomycin or CHX on 
PKAC protein levels. This fits with previous observations that PKAC has a long half-
life (T1/2 = 100 hours, (Schwanhäusser et al, 2011)). However in the presence of 
ARHGAP36, PKAC levels were much decreased, and a second higher molecular 
weight band became apparent. The addition of epoxomicin had no effect on PKAC, 
although the proteasomal substrate β -Catenin rapidly accumulated over the same 
timecourse (Figure 4.5a&b). In contrast, bafilomycin treatment partially restored 
PKAC levels.  
 
The same effect on PKAC could be observed at the endogenous level by 
immunofluorescence in MDCK cells. Cells were first transfected with ARHGAP36 for 
eight hours, then pretreated with epoxomicin or bafilomycin for 30 minutes, before 
addition of CHX for a further eight hours. With the addition of CHX PKAC levels 
were clearly reduced in ARHGAP36 overexpressing cells. Bafilomycin, but not 
epoxomicin, caused a build up of PKAC on enlarged vesicles that colocalised with 
ARHGAP36 (Figure 4.5c).  
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  4.2.6. ARHGAP36 and PKAC colocalise along the endolysosomal pathway 
In order to confirm PKAC is degraded in the lysosome I wanted to assess 
colocalisation with markers of the endolysosomal pathway. In U2OS cells 
overexpressed PKAC partially colocalised together with ARHGAP36 and the early 
endosomal marker EEA1, as well as with the MVB marker HRS (Figure 4.6a). In 
HeLa cells partial colocalisation could be seen with HRS, EEA1 and also with the 
late endosomal marker Rab7 (Figure 4.6b & c). Furthermore when HeLa cells were 
pretreated with bafilomycin for 30 mins and CHX for another six hours before fixing, 
PKAC-positive vesicles were affected in the same way as EEA1, with colocalisation 
becoming more pronounced. Before treatment both vesicle populations were 
diffusely distributed throughout the cell, whereas after treatment vesicles became 
more tubular and concentrated in the perinuclear region, in agreement with previous 
observations (Clague et al, 1994) (Figure 4.6c).   
 
In MDCK cells endogenous PKAC partially colocalised together with ARHGAP36 
and overexpressed HRS, as well as overexpressed LAMP-1, a lysosomal marker 
(Figure 4.7). Endogenous PKAC could also clearly be seen inside enlarged vesicles 
caused by the overexpression of Rab5-Q79L, a constitutively active GTPase variant 
(Stenmark et al, 1994). These experiments suggest that ARHGAP36 targets PKAC, 
a cytosolic protein, for endolysosomal degradation. The endolysosomal degradation 
pathway is usually reserved for transmembrane receptors. One other cytosolic 
kinase, GSK3 has been suggested to enter MVBs, but its fate is unknown as it does 
not seem to be subsequently degraded (Taelman et al, 2010). The absence of 
ubiquitin from this story caused much debate, as ubiquitylation of a cargo is 
generally thought to be required for its recognition by the ESCRT machinery and 
subsequent internalisation into MVBs (Metcalfe & Bienz, 2011). I thus wanted to 
explore whether PKAC is ubiquitylated and how this may be regulated by 
ARHGAP36. 
 
4.2.7. ARHGAP36 mediates PKAC ubiquitylation 
I first wanted to see if PKAC was ubiquitylated and whether the amount of 
ubiquitylated PKAC is increased in the presence of ARHGAP36. I pulled down 
PKAC-YFP in the presence or absence of Flag-ARHGAP36 and assessed its 
ubiquitylation status. I also cotransfected His tagged ubiquitin. In the presence of 
ARHGAP36, the amount of PKAC-YFP that was pulled down with anti-GFP 
appeared reduced and several higher molecular weight forms became apparent.   
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before fixing. Cells were stained with antibodies against GFP, Flag and EEA-1. 
Scale bars: 10 µm throughout.
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Figure 4.7 Endogenous PKAC colocalises with HRS, LAMP-1 and is 
enriched inside Rab5-Q79L vesicles. Confocal micrographs of MDCK cells 
transfected with Flag-ARHGAP36 together with GFP-HRS, LAMP1-YFP, or 
GFP-Rab5-QL. Cells were fixed and subjected to immunofluorescence using 
antibodies against GFP, Flag and PKAC. Scale bars: 10 µm. For Rab5-QL line 
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  Probing the same immunoprecipitates with an anti-ubiquitin antibody, showed that a 
small amount of ubiquitin was present in the absence of ARHGAP36, however this 
was massively increased in the presence of ARHGAP36 (Figure 4.8a).  
 
4.2.8. ARHGAP36 promotes PKAC ubiquitylation at a single lysine K285  
In order to identify any ubiquitin sites on PKAC regulated by ARHGAP36, I designed 
SILAC-based mass spectrometry experiments, together with Erik McShane (AG 
Selbach, MDC). SILAC (Stable isotope labelling by amino acids in cell culture) 
involves culturing cells in media supplemented with heavy isotope labelled amino 
acids, specifically arginine and lysine, for a minimum of five passages, until these 
isotopes become incorporated into all newly synthesised proteins (Ong et al, 2002; 
Ong & Mann, 2007). Cell lysates derived from cells grown in ‘light’ or normal media, 
can then be mixed together 1:1 with ‘heavy’ labelled cells and subsequently 
subjected to tryptic digest for quantitation by mass spectrometry. As trypsin cleaves 
after arginines and lysines, each peptide should be efficiently labelled (Olsen et al, 
2004). The relative intensity of heavy and light counterparts of each peptide then 
informs on the relative abundance of the parent protein in each condition. I labelled 
HEK293T cells with heavy or light media for a minimum of five passages, before 
transfecting cells with PKAC-Flag and YFP-ARHGAP36 or YFP-Cherry, so that 
PKAC would be differently labelled in the presence and absence of ARHGAP36. I 
lysed cells in RIPA, subjected proteins to Flag IP, then prior to the last washing step 
mixed heavy and light samples. After elution in 6M guanidine hydrochloride, 
samples were processed by Erik McShane. We found many PKAC peptides but only 
a single ubiquitin site, K285, identifiable by the additional isopeptide linked Gly-Gly 
remnant on the lysine side chain (Peng et al, 2003). This was also the only peptide 
to be regulated by ARHGAP36 (Figure 4.8b-d & Figure 4.9).   
 
4.2.9. Lysine 285 is required for ARHGAP36-mediated PKAC poly-
ubiquitylation  
I next mutated this site to arginine, K285R, so it could no longer be ubiquitylated to 
see if PKAC could be stabilised. I pulled down YFP tagged PKAC-WT or PKAC-
K285R in the presence and absence of Flag-ARHGAP36 and His-ubiquitin and 
assessed their ubiquitylation status. The lack of higher molecular weight bands with 
PKAC-K285R is immediately apparent, even upon probing with the GFP-antibody. 
The corresponding ubiquitin smear seemed to be completely lost with PKAC-K285R 
(Figure 4.10a). PKAC-K285R still bound to ARHGAP36, thus the lack of   
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Figure 4.8 ARHGAP36 induces PKAC ubiquitylation (a) HEK293T cells were 
transfected with PKAC-YFP or YFP-Cherry control, Flag-ARHGAP36 and His-
Ubiquitin as indicated. Lysates were subjected to GFP IP. Blots representative of 
three similar experiments (b) SILAC-labelled HEK293T cells were transfected 
with PKAC-Flag in the presence or absence of YFP-ARHGAP36. Lysates were 
subjected to Flag IP. Heavy/Light (H/L) ratio plot of the normalised peptide 
evidences matching PKAC. Only one peptide, highlighted in red, was upregu-
lated in the presence of ARHGAP36 and this was the only ubiquitylated PKAC 
peptide identified. Panel b courtesy of Erik McShane (AG Selbach, MDC) (c) 
Sequences of unique peptides identified in (b). The underlined lysine in the top 
sequence is the ubiquitin modified K285. (d) Structure of the PKAC-PKARIIβ 
complex showing the position of K285 on PKAC that undergoes ubiquitylation. 
Panel d courtesy of Oliver Daumke (MDC).
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Figure 4.9 ARHGAP36 mediates PKAC ubiquitylation at K285
One out of two MS/MS spectra identifying the GlyGly modified peptide of PKAC. Amino acid sequence, modified amino acid 
and the corresponding ions are shown. The mass shift introduced by the ubiquitylation is annotated in both the b (blue) and y 
(red) series. Figure kindly provided by Erik McShane.
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  polyubiquitylation could not be attributed to a lack of binding to ARHGAP36. This 
was supported by inspection of the published holoenzyme structure, which shows 
that K285R is at a considerable distance from the pseudo/substrate binding domain 
(see Figure 4.8d). It also appears to be readily accessible, however a part of PKAR 
is missing from this structure that could possibly cover this site (Zhang et al, 2012). 
PKAC-WT was also pulled down via His-Ubiquitin IP and presented with multiple 
prominent higher molecular weight forms in the presence but not the absence 
ARHGAP36. In contrast, these high molecular weight species were not apparent for 
the K285R mutant. PKAC-K285R presence was much reduced in the His-Ubiquitin 
IP, to the level of PKAC-WT in absence of ARHGAP36 (Figure 4.10b). Note that 
PKAC-K285R does still appear to be mono-ubiquitylated (see Figure 4.10a, GFP IP, 
GFP blot, lane 4, arrow).  
 
Direct binding to ARHGAP36 was required for PKAC ubiquitylation, as the 
pseudosubstrate mutant ARHGAP36-RRV, is unable to promote ubiquitylation of 
PKAC (Figure 4.10c).  
 
4.2.10. PKAC-K285R is resistant to ARHGAP36 mediated degradation 
CHX chase experiments showed that both PKAC-WT and PKAC-K285R are stable 
for at least nine hours, in agreement with previous data (Schwanhäusser et al, 
2011). However when ARHGAP36 was co-transfected, PKAC-WT was turned over 
within three hours, whereas PKAC-K285R was stable throughout (Figure 4.10d). By 
IF, PKAC-WT was clearly lost in the presence of ARHGAP36 and CHX after six 
hours. Epoxomicin could not rescue this effect, but a build up of PKAC-positive 
vesicles could be seen with addition of either bafilomycin or the lysosomal protease 
inhibitor leupeptin. The polyubiquitylation deficient mutant PKAC-K285R was 
unaffected by either treatment and remained stable throughout (Figure 4.11). I thus 
conclude that polyubiquitylation of PKAC at K285 is absolutely required for 
ARHGAP36 mediated lysosomal degradation.  
 
4.2.11. PKAC is decorated with K63-linked ubiquitin 
Different ubiquitin chain linkages are known to be involved in different degradation 
or signalling pathways. While K48-linked ubiquitin chains normally target substrates 
to the proteasome, K63-linked chains have been implicated in lysosomal targeting 
(Komader and Rape 2012). I wanted to determine the ubiquitin chain linkages  
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mutant or CFP-Cherry control. Lysates were immunoblotted with the indicated 
antibodies. (d) HEK293T cells were transfected with PKAC-YFP or PKAC-K285R-
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  attached to PKAC, especially as the ubiquitylation pattern consistently showed 
multiple discrete higher molecular weight bands. I first employed the UbiCREST 
assay developed in the lab of David Komander, which utilises the cleavage 
specificity of the DUBs to establish which linkages are within the chain (Mevissen et 
al, 2013; Hospenthal et al, 2015). After pulling down PKAC-YFP in the presence of 
Flag-ARHAGP36, the IP was split into aliquots and incubated with a panel of DUBs. 
USP2, a non linkage-specific DUB, reliably removed the whole smear, confirming 
this modification as ubiquitin (Figure 4.12a). None of the other DUBs were able to 
remove the entire smear, even after increasing the incubation time from the 
recommended 30 min to 45 min. However I consistently saw the appearance of a 
lower molecular weight species upon incubation with AMSH, a K63 chain editing 
DUB (McCullough et al, 2004, 2006; Komander et al, 2009b). This is most likely a 
mono-ubiquitylated species that would be resistant to AMSH. This partial cleavage 
may indicate the presence of complex mixed chains, which have also been 
implicated in lysosomal sorting (Boname et al, 2010). However, discussion with 
experts in the field revealed others had also experienced problems with DUB 
efficiency to completely remove chains from immunoprecipitated substrates 
(personal communication Anja Bremm, Buchmann Institute for Molecular Life 
Sciences, Frankfurt).  
 
We then turned to Selected Reaction Monitoring mass spectrometry (SRM-MS) to 
try to quantitatively assess the type of ubiquitin chain linkages associated with 
PKAC. This utilises AQUA-peptides, as they allow Absolute QUAntification (Gerber 
et al, 2003; Kettenbach et al, 2011). These are heavy isotope labelled peptides 
corresponding to the digested forms of each of the possible ubiquitin chain linkages. 
These peptides are spiked as specific standards into the reaction at known amounts 
such that any ubiquitin linkages attached to the substrate can be accurately 
quantified (Mirzaei et al, 2010). I pulled down PKAC in the absence or presence of 
ARHGAP36 and washed under stringent conditions in order to get rid of any 
proteins that are non-covalently bound to PKAC and only detect PKAC-specific 
post-translational modifications. SRM-MS was then performed by Patrick Beaudette 
(AG Dittmar, MDC). In the absence of ARHGAP36, a small amount of K48-linked 
ubiquitin chains were detected. In the presence of ARHGAP36 there was no change 
in K48 levels, but a strong increase in K63 (Figure 4.12b). No other chain linkages 
were identified at significant levels. This confirms that PKAC is decorated with K63-
linked ubiquitin chains and further supports that PKAC is degraded by the lysosome.   
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Figure 4.12 PKAC is decorated with K63 linked ubiquitin (a) HEK293T cells 
were transfected with His-Ubiquitin, PKAC-YFP and Flag-ARHGAP36. Lysates 
was subjected to a single GFP IP, then divided and incubated for 45 minutes at 
37°C with the indicated DUB. Eluates were immunoblotted with antibodies 
against PKAC or Ubiquitin. Asterisk indicates background antibody band. Blots 
representative of three independent experiments. (b) HEK293T cells were trans-
fected with PKAC-YFP in the presence or absence of Flag-ARHGAP36 and 
subjected to GFP IP followed by SRM-MS based relative quantitation of polyu-
biquitin linkage specific peptides. Data was normalised using the signal intensity 
of PKAC derived from a shotgun MS analysis of the same samples. Samples 
were measured in duplicate and the top two transitions used for quantitation. The 
error bars represent the standard deviation of the four calculated area ratios. 
Panel b contributed by Patrick Beaudette (AG Dittmar, MDC).
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  4.2.12. PKAC degradation requires the ESCRT pathway 
Lysosomal targeting of ubiquitylated cargo relies on the ESCRT complexes. To 
provide further proof that PKAC is degraded at the lysosome, I wanted to assess the 
involvement of the ESCRT machinery. I first attempted to knock down the ESCRT-0 
component HRS, however this proved difficult. In HEK293T cells I could only 
partially reduce HRS protein levels, despite attempting both single and double knock 
down protocols (Figure 4.13a). Knock down efficiency was better in HeLa cells, 
however transfection efficiency of ARHGAP36 plasmids was not sufficient to see a 
global decrease in PKAC levels. Instead I used Vps4, the AAA-ATPase that is 
involved in the recycling of ESCRT components in the final step when intraluminal 
vesicles pinch off into the MVB lumen (Williams & Urbé, 2007). I overexpressed 
Vps4-WT or the GTPase-deficient mutant, Vps4-E223Q (Bishop & Woodman, 2000; 
Sachse et al, 2004), and compared the turnover of PKAC-Flag over time. In the 
absence of ARHGAP36 neither Vps4-WT nor Vps4-EQ had an effect on PKAC-
Flag. Upon cotransfection of ARHGAP36 and Vps4-WT, PKAC-Flag was readily 
degraded. In contrast, in Vps4-EQ cotransfected cells, PKAC-Flag still appeared to 
be ubiquitylated, however it was no longer degraded (Figure 4.13b). This suggests a 
role for the ESCRT machinery in ARHGAP36 induced PKAC degradation. 
 
4.2.13. The ARHGAP36 interactome contains candidate E3 ligases 
The original mass spectrometry screen that identified PKAC as an interactor of 
ARHGAP36 also turned up other hits. Three of them were ubiquitin E3 ligases: 
Praja2, Stub1 and Huwe1. We thought that it was conceivable that these could be 
the E3 ligases responsible for ubiquitylation of PKAC, with ARHGAP36 acting as a 
scaffold to bring substrate and ligase together. Praja2 is a RING E3 ligase (Yu et al, 
2002), which is already known to ubiquitylate the PKA regulatory subunits, 
mediating their proteasomal degradation (Lignitto et al, 2011). Stub1, aka CHIP, is a 
small (35kDa) U-box domain containing E3, while Huwe1 is a very large (481kDa) 
HECT domain containing E3.  
 
4.2.14. E3 overexpression does not affect PKAC levels 
YFP-expression constructs for each ligase were overexpressed in MDCK cells to 
assess localisation of the encoded proteins. All E3s appeared mostly cytosolic with 
no apparent distinctive intracellular structures (Figure 4.14a). I next wanted to 
assess if ARHGAP36 could recruit any of the E3 ligases, however there was no 
change in E3 localisation upon co-expression of ARHGAP36 (Figure 4.14b). I then  
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Figure 4.13 ARHGAP36 induced PKAC degradation requires Vps4  
(a) HEK293T cells were transfected with 40 nM HRS siRNA the day 
after seeding. At 48 hours cells were transfected with YFP-ARHGAP36 
or YFP-Cherry control. Cells were harvested 72 hours after knock down. 
Lysates were immunoblotted with the indicated antibodies. Lipo: reagent 
only control. NT1: non-targeting oligo control. ( b) HEK293T cells were 
transfected with GFP-Vps4-WT or GFP-Vps4-EQ, PKAC-Flag and 
Cherry-ARHGAP36 or Cherry control as indicated. Cells were treated 
with cycloheximide (CHX, 50 µg/ml) and harvested at the indicated time 
points. Lysates were immunoblotted with the indicated antibodies. PKAC-
Flag levels were densitometrically evaluated and normalised to the 
amount present in the first lane of each gel. Blots representative of three 
independent experiments.
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Figure 4.14 ARHGAP36 has no effect on the localisation of its 
E3 ligase interactors (a) YFP-tagged E3 ligases were overex-
pressed in MDCK cells and images collected by live cell confocal 
microscopy. (b) YFP-tagged E3 ligases were co-expressed with 
CFP-ARHGAP36 in MDCK cells and images collected by live cell 
confocal microscopy. Scale bars: 10 µm.
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  wanted to see if any of the E3 ligases could cause PKAC degradation, however 
overexpression did not have any effect on endogenous PKAC levels, or localisation, 
by IF (Figure 4.15a). After eight hours of ARHGAP36 expression, endogenous 
PKAC is still present and co-localises with ARHGAP36 on vesicles (Figure 4.1b) I 
co-overexpressed the E3 ligases for this length of time, to see if they could increase 
the degradation rate of PKAC. PKAC was still found on vesicles, with no change in 
comparison to cells cotransfected with ARHGAP36 and a control plasmid (Figure 
4.15b). Huwe1 expression was problematic throughout, due to its large size it was 
hard to express and transfection efficiency was low. Therefore solid conclusions 
could not be drawn for this E3. Huwe1 is also listed in the CRAPome, a mass 
spectrometry database collating commonly identified background proteins  
(Mellacheruvu et al, 2013). It was found in 17% of experiments, suggesting this hit 
could be unspecific. For this reason, as well as difficulties working with a protein of 
this size, the other E3s were prioritised. 
 
4.2.15. E3 knockdown does not affect PKAC levels 
Having established that overexpression of the E3 ligases had no effect on PKAC 
levels, I next sought to knock them down to see if PKAC levels could be stabilised. 
Praja2 and Stub1 were knocked down using a smart pool comprised of four oligos 
for 48 hours with a single hit in HEK293T cells. Praja2 and Stub1 knock down were 
confirmed at the protein level via antibody staining. There was no effect on PKAC 
levels upon either E3 knock down. Co-expression of ARHGAP36 for the last 24 
hours of knock down consistently caused a decrease in PKAC levels independent of 
the presence of either ligase (Figure 4.16a). I then knocked down Praja2 and Stub1 
together, to see if they could compensate for each other. However simultaneous 
knock down of both Praja2 and Stub1 had no effect on PKAC, even when 
ARHGAP36 was overexpressed (Figure 4.16b). Huwe1 was also knocked down 
alone and in combination with Praja2 and Stub1. Although its knock down was not 
verified by antibody staining, initial experiments revealed no alteration in PKAC 
levels, even in the presence of ARHGAP36. Interestingly ARHGAP36 
overexpression promoted a decrease in Stub1 levels. 
 
4.2.16. Stub1 and Praja2 interact with ARHGAP36 
In order to at least confirm the interaction of Praja2 and Stub1 with ARHGAP36, I 
performed immunoprecipitation experiments. ARHGAP36 was able to pull down 
both Praja2 and Stub1 (Figure 4.17a). Conversely, Stub1 could pull down both   
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Figure 4.15 E3 interactor overexpression has no effect on PKAC levels, 
even in the presence of ARHGAP36 (a) YFP-tagged E3 ligases were overex-
pressed in MDCK cells. After 24 hours cells were fixed and subjected to immuno-
flouresence using antibodies against GFP and PKAC. Asterisk in PKAC channel 
indicates E3 transfected cells. (b) YFP-tagged E3 ligases were co-expressed with 
Flag-ARHGAP36 in MDCK cells. After eight hours the cells were fixed and 
subjected to immunofluorescence using antibodies against GFP, ARHGAP36 and 
PKAC. Scale bars: 10 µm. 
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Figure 4.16 Knockdown of Praja2 or Stub1 has no effect on 
ARHGAP36 mediated PKAC degradation (a) HEK293T cells were 
transfected using Lipofectamine RNAiMAX with 40 nM siRNA 
SMARTpools against Praja2, Stub1, the control oligo NT1, or the 
reagent alone (Lipo). After 24hours cells were transfected with YFP-
ARHGAP36 or YFP-Cherry using PEI. After a further 24 hours cells 
were harvested, yielding a 48 hour total knockdown. Lysates were 
probed with the indicated antibodies. (b) As in (a) except where 
indicated, cells were treated with 40 nM each Stub1 and Praja2 
together.
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Figure 4.17 ARHGAP36 interacts with Praja2 and Stub1 (a) HEK293T cells 
were transfected with Flag-ARHGAP36 together with YFP-Praja2, YFP-Stub1 or 
YFP-Cherry control. Lysates were subjected to Flag IP and immunoblotted with 
antibodies against Flag and GFP. (b) As in (a) except cells were transfected with 
Flag-Stub1 together with PKAC-YFP, YFP-ARHGAP36 or YFP-Cherry control. 
Figure 4.18 Stub1 is a PKA substrate (a) HEK293T cells were transfected with 
YFP-ARHGAP36 or a YFP-Cherry control. Lysates were subjected to GFP IP and 
immunoblotted with PKA p-Substrate and GFP antibodies. Arrow indicates the 
band which was subsequently identified as Stub1. Asterisk indicates the heavy 
chain of the antibody used for IP. (b) HEK293T cells were transiently transfected 
with YFP-Stub1 or a YFP-Cherry control. 24hours after transfection, cells were 
stimulated with 10 μM Forskolin and 100 μM IBMX for 20 mins, before harvesting. 
Lysates were subjected to IP using a PKA p-Substrate antibody and immunoblot-
ted with antibodies against p-Substrate and GFP. Asterisk indicates the heavy 
chain of the antibody used for IP.
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  cotransfected ARHGAP36 and PKAC (Figure 4.17b). PKAC is already known to 
interact at least indirectly with Praja2 via PKAR (Lignitto et al, 2011). The interaction 
of ARHGAP36 with Praja2 and Stub1 was thus confirmed, however the nature of 
these interactions is still unclear. 
 
4.2.17. Stub1 is a possible PKA substrate 
Immunoblotting of an YFP-ARHGAP36 IP with a PKA phospho-substrate antibody 
suggested that one particular substrate was consistently pulled down with 
ARHGAP36 (Figure 4.18a). To identify this protein of around 35 kDa, the YFP-
ARHGAP36 IP was repeated, the eluate run on a gel, stained and the band cut out 
and analysed by mass spectrometry by Erik McShane (AG Selbach, MDC). The top 
hit was none other than Stub1. PKA phosphorylation site prediction software turned 
up three candidate sites, two of which had also been identified in phosphosite. GFP-
Stub1 could also be pulled down with the PKA p-Substrate antibody (Figure 4.18b).  
 
4.3. Discussion 
Main Chapter Findings 
• ARHGAP36 mediates PKAC degradation  
• Unusually for a cytosolic protein, PKAC degradation occurs at the lysosome 
• ARHGAP36 mediates K63 linked ubiquitylation of PKAC at a single site, 
K285 
 
4.3.1. Monoubiquitylation vs Polyubiquitylation 
ARHGAP36 promotes ubiquitylation of a single site on PKAC, K285. Mutation of this 
site to arginine, K285R, stabilises PKAC completely and abolishes its 
polyubiquitylation. PKAC-K285R still appears to be mono-ubiquitylated, however 
this does not lead to its degradation. Further mass spectrometric analysis of PKAC-
K285R in the presence of ARHGAP36 did identify another ubiquitin site, K279. 
However, ubiquitylation at this site was only present on the mutant protein, and was 
much less abundant than at K285 in PKAC-WT. This could be an attempt of the E3 
ligase to compensate, by ubiquitylating the next closest lysine, upon mutation of the 
primary site. This mono-ubiquitylation is however not sufficient to trigger 
downregulation of PKAC. Interestingly, it has previously been shown for EGFR that 
monoubiquitylation is sufficient for initial internalisation, but polyubiquitylation is 
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  required for further endosomal sorting and lysosomal degradation (Huang et al, 
2013).  
 
4.3.2. K63 linked ubiquitylation 
I have shown that ARHGAP36 mediates K63 linked ubiquitylation of PKAC. This 
chain linkage is already widely implicated in endolysosomal trafficking (Duncan et al, 
2006; Lauwers et al, 2009; Erpapazoglou et al, 2012). The UbiCREST assay may 
implicate the presence of more complex mixed chains (e.g. K63 and K11-linked 
chains), which have previously been implicated in endolysosomal targeting 
(Boname et al, 2010). However, as others also experienced problems with 
immounoprecipitated substrates, and the SRM data only identified an increase in 
K63 linked chains upon ARHGAP36 co-expression, this would rather argue for an 
exclusive role of this chain linkage. Further experiments would be needed to clarify 
this point.  
 
4.3.3. ARHGAP36 inclusion in MVBs 
Some overexpressed ARHGAP36 appears to translocate inside Rab5-Q79L 
enlarged endosomes together with endogenous PKAC. However, the majority of the 
protein does not appear to be degraded, as it was stable throughout CHX chase 
experiments as assessed by WB (Figure 4.10d & 4.13b) and IF (Figure 4.11). The 
ubiquitin E3 ligase and multi subunit adaptor protein c-Cbl has also been seen 
inside MVBs. It ubiquitylates EGFR and has been proposed to remain associated 
with its substrate along its endocytic journey (de Melker et al, 2001). The ESCRT-I 
protein Tsg101 is a well-known marker for internal vesicles, and is even thought to 
be co-degraded with cargo as a possible feedback mechanism to limit receptor 
degradation (Malerød et al, 2011).	   
 
4.3.4. E3 ligase identification 
The E3 ligase involved in ARHGAP36-mediated ubiquitylation of PKAC has yet to 
be identified. Since I have not found any evidence for an involvement of Praja2 in 
this process, I would argue for completely different mechanisms of degradation for 
PKAR and PKAC. Their degradation is spatially separated, PKAC in the lysosome, 
and PKAR in the proteasome, and this seems to involve different sets of proteins. 
As there are over 600 E3 ligases, identifying the E3 responsible for PKAC 
ubiquitylation will be a daunting task. Stub1 does not seem to control PKAC stability, 
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  however it appears to be phosphorylated by PKAC and is itself downregulated by 
ARHGAP36. Phosphorylation of Stub1 by PKAC will need to be further confirmed, 
as the phospho-substrate antibody used for IP can potentially also recognise Akt 
and PKC substrates, albeit to a lesser extent. Regardless of the kinase, it would be 
interesting to see if there is an effect of this modification on Stub1 function. Further 
experiments would also be required to establish how ARHGAP36 affects Stub1 
stability. For both Praja2 and Stub1 it would be interesting to know how they bind to 
ARHGAP36, and whether simultaneous binding to PKAC is possible.  
 
4.3.5. Cross Regulation of PKAC and PKAR levels 
It has previously been shown indirectly that in a wide variety of tissues PKAC and 
PKAR subunit proteins are present at approximately the same levels (Hofmann et 
al, 1977). Safeguarding mechanisms to ensure proper responsiveness of the 
holoenzyme to cAMP have thus long been hypothesised. In S49 mutant cell lines 
that lack PKAC, the PKAR subunits were shown to be much less stable (Steinberg 
& Agard, 1981a). It could also be shown that much less PKAR subunits are 
synthesised in these cells. Conversely, in wild type S49 cells that do express PKAC, 
kinase activation was shown to stimulate PKAR synthesis (Steinberg & Agard, 
1981b). Thus active free PKAC can lead to an increase in PKAR. It was later 
confirmed that PKARIα transcription is indeed stimulated by cAMP (Solberg et al, 
1997). In cells where PKAC is exogenously overexpressed, a corresponding 
increase in PKAR is also observed (Uhler & McKnight, 1987). Furthermore, PKARIβ 
and PKARIIβ knock out mice both show a compensatory increase in PKARIα levels 
(Amieux et al, 1997). ARHGAP36 may provide additional buffering capacity in 
situations of PKAC excess.   
 
4.3.6. PKAR degradation  
PKA signalling is known to play a critical role in synaptic plasticity. This requires 
sustained signalling through PKAC (Sweatt & Kandel, 1989). The ubiquitin-
proteasome system has long been implicated in this mechanism through the 
degradation of PKAR. This shifts the balance of the R/C ratio and leads to persistent 
and eventually autonomous PKAC activation, despite basal cAMP levels 
(Greenberg et al; Hegde et al, 1993; Chain et al, 1995, 1999). Recently Praja2, a 
neuronal E3 ligase, was shown to mediate PKAR ubiquitylation and proteasomal 
degradation (Lignitto et al, 2011). Praja2 is an AKAP, which binds PKAR via an 
amphipathic a-helix located N-terminally from its RING domain. Praja2 is also a PKA 
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  substrate, and phosphorylation is thought to increase its catalytic activity. Praja2 
thus mediates a positive feed forward loop. Elevation of cAMP-levels causes 
dissociation of the holoenzyme, thus activation of PKAC, which phosphorylates 
Praja2, which in turn ubiquitylates PKAR. PKAR degradation thus leads to an 
increase in free and active PKAC. Lignitto and co-authors could show that siRNA 
knockdown of Praja2 in rat brain leads to decreased p-CREB levels upon 
stimulation. They further demonstrated that Praja2 knockdown affects long-term 
potentiation in the rat brain. ARHGAP36 could be involved in resetting the pathway 
in the brain. 
 
4.3.7. Hints at PKAC degradation in the literature 
Whereas many protein kinases are ubiquitylated and degraded upon activation (Lu 
& Hunter, 2009; Liu et al, 2012), this is the first proposed mechanism for ubiquitin-
dependent turnover of PKAC. PKAC is intrinsically active, with its activity regulated 
by binding to PKAR. Therefore it was mostly thought that PKA signalling is reset 
through holoenzyme reassociation.  
 
Loss of PKAC upon prolonged stimulation was first observed for a porcine kidney 
cell line (Hemmings, 1986). In this case the loss of PKAC was strongly accentuated 
upon IBMX addition, which inhibits phosphodiesterase activity. This argues that 
normally cAMP would be degraded over short periods, so the holoenzyme can 
reassociate. Then mechanisms may need to come into play to degrade any 
remaining free PKAC left over at longer time points. ARHGAP36 could be involved 
in such a mechanism. 
 
It has been shown in thyroid follicular cells that under constant hormone stimulation 
the PKA pathway becomes unresponsive, and CREB-dependent transcriptional 
activation ceases. Over shorter periods this was shown to be due to 
dephosphorylation of CREB at Ser-133, however after longer periods of sustained 
activation phosphatase inhibitors were unable to rescue this effect. It was claimed 
that this was due to a loss of PKAC, however the quality of western blotting was 
questionable (Armstrong et al, 1995). Loss of PKAC with constant stimulation was 
also seen over time in a growth hormone producing pituitary cell line, however this 
was assessed indirectly via PKI-binding assays (Richardson et al, 1990a). 
Nevertheless ARHGAP36 may play a role in such a hormone-induced refractory 
period.  
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One recent paper implicated a cell-type specific role of the Regγ (PSME3) 
proteasome activator in regulating PKAC stability (Liu et al, 2014). It had previously 
been described that Regγ could mediate ubiquitin and ATP independent 
degradation of SRC-3 and p21 (Li et al, 2006, 2007). PKAC was shown to be more 
abundant and stable in Regγ knock out cells. I saw no effect of proteasome 
inhibitors on ARHGAP36 induced PKAC degradation.  
 
4.3.8. Kinase inhibition by endolysosomal inclusion 
Surprisingly for a cytosolic protein, ARHGAP36 targets PKAC not to the 
proteasome, but to the endolysosomal pathway. One other cytosolic kinase, GSK3, 
has also been seen to enter MVBs, however it is not subsequently degraded by the 
endolysosomal system (Taelman et al, 2010). GSK3ß is a central component of the 
destruction complex in the canonical Wnt signalling pathway (Wu & Pan, 2010). In 
the absence of a Wnt stimulus, GSK3ß together with CK1 takes part in the 
sequential phosphorylation of β-catenin, which as a result is recognised by the 
SCFßTRCP ubiquitin-ligase, ubiquitylated and degraded at the proteasome 
(MacDonald et al, 2009). Upon pathway activation, β-catenin ubiquitylation is 
prevented, so that newly synthesised beta-catenin can accumulate and drive target 
gene expression in the nucleus. GSK3ß inactivation is critical for this. Taelman and 
colleagues claimed that when the activated Frizzled receptor and its co-receptor 
LRP5/6 become endocytosed, GSK3 that is bound to the cytoplasmic tail of LRP5/6 
becomes internalised into MVBs. They used cryoimmunoelectron microscopy to 
show convincingly that some GSK3 is located inside MVBs upon Wnt stimulation. 
They could also show that accumulation of β-catenin and Wnt pathway activation 
requires HRS and Vps4, implying a role for the ESCRT machinery. However they 
did not show or discuss a role for ubiquitin in this process, although the ESCRT 
pathway, and particularly HRS are known to specifically recognise ubiquitylated 
cargo for translocation into the internal vesicles of MVBs. The authors thus 
proposed that GSK3 may be actively sequestered in the endolysosomal pathway 
without providing evidence for downregulation of this critical kinase. This paper led 
to much discussion in the field (Metcalfe & Bienz, 2011).  
 
In contrast to this story, I have shown that PKAC is ubiquitylated, providing a 
mechanism by which it can engage with the ESCRT machinery. I have also shown 
that this process requires active Vps4, suggesting a role for the ESCRT pathway. 
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  Furthermore, unlike GSK3, ARHGAP36-mediated translocation of PKAC into the 
endolysosomal pathway results in its degradation.  
 
Interestingly GSK3 is also thought to be inhibited by pseudosubstrate binding of 
LRP6 (Cselenyi et al, 2008; Mi et al, 2006; Piao et al, 2008; Wu et al, 2009). Thus 
parallels can be drawn with PKAC, which is subjected to bimodal inhibition by 
ARHGAP36. Pseudosubstrate binding ensures immediate inhibition of the kinase, 
and internalisation into MVBs ensures this inhibition is sustained, as the kinase can 
no longer access its substrates. For PKAC, degradation is the final step. One could 
argue that this may turn out to be a general mechanism for long-term signal 
termination of cytosolic signalling proteins.  
 
The Taelman paper implies that entry into the endolysosomal pathway could be 
facilitated by any membrane associated interaction partner that itself is sorted into 
the endocytic pathway. ARHGAP36 could thus mediate PKAC endolysosomal 
sorting as it independently localises to the plasma membrane and also to vesicular 
structures. I have shown that the ARHGAP36 arginine rich region is sufficient to 
target ARHGAP36 to membranes (Figure 3.2). The positively charged arginines 
could hydrostatically associate with the negatively charged plasma membrane. A 
polylysine charged region plays a role in KRas4b association with the membrane 
(Hancock et al, 1990; Jang et al, 2015), and basic regions in ESCRT-III proteins are 
thought to mediate binding to endosomal membranes (Williams & Urbé, 2007). 
Isoform 1 of ARHGAP36 contains a signal peptide, however this could also be a 
transmembrane protein. More investigation will be required to determine this, and 
whether it is of physiological relevance. It is also tempting to speculate whether 
ARHAGP36 could play a more general role in endocytic sorting.  
 
4.3.9. Global or local degradation? 
From my experiments with overexpressed ARHGAP36, all cellular PKAC was 
degraded, however this may not be the case in the endogenous context. A pool of 
PKAC may be turned over, for example at the membrane or within the primary cilia, 
in response to acute upregulation or stabilisation of ARHGAP36. This could be 
coupled to specific GPCR receptor stimulation within this space. Alternatively PKAC 
degradation could also take place in a constitutive manner in order to decrease 
sensitivity of cells to cAMP, leading to a tonic suppression of the pathway wherever 
ARHGAP36 is expressed.   
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   ARHGAP36 is a suppressor of PKA Chapter 5.
signalling  
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  5.1. Introduction 
ARHGAP36 has a dramatic inhibitory effect on PKA, firstly by direct inhibition and 
secondly by promoting its degradation. One would expect that as a result of this, 
signalling downstream of PKA is abolished. In this chapter I will aim to answer the 
following questions: 
 
• Does ARHGAP36 expression affect PKA signalling outputs? 
• Where is ARHGAP36 expressed? 
• Does ARHGAP36 regulate PKAC in an endogenous setting? 
 
5.2. Results 
5.2.1. ARHGAP36 abolishes CREB phosphorylation  
PKA phosphorylation controls many cellular processes. The transcriptional effects of 
PKA are partially mediated through the cAMP response element binding protein 
(CREB). This transcription factor is activated upon phosphorylation by PKA 
(Gonzalez & Montminy, 1989). Upon activation, CREB binds CRE sequences and 
activates transcription of target genes. CREB activation in the nucleus can be easily 
assessed by monitoring its phosphorylation status using phospho-specific 
antibodies. I transfected MDCK cells in OptiMEM with YFP-ARHGAP36 or YFP as a 
control. In unstimulated cells, there was hardly any phospho-CREB (p-CREB) signal 
in untransfected cells or those transfected with either construct (Figure 5.1a). Upon 
stimulation with 10 µM Forskolin and 100 µM IBMX for 20 min, all untransfected cell 
nuclei became positive for p-CREB staining. The same was true for YFP-transfected 
cells, however YFP-ARHGAP36 transfected cells remained p-CREB negative 
(Figure 5.1b). I counted the p-CREB positive nuclei of transfected cells and could 
show that ARHGAP36 causes more than a 90% reduction in CREB activation 
(Figure 5.1c). Overexpression of 36i, the 25 amino acids comprising the 
pseudosubstrate motif, also effectively inhibited CREB phosphorylation (Figure 5.2). 
Both N- and C-terminally tagged constructs were tested, as it is possible that the 
fluorophore could mask the pseudosubstrate site in this small protein. Both were 
found to be equally effective. CREB inhibition could thus be attributed to the 
pseudosubstrate binding and direct inhibition of PKAC, since 36i does not trigger 
PKAC downregulation. Both N- and C -terminally tagged PKI constructs could also 
inhibit CREB phosphorylation, serving as a positive control for inhibition of this PKA-
dependant process. Importantly, the pseudosubstrate mutant ARHGAP36-RRV,   
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Figure 5.1 ARHGAP36 inhibits CREB phosphorylation (a) MDCK cells express-
ing YFP-ARHGAP36 or YFP control in OptiMEM were fixed without any stimulation 
and subjected to immunofluorescence using antibodies against GFP and phospho-
CREB. Images were collected by confocal microscopy. Images representative of 
three independent experiments. Scale bars: 10 μm. (b) As in (a) except cells were 
treated with 10 μM Forskolin and 100 μM IBMX for 20 minutes before fixation. (c) 
Quantitative analysis of nuclear phospho-CREB staining in cells expressing the 
indicated constructs as in (b) (n>100 for each of three independent experiments, 
shown as mean ±s.d. *** p<0.001). 
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  which cannot interact with nor inhibit PKAC, was unable to suppress CREB 
phosphorylation. 
 
5.2.2. ARHGAP36 inhibits AQP2 trafficking 
Trafficking of the water channel aquaporin-2 (AQP2) is also a PKA dependant 
process. This occurs in the collecting duct cells of the kidney and is an important 
process for water homeostasis. Under basal conditions AQP2 is located on vesicles 
in the cytoplasm. However, upon vasopressin stimulus and cAMP production, 
activated PKA phosphorylates AQP2 (Katsura et al, 1997; Fushimi et al, 1997). This 
mediates the translocation and insertion of AQP2 into the plasma membrane, where 
it can affect water reabsorption. Using a mouse kidney collecting duct cell line, 
MCD4, which stably expresses AQP2 (Iolascon et al, 2007), I could assess the 
effect of ARHGAP36 on AQP2 translocation. I transfected MCD4 cells overnight in 
OptiMEM with YFP-ARHGAP36 or a YFP control plasmid. Cells were then fixed and 
stained for GFP and AQP2, as well as for the tight junction marker ZO-1 in order to 
identify the cell membrane. In unstimulated cells, AQP2 was indeed localised mainly 
to vesicles in the cytoplasm and did not colocalise with ZO-1 (Figure 5.3a). When 
cells were stimulated prior to fixation with 10 µM Forskolin and 100 µM IBMX for 20 
min, a portion of AQP2 relocalised to the plasma membrane. YFP transfection had 
no effect on AQP2 translocation, whereas in YFP-ARHGAP36 expressing cells, 
AQP2 remained on vesicles in the cytoplasm (Figure 5.3b). This could be clearly 
shown by the lack of colocalisation with ZO-1, which is also depicted as a line-scan 
intensity plot in Figure 5.3b. In contrast, clear colocalisation of AQP2 and ZO-1 
could be seen in YFP-expressing cells.  
 
5.2.3. ARHGAP36 expression is largely restricted to embryonic skeletal 
muscle 
With such an extreme effect on PKAC itself, as well as signalling downstream, we 
hypothesised that ARHGAP36 expression must be tightly regulated both spatially 
and perhaps temporally throughout development. In order to address this question I 
designed an in situ hybridisation probe, to recognise Arhgap36 mouse mRNA. At 
that time we did not have a validated antibody.  
 
I initially tested my probe on sections from E14 and E16 mice. I saw a striking 
expression in the tongue, the diaphragm, and the intercostal muscles (Figure 5.4). 
In discussion with experts, we realised that Arhgap36 mRNA was present in all   
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Figure 5.3 ARHGAP36 inhibits AQP2 trafficking (a) MCD4 cells stably expressing Aquaporin2 (AQP2) were transfected with YFP-ARHGAP36 
or YFP control in OptiMEM. 24 hours post-transfection, without any stimulation, cells were fixed and subjected to immunofluorescence using 
antibodies against GFP, AQP2 and the tight junction protein ZO-1, to visualise the plasma membrane at cell-cell contact sites. Images were 
collected by confocal microscopy. Scale bars: 10 µm. Line scan fluorescence intensity profiles are shown on the right. In red: AQP2, in blue: ZO-1. 
Images representative of three similar experiments. (b) As in (a) except cells were treated with 10 µM Forskolin for 20 minutes before fixing.
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Figure 5.4 Arhgap36 is expressed in embryonic skeletal muscle. In situ  hybrid-
ization using an Arhgap36-specific probe on wild-type E14 mice. Left panel anti-
sense probe, right panel negative control using sense probe. Positive blue staining 
can be seen in: 1- extraocular muscles, 2- back muscles, 3- intercostal muscles, 
4-diaphragm, 5- muscles of the hindlimb. Note that the heart (*), a cardiac muscle, 
is not positively stained. 
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  skeletal muscles. Upon seeing such strong expression in skeletal muscle, I wanted 
to use the C2C12 muscle cell line as a model, however no Arhgap36 mRNA could 
be detected. As these cells are derived from adult mouse muscle fibres, I wondered 
whether Arhgap36 is actually still expressed in adult muscle. In collaboration with 
Nora Mecklenburg (AG Hammes-Lewin, MDC) and Maciej Czajkowski (AG Rocks, 
MDC) Arhgap36 expression was surveyed across the developmental stages. These 
expression data suggest that Arhgap36 is present in skeletal muscle from formation, 
up until birth. Expression starts as early as E10 in the somites, however is quickly 
lost after birth, and completely gone at P2 (Figure 5.5).  
 
5.2.4. ARHGAP36 is absent from commonly used cell lines 
The restricted expression pattern explains why we had failed to detect Arhgap36 
mRNA by qRT-PCR in a number of commonly used cell lines, such as those used in 
this thesis so far. I then queried disease databases and found that ARHGAP36 was 
upregulated in neuroblastoma cell lines (nextbio.com), and even identified as part of 
a neuroblastoma signature (Lee et al, 2014). qRT-PCR revealed a substantial 
increase in mRNA levels in SK-N-BE(2) cells, and an even greater increase in NGP 
cells (25 and approximately 3000 fold respectively compared to HeLa cells, Maciej 
Czajkowski, AG Rocks, unpublished data). Both of these cell lines are derived from 
human neuroblastoma. I then wanted to confirm ARHGAP36 expression at the 
protein level. I ran 10 µg of protein lysate from NGP and SK-N-BE(2) cells, as well 
as HeLa, HEK293T and U2OS for comparison, and assessed expression by WB 
with a commercial ARHGAP36 antibody. I detected a strong band at the relevant 
size only in NGP cells (Figure 5.6a). This band between 40 and 50 kDa could 
correspond to human Isoform 3, which is predicted to have a MW of 46 kDa. I have 
already confirmed that Isoform 3 can both interact with PKAC and cause its 
degradation (Figure 3.8 and 4.4).  
 
5.2.5. ARHGAP36 is expressed in neuroblastoma cells 
I next attempted to knock down ARHGAP36 in NGP cells using siRNA in order to 
first confirm the specificity of the antibody. Cells were cultured for 48 hours before 
transfection with Lipofectamine RNAiMAX, NT1 or a smart pool comprising four 
oligos targeting ARHGAP36. 24 hours after siRNA transfection, cells were lysed 
directly in the well with RIPA buffer. Western blotting revealed that the ARHGAP36 
band at 46 kDa is specific, as it is reduced upon treatment with siRNA (Figure 5.6b). 
When I ran much more SK-N-BE(2) protein I could also see an ARHGAP36 band at   
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Figure 5.5 Arhgap36 expression is developmentally regulated. 
In situ hybridization using an Arhgap36-specific probe on wild-type mice at the indicated developmental stages. Blue indicates posi-
tive Arhgap36 staining. Images are representative of the expression in at least three different embryos for each time point. Scale 
bars: 1 mm. Figure contributed by Maciej Czajkowski (AG Rocks, MDC) and Nora Mecklenberg (AG Hammes, MDC).
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Figure 5.6 ARHGAP36 is expressed in neuroblastoma cells (a) 10 μg 
lysate of the indicated cell lines were immunoblotted with the indicated 
antibodies. A  band at  the r ight  s ize,  46 kDa, corresponding to isoform 
3 of ARHGAP36, was only obsereved in NGP cells. (b) ARHGAP36 was 
knocked down using an siRNA SMARTpool in NGP cells for 24 hours.   
Lipo: reagent only control, NT1: non-targeting oligo control. 10 μg lysate 
was immunoblotted with the indicated antibodies. (c) ARHGAP36 was stably 
knocked down in SK-N-BE(2) cells using lentiviral infection of shRNA. 
Stuffer: control. A9, A10, G11, G12: ARHGAP36 shRNA. 20 μg lysate was 
immunoblotted with the indicated antibodies. All blots representative of three 
similar experiments.
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  46 kDa. I therefore also attempted to knock down ARHGAP36 using siRNA in SK-N-
BE(2) cells, however there was no obvious effect. I then set out to create stable 
ARHGAP36 knockdown cell lines using lentiviral infection of ARHGAP36 targeting 
shRNAs. Cells were infected with viruses one day after seeding, and the following 
day 2 µg/µl puromycin was added to select for cells which had integrated the viral 
plasmid. Cells were then expanded in the presence of puromycin. As a control I 
infected cells with a virus containing a random stuffer sequence as opposed to 
ARHGAP36 shRNA. These cells have therefore undergone the same procedure as 
ARHGAP36 knock down cells, namely viral infection, followed by puromycin 
selection. I could demonstrate knockdown of the 46 kDa band with 3 out of 4 
ARHGAP36 shRNAs (Figure 5.6c). ARHGAP36 is thus also expressed in SK-N-
BE(2) cells, albeit at much lower levels. I therefore focused on NGP cells to 
characterise the role of endogenous ARHGAP36. 
 
5.2.6. ARHGAP36 and PKAC are expressed at equimolar levels in NGP cells 
I next conducted a snapshot analysis of the NGP proteome with the help of Erik 
McShane (AG Selbach, MDC) and Patrick Beaudette (AG Dittmar, MDC). Intensity 
based absolute quantitation (iBAQ, Schwanhäusser et al, 2011) was used to 
compare protein levels of ARHGAP36 to PKAC and other components of the 
pathway. This technique divides the protein intensity, derived from the sum of all 
peptide intensities, by the number of theoretically observable peptides, derived from 
an in silico trypsin digest of the proteome. For absolute quantitation, protein 
standards must be spiked in at known amounts, to create a standard curve, 
however without this it is still possible to compare protein levels to one another. 
PKACα was the majorly expressed catalytic isoform, and was expressed in 
approximately equimolar levels to ARHGAP36 (Figure 5.7a). PKACβ was expressed 
at much lower levels such that the pooled total of catalytic subunits was 
approximately equal to ARHGAP36 (Figure 5.7b & c). ARHGAP36 is thus present at 
sufficiently high levels to theoretically form a 1:1 complex with PKAC.  
 
The predominantly expressed R subunit was R1α, which was 3 fold more highly 
expressed than ARHGAP36. R2α was expressed at only slightly higher levels than 
ARHGAP36, whereas R2β was expressed at a much lower level. Finally, no 
peptides were detected for R1β.  The sum total of PKAR subunits was 4.4 fold that 
of ARHGAP36 (Figure 5.7c). We did not detect PKI.  
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Figure 5.8 Endogenous PKAC interacts with endogenous ARHGAP36 (a) NGP 
cell lysates were immunoprecipitated with an ARHGAP36 antibody or an IgG rabbit 
control. Seperate gels were immunoblotted for ARHGAP36 or PKAC. 25% less lysate 
and eluate were run for ARHGAP36 than for PKAC. Blots representative of three simi-
lar experiments. (b) As in (a) except where indicated cells were stimulated for 30 min 
with 10 µM Forskolin and 100 µM IBMX (F/I). 
Figure 5.7 ARHGAP36 and PKAC are expressed at equimolar levels in NGP 
cells  (a) Histogram displaying the distribution of the relative abundance of all mea-
sured proteins. ARHGAP36 and PKAC are found within the same bin (pink). (b) Bar 
plot of log 10 abundance of the indicated proteins relative to ARHGAP36. GAPDH 
and PKAC are expressed in a 437 fold and 0.95 fold abundance relative to 
ARHGAP36, respectively. PKAC is the summed total of PKACα and PKACβ. (c) Bar 
plot of log 2 abundance of the indicated proteins relative to PKAC total, the summed 
total of PKACα and PKACβ. PKAR is the summed total of RIα, RIIα and RIIβ. Figures 
kindly provided by Erik McShane (AG Selbach, MDC). 
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  5.2.7. Endogenous ARHGAP36 interacts with endogenous PKAC 
After confirming the presence of ARHGAP36 and PKAC in NGP cells, the next step 
was to see if endogenous ARHGAP36 regulates endogenous PKAC in these cells. 
First I attempted to co-immunoprecipitate ARHGAP36 and PKAC. I supplemented 
my RIPA lysis buffer with ADP and MgCl2 as nucleotide and metal ion presence was 
shown to be critical for pseudosubstrate binding to PKAC (Herberg & Taylor, 1993). 
15 cm dishes of NGP cells were scraped directly in 500 µl RIPA buffer in order to 
concentrate lysates as much as possible. 4.5 mg NGP lysates were incubated first 
with 4 µg ARHGAP36 antibody or IgG rabbit control for one hour at 4 °C, before 
addition of beads for a further 30 min. I could pull down endogenous PKAC with 
endogenous ARHGAP36 (Figure 5.8a), proving that this interaction does happen at 
the endogenous level in vivo. Interestingly stimulation of cells with 10 µM Forskolin 
and 100 µM IBMX for 30 minutes prior to harvesting did not increase the amount of 
PKAC pulled down with ARHGAP36 (Figure 5.8b). 
 
5.2.8. ARHGAP36 knockdown leads to an increase in PKAC protein levels and 
activity in NGP cells 
I then wanted to see whether ARHGAP36 knock down had an effect on PKAC 
stability or activity. I knocked down ARHGAP36 for 24 hours and stimulated cells 
with 10 µM Forskolin and 100 µM IBMX for 30 minutes prior to harvesting directly in 
RIPA. Lysis buffer was supplemented with phosSTOP to specifically inhibit cellular 
phosphatases and ensure any effects on phosphorylation were captured. Knock 
down of ARHGAP36 led to a reproducible and significant increase in PKAC levels 
(37%) and also activity, as seen by an increase in pCREB levels (78%) (Figure 
5.9a). ARHGAP36 knock down and similar, albeit overall weaker effects on PKAC 
and p-CREB levels could also be seen when deconvoluting the SMARTpool into 
individual oligos (Figure 5.9b). Out of the 4 oligos (9-12), oligo 11 was clearly not as 
effective at knocking down ARHGAP36, and thus had a lesser effect on PKAC and 
p-CREB. The extent of ARHGAP36 knockdown negatively correlates with PKAC 
and p-CREB levels, as determined by the Pearson’s sample correlation coefficient. I 
also created NGP cell lines with stable knock down of ARHGAP36 using lentiviral 
infection of shRNA, as for SK-N-BE(2). Using these cells I could further show a 
reproducible and significant increase in CREB phosphorylation upon knockdown, 
even in the absence of stimulus, with two different viruses (Figure 5.9c 68% and 
107%). However, I did not see a clear effect on PKAC levels, which may be 
accounted for by compensatory mechanisms in the stable cell line setting. As   
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Figure 5.9 ARHGAP36 antagonises PKAC in an endogenous setting (a) NGP 
cells were treated with an siRNA SMARTpool against ARHGAP36 for 24 hours. Cells 
were stimulated with 10 μM Forskolin and 100 μM IBMX before harvesting. 
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plotted against ARHGAP36 values. Linear regression analysis indicates a negatively 
correlated distribution (Pearson’s sample correlation coefficient, PKAC: r = -0.87, 
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  discussed in Chapter 4, manipulation of PKAC or PKAR levels commonly leads to a 
corresponding increase or decrease in the other protein (Steinberg & Agard, 1981a, 
1981b; Uhler & McKnight, 1987).  
 
5.2.9. ARHGAP36 and PKAC expression levels are negatively correlated in 
NGP cells 
Immunofluorescence of wild-type NGP cells showed that endogenous ARHGAP36 
localised like the overexpressed protein, to the plasma membrane, and also some 
vesicular structures (Figure 5.10a). Upon siRNA knockdown of ARHGAP36, this 
antibody staining was partially reduced, confirming specificity of the ARHGAP36 
antibody also for immunofluorescence. At steady state however, ARHGAP36 
expression appeared to be heterogeneous in this non-clonal cell line, with protein 
levels varying dramatically from cell to cell. Interestingly where ARHGAP36 levels 
where high, PKAC levels were low (Figure 5.10b). Together with Markus Müller (AG 
Rocks, MDC) I was able to quantify this effect, by utilising cell tracker (Molecular 
Probes), a dye that can freely pass into cells, but once taken up is converted into a 
product that can no longer escape. This allowed individual cells to be segmented 
and their levels of ARHGAP36 and PKAC quantitated. The ratio of PKAC to 
ARHGAP36 could then be represented (Figure 5.10b pseudo-coloured image). The 
levels of ARHGAP36 and PKAC were plotted against each other and showed a 
negative correlation (Figure 5.10b scatter plot, Pearson’s coefficient: -0.296). By 
immunofluorescence microscopy, SK-N-BE(2) cells also appeared to have 
heterogeneous ARHGAP36 expression levels. However the majority of cells showed 
just background nuclear staining. A very small number of cells exhibited a significant 
ARHGAP36 signal (less than 1%), which was associated predominantly with 
vesicles and accumulated on structures in the perinuclear region (Figure 5.11). 
 
5.2.10. ARHGAP36 and PKAC colocalise inside Rab5QL vesicles 
We could not see any convincing colocalisation between endogenous ARHGAP36 
and PKAC. This is not surprising as the two proteins show negative correlation and I 
have shown that ARHGAP36 causes the efficient degradation of interacting PKAC. I 
thus overexpressed GFP-Rab5-Q79L, in order to induce enlarged endosomes and 
hopefully trap some PKAC before it is degraded. I could indeed see endogenous 
PKAC inside these enlarged endosomes, colocalising together with ARHGAP36 
(Figure 5.12). I had expected to perhaps see ARHGAP36 only on the outer 
membrane of Rab5-QL in endosomes, however some ARHGAP36 was also present  
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Figure 5.10 ARHGAP36 and PKAC levels are negatively correlated in NGP 
cells (a) Confocal micrographs of NGP cells subjected to immunofluorescence 
using an antibody against ARHGAP36. Scale bar: 10 μm. (b) Confocal micro-
graphs of Cell Tracker Deep Red treated NGP cells that were subjected to 
immunofluorescence using antibodies against ARHGAP36 and PKAC. Images 
representative of three similar experiments. Cells were segmented and the 
ratio of average PKAC over ARHGAP36 fluorescence intensity of single cells is 
shown in the pseudocolour image. Scale bar: 10 μm. The scatterplot shows the 
normalised single cell average intensity of PKAC plotted against ARHGAP36 
(red dots, n=225 cells). Linear regression analysis (continuous line) indicates a 
negatively correlated distribution (Pearson’s sample correlation coefficient r = 
-0.296). Dashed line indicates theoretical maximal positive correlation (r = 1). 
Image analysis was performed with the help of Markus Müller.
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Figure 5.12 ARHGAP36 and PKAC colocalise inside Rab5-QL induced 
vesicles. Confocal micrographs of NGP cells transfected with GFP-Rab5-
QL. Cells were fixed and subjected to immunofluorescence using antibod-
ies against GFP, ARHGAP36 and PKAC. Images representative of three 
similar experiments. Scale bar: 5 μm
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Figure 5.11 ARHGAP36 levels are heterogeneous in SK-N-BE(2) cells 
Confocal micrographs of SK-N-BE(2) cells subjected to immunofluores-
cence using an antibody against ARHGAP36. Scale bar: 10 μm. 
147
	  inside. In Chapter 4 I had already observed overexpressed ARHGAP36 inside these 
enlarged endosomes together with endogenous PKAC. However whereas PKAC 
was only localised inside, ARHGAP36 was still present on the outer membrane of 
the vesicles, as well as elsewhere in the cell (Figure 4.7). CHX chase experiments 
had also shown that overexpressed ARHGAP36 protein levels do not change with 
CHX treatment, in the same time that overexpressed PKAC is efficiently degraded 
(Figure 4.10d). It would be interesting to repeat the CHX chase experiments in NGP 
cells looking at both endogenous ARHGAP36 and PKAC. This would help to 
establish whether a subpopulation of ARHGAP36 is degraded together with PKAC. 
A precedence for this has already been discussed above with respect to the E3 
ligase Cbl and the ESCRT-I component Tsg101 which become internalised into 
MVBs together with cargo (de Melker et al, 2001; Malerød et al, 2011).  
 
5.3. Discussion 
Main Chapter Findings 
• ARHGAP36 suppresses PKA signalling 
• ARHGAP36 expression is tissue specific and developmentally regulated 
• ARHGAP36 is expressed in neuroblastoma cell lines 
• Endogenous ARHGAP36 controls endogenous PKAC activity and stability 
 
5.3.1. ARHGAP36 supresses a wide range of PKA signalling responses 
I have shown that PKA signalling responses are suppressed in the presence of 
ARHGAP36. CREB is the main mediator of the PKA transcriptional response, and is 
ubiquitously expressed. AQP2 trafficking is a more specific process that takes place 
in the collecting duct cells of the kidney. I have also described in Chapter 3 how 
Hedgehog signalling is activated in the presence of ARHGAP36, as PKA is a 
negative master regulator of this pathway. ARHGAP36 can thus oppose PKA 
signalling in a wide variety of contexts. These are just three examples, however I 
hypothesise that ARHGAP36 could antagonise PKAC wherever it is expressed. 
 
5.3.2. Arhgap36 expression is developmentally regulated 
We found that Arhgap36 is regulated during development and specifically found in 
embryonic skeletal muscle. Previous work also indicated developmental regulation 
of Arhgap36. Rack and colleagues assayed whole embryos at E7, E10, E15 and 
E17, and found increasing Arhgap36 mRNA levels throughout the developmental 
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  stages. When looking at specific adult tissues they also observed no expression 
except in the spinal cord and to a lesser extent the brain.  
 
5.3.3. ARHGAP36 in skeletal muscle 
Myogenesis involves specification of embryonic precursors into myoblasts, which 
then differentiate and finally fuse into multinucleate myotubes. This process is 
controlled by four transcription factors. Three of the four, MyoD, Myf5 and Myr4 are 
determination factors, whereas Myogenin is a differentiation factor (Buckingham & 
Rigby, 2014). Myogenin thus controls the conversion of myoblasts into myofibres.  
 
A study comparing differences in wild-type versus myogenin knock-out mice, found 
that Arhgap36 expression is massively reduced in the absence of this transcription 
factor (Davie et al, 2007). In fact Arhgap36 was one of the most downregulated 
genes in the entire screen. They could further confirm that Arhgap36, at the time 
only known as RIKEN1100001E04, was expressed in the same fibres as myogenin 
in the tongue of embryonic wild-type mice. They could also show myogenin and 
MyoD bound to the Arhgap36 sequence upstream of the transcription initiation site. 
They further hypothesised the presence of another possible binding site within the 
first intron.  
 
We carried out preliminary experiments to see if Arhgap36 expression is reinitiated 
upon injury. Together with the lab of Simone Spuler (ECRC, Berlin) we tried 
regeneration experiments, where adult mouse tibialis anterior muscle was injected 
with cholera toxin, or DMSO as a control, in order to wound the muscle and initiate 
the wound-healing program. Arhgap36 presence was assessed by in situ 
hybridisation 3, 6 and 12 days after injection. We saw no upregulation of Arhgap36 
upon wound healing and muscle regeneration. This is surprising as the same gene 
program controls the activation of satellite cells and their differentiation into new 
muscle fibres (Montarras et al, 2013). ARHGAP36 can be found repeatedly 
upregulated in biopsies obtained from myopathy patients or probands after muscle 
exercise (NCBI GEO profiles). It will be interesting to reassess the role of 
ARHGAP36 in muscle regeneration in future gene-targeting studies.  
 
5.3.4. ARHGAP36 in neuroblastoma  
Neuroblastoma is a rare childhood cancer of neuroendocrine origin. It is an 
extremely heterogenous disease, with diverse outcomes: tumours can metastasise 
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  or even spontaneously regress (Cheung & Dyer, 2013). It is thus thought that many 
cases are never even detected (Brodeur & Bagatell, 2014). It is derived from neural 
crest cells, and is mostly diagnosed associated with the adrenal gland. 
Approximately 22% of tumours have amplified MYCN and 8-10% ALK1, but apart 
from this there is a lack of candidates for targeted treatment. 	  
 
Neuroblastoma cell lines are known to contain heterogenous cell populations 
(Thiele, 1998). This is thought to be due to the fact that the tumours originally derive 
from multi-potent neural crest progenitors. Cells were characterised as having 
mainly neuronal or melanocytic properties, two neural crest derivative cell types. 
Some studies have aimed to isolate these different cell types from mixed 
populations, however these cells have been shown to have the capacity to 
spontaneously differentiate and change phenotype (Biedler et al, 1978; Ciccarone et 
al, 1989). It could be of interest to characterize the properties of cells with high 
ARHGAP36 levels, to determine if they are more neuronal or have properties of 
other neural crest cell derivatives. 
 
NGP cells were isolated from the lung after treatment, but the original site of the 
tumour was unknown (Brodeur & Goldstein, 1976). The SK-N-BE(2) line was 
isolated from bone marrow after treatment, its original site is also unknown. 
Interestingly another cell line, SK-N-BE(1), was isolated from the same patient just 5 
months earlier before treatment (Biedler et al, 1978). It would be interesting to 
compare the number of ARHGAP36 expressing cells in these two lines. A number of 
these paired lines exist.  
 
ARHGAP36 was identified as an interactor of CLN5 in a mass spectrometry screen 
in SH-SY5Y cells (Scifo et al, 2013). These cells are a neuronal type subclone of the 
SKNSH neuroblastoma cell line. CLN5 (ceroid lipofuscinosis neuronal protein 5) is a 
lysosomal protein that has been implicated in endocytic sorting (Mamo et al, 2012). 
CLN5 mutations lead to a variant of neuronal ceroid lipoduscinoses (NCL) 
(Savukoski et al, 1998). Most of these mutations were found to abolish the 
lysosomal localisation of CLN5 (Isosomppi et al, 2002; Schmiedt et al, 2010). As 
ARHGAP36 mediates the endolysosomal degradation of PKAC in neuroblastoma 
cells, this interaction is of particular interest. 
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  5.3.5. Competitive binding? 
We previously hypothesised that ARHGAP36 binds PKAC in the same manner as 
PKI and thus would not be able to compete for PKAC binding in the holoenzyme 
setting. In this case one would expect to see increased binding between 
ARHGAP36 and PKAC upon pathway activation, when PKAC is released by PKAR. 
However, this was not the case. Stimulation of NGP cells with forskolin did not 
increase the interaction (Figure 5.8). It could be that PKA activity in these cells is 
uncoupled from cAMP. Indeed, in initial western blotting experiments, stimulation did 
not lead to a major increase in phosphorylation of substrates compared to basal 
levels. However, another possibility is that ARHGAP36 could compete with PKAR 
for binding. ARHGAP36 could potentially bind to the holoenzyme via an alternate 
site in order to displace PKAR and facilitate pseudosubstrate binding. In this case 
binding may be independent of cellular cAMP levels. Further experiments would be 
required to determine if ARHGAP36 has the potential to bind PKAR. The 
ARHGAP36-RRV pseudosubstrate mutant that no longer binds PKAC will be useful 
in establishing this.  
 
5.3.6. Bimodal antagonism 
It is hard to dissect the inhibitory and degradative properties of ARHGAP36, as one 
leads to the other, and if PKA is absent it obviously cannot be active. However, I 
could see that expression of ARHGAP36-36i, which contains the pseudosubstrate 
domain but cannot trigger PKAC degradation, was sufficient to inhibit CREB 
activation. In NGP cells I saw an increase in PKAC protein levels upon ARHGAP36 
knock down, arguing that ARHGAP36 also mediates PKAC degradation here. It 
would be interesting to knock down the E3 ligases identified in the interactome in 
NGP cells and assess if PKAC protein levels are affected. Our mass spectrometry 
data demonstrated that Stub1 and Huwe1 are indeed expressed in NGP cells, 
however Praja2, a supposedly neuronal specific gene, was not detected and thus is 
not within the top 4518 abundantly expressed proteins. 
 
It is of course possible that the degradative properties of ARHGAP36 could be 
uncoupled from PKAC inhibition dependent on the cell-type or the signalling state of 
the cell. In response to low levels of EGF stimulus, EGFR is thought to be mostly 
recycled back to the plasma membrane, whereas in response to high levels of EGF 
it is degraded in the lysosome (Sigismund et al, 2008). The same principle could 
apply for ARHGAP36 regulation of PKAC. Pseudosubstrate binding alone could 
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  mediate short-term inhibition in response to low-level stimulus, whereas degradation 
may only take place upon high level or repetitive exposure to stimulus. In general, 
degradation could be responsible for a tonic suppression of the pathway, whereas 
pseudosubstrate binding alone may mediate acute reversible inhibition.  
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   Discussion  Chapter 6.
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  6.1. Summary 
In this thesis I have shown that ARHGAP36 binds the PKA catalytic subunit directly 
and inhibits it via a pseudosubstrate motif. Furthermore, ARHGAP36 binding leads 
to depletion of PKAC levels. ARHGAP36 mediates K63 linked polyubiquitylation of 
PKAC at a single site, K285. Unexpectedly for a cytosolic protein PKAC is then 
degraded via the endolysosomal system in a Vps4 dependent manner. ARHGAP36 
can thus drastically suppress PKA signalling in a wide variety of settings. With such 
a striking effect on a ubiquitous pathway it is not surprising that ARHGAP36 
expression is extremely restricted. I observed it only in embryonic skeletal muscles. 
It is, however, upregulated in neuroblastoma cells, where I could show that it 
modulates PKAC activity and stability in an endogenous setting. 
 
6.2. Open Mechanistic Questions 
I will discuss here some of the outstanding questions from my work. One of the key 
points raised throughout these sections is how the interaction between ARHGAP36 
and PKAC is regulated. 
 
6.2.1. Why is PKAC not degraded by the proteasome? 
PKAC degradation is mediated via the endolysosomal pathway, and not by the 
proteasome which is unusual for a cytosolic protein. It is possible that PKAC is not 
amenable to unfolding by the AAA-ATPases of the proteasomal regulatory particle, 
which is a prerequisite for entry into the core particle and thus degradation (Finley et 
al, 2016). Interestingly, PKAC has been implicated in phosphorylation of regulatory 
particle proteasomal subunits, which leads to enhanced proteasome activity (Zhang 
et al, 2007; Lokireddy et al, 2015). PKAC may thus be unsusceptible to proteasomal 
degradation in order to allow it to phosphorylate proteasomal subunits and stimulate 
their activity without itself being degraded. I found that PKAC is decorated with K63 
linked chains. As well as mediating endolysosomal trafficking, this may ensure it is 
not degraded by the proteasome. All the DUBs associated with the proteasome 
have the ability to cleave K63 linked chains, and thus rescue substrates from 
degradation (Jacobson et al, 2009). Endosomal ubiquitin receptor binding of K63-
linked chains has also been argued to block proteins modified with this linkage from 
proteasomal ubiquitin receptor binding and thus shield them from proteasomal 
degradation (Nathan et al, 2013). 
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  In contrast to PKAC, PKAR is degraded by the proteasome. In the regulation of 
synaptic plasticity, PKAR degradation facilitates an alteration in the R/C ratio and 
thus an increase in PKAC activity (Greenberg et al, 1987; Sweatt & Kandel, 1989). 
The spatial separation of PKAR and PKAC degradation may be important in such 
mechanisms, by ensuring that PKAC is not co-degraded. Endolysosomal 
degradation of PKAC could also be a mechanism to degrade only the fraction of 
cellular PKAC that is localised together with ARHGAP36 at the plasma membrane 
or on endosomes. This could help to further compartmentalise PKA signalling 
responses, and ensure timely inactivation of PKAC in this context. This would also 
ensure that inactivation and degradation of PKA in one part of the cell, does not lead 
to a loss of activity at other subcellular localisations.  
 
6.2.2. Lysosomal degradation of cytosolic kinases: a more general 
mechanism? 
Other cytosolic kinases are also known to be degraded by the lysosome, however 
they take different routes to reach this destination. PKAC is trafficked along the 
endocytic pathway before arriving at the lysosome. In contrast, Src and Ret, both 
non-receptor tyrosine kinases, have been shown to be sequestered into 
autophagosomes which then fuse with lysosomes (Sandilands et al, 2011, 2012). 
This has so far been shown to be ubiquitin independent. This process occurs in 
response to the loss of their binding partner focal adhesion kinase (FAK), a 
signalling hub at focal adhesions, which would normally anchor them there. 
Autophagy of Src and Ret is thought to be a mechanism that promotes cancer cell 
survival by allowing cells to cope with FAK loss and the subsequent increase in 
these untethered kinases. This has been termed ‘signalophagy’: autophagy of 
signalling proteins (Khaminets et al, 2016). The identification here that PKAC is also 
degraded in the lysosome, albeit in a process that depends on ubiquitin and the 
ESCRT-machinery, may suggest that lysosomal degradation of cytosolic signalling 
proteins is a more general way to achieve long-term signal termination. This is a 
well-established mechanism for transmembrane receptor tyrosine kinases, such as 
the Epidermal Growth Factor Receptor (EGFR) (Lu & Hunter, 2009; Liu et al, 2012). 
Like PKAC, GSK3β is also sequestered by the endosomal pathway into MVBs, 
although it is not thought to be subsequently degraded (Taelman et al, 2010). 
However, this still results in protection of cytosolic substrates from GSK3β 
phosphorylation. 
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  6.2.3. What are the roles of the uncharacterised regions of ARHGAP36?  
Just 25 amino acids were required for pseudosubstrate inhibition of PKAC (36i), and 
77 amino acids for its degradation (ARHGAP36-N2). I have therefore only 
characterised the function of a small part of ARHGAP36. It will be interesting to find 
out what the rest of the protein contributes. In this respect the GAP domain is 
particularly interesting as it may still mediate binding to Rho proteins, even if it is 
catalytically inactive, and thus serve to integrate Rho and PKA signalling pathways. 
The Rho GAP family protein OCRL contains a catalytically inactive GAP domain, but 
still binds to Rac1 and Cdc42, and is rather thought to act as a Rho effector protein 
(Faucherre et al, 2003; Mehta et al, 2014). It is possible that binding of ARHGAP36 
to Rho-family members either blocks or stimulates PKAC binding, thus adding 
another layer of regulation to the interaction. 
 
6.2.4. Can ARHGAP36 compete with PKAR for PKAC binding? 
It still needs to be determined if ARHGAP36 can compete with PKAR for binding to 
PKAC, or whether it merely binds to free PKAC in the same manner as PKI. Another 
part of ARHGAP36 may be involved in binding to PKAR and mediate its 
displacement from the PKAC catalytic site. If ARHGAP36 cannot compete with 
PKAR for PKAC binding, then inhibition and degradation is thus coupled to cAMP 
levels, as PKAC is only released from PKAR upon cAMP binding. This would 
constitute another incidence where activation of a kinase is coupled to its 
degradation (Lu & Hunter, 2009; Liu et al, 2012). It would be interesting to see if 
ARHGAP36 itself is reactive to other cellular stimuli.  
 
6.2.5. Which E3 ligase mediates PKAC ubiquitylation, and is recruitment and 
thus degradation regulated? 
This is the first description of ubiquitin-mediated degradation of PKAC. The E3 
ligase mediating PKAC ubiquitylation has still to be identified. As there are over 600 
E3 ligases, this will be a daunting task. ARHGAP36 interacts with multiple E3 
ligases, that were identified in an unbiased fashion, however I have so far not 
obtained any evidence that Praja2, Stub1 or Huwe1 are involved in the degradation 
of PKAC. Perhaps ARHGAP36 recruitment of an E3 ligase is also regulated, such 
that ubiquitylation and degradation of PKAC is only initiated upon high or repeated 
exposure to stimulus. There is already precedence for such degradation of PKAC in 
the literature. Constant stimulation of thyroid follicular cells, growth-hormone 
producing pituitary cells and porcine kidney cells all led to an eventual decrease in 
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  PKAC protein levels (Hemmings, 1986; Armstrong et al, 1995; Richardson et al, 
1990a). ARHGAP36 could thus be involved in a hormone-induced refractory period. 
Alternatively this could occur in a constitutive manner, to completely suppress PKA 
signalling wherever ARHGAP36 is expressed. The inhibitory and degradative 
properties of ARHAGP36 may be differentially regulated, and possibly segregated, 
dependent on the cell type. 
 
6.3. Physiological Relevance and future perspectives 	  
6.3.1. ARHGAP36 and the cAMP-PKA axis during development 
6.3.1.1. PKA in Myogenesis 
A role for PKA has been implicated at multiple stages of myogenesis (Knight & 
Kothary, 2011). It was found that PKA phosphorylation of CREB, stimulated by non-
canonical Wnt signalling, led to the initial expression of the myogenic transcription 
factors (Chen et al, 2005). It is not clear whether this is direct, however Myf5 
contains a CRE element, as does Pax3, a transcription factor further upstream of 
the myogenic programme. ARHGAP36 expression is under the control of myogenic 
transcription factors (Davie et al, 2007). PKA activity itself may thus indirectly lead to 
ARHGAP36 expression. The interplay of Shh and Wnt signals regulates the 
specification of the dermomyotome, which gives rise to the myotome and myogenic 
progenitors, from the somites. Wnt regulation of PKA signalling thus provides a 
mechanism of how Wnt could also antagonize Shh signalling (Pourquié, 2005). 
 
Later in myogenesis the role of PKA in differentiation of myoblasts is unclear, with 
some studies claiming it inhibits myoblast fusion and others claiming it enhances it 
(Winter et al, 1993; Mukai & Hashimoto, 2008; Knight & Kothary, 2011). cAMP 
levels are thought to drop dramatically after myoblast fusion (Siow et al, 2002). 
Older studies focused mainly on CREB activation and transcription downstream of 
PKAC, however it is now becoming apparent that PKAC has many different roles 
throughout the cell. It is thus conceivable that PKA may have differential activities 
within the same cell. PKAC is clearly dynamically regulated throughout myogenesis. 
It will be interesting to explore exactly how ARHGAP36 contributes to its activity 
profile during muscle development. 
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  It has also been hypothesised that PKAC and PKAR levels and lifetimes vary 
between myoblasts and myotubes. PKAC is supposedly longer lived in myoblasts 
than myotubes, whereas for PKAR it is the opposite (Lorimer et al, 1987; Lorimer & 
Sanwal, 1989). The lifetimes of both subunits decrease in myoblasts upon cAMP 
stimulation. It will be extremely interesting to explore the role of ARHGAP36 in 
regulating PKAC stability throughout myogenesis.  
 
6.3.1.2. Dissecting the role and cellular localisation of ARHGAP36 in 
development 
The restricted embryonic expression of ARHGAP36 made it extremely difficult to 
investigate the role of endogenous ARHGAP36. The generation of knock-out (KO) 
mice will facilitate this. Cell lines derived from Arhgap36 KO mice will allow the 
comparison of PKAC activity, levels and turnover between KO and wild-type cells. 
Analysing the phenotypes of Arhgap36 mutant mice will also facilitate pinpointing 
when and where Arhgap36 expression is important in myogenesis. The plan is to 
generate and assess both skeletal muscle specific and complete knockouts.  
 
Non-myogenic associated phenotypes of the complete KO will also help to ascertain 
whether Arhgap36 is expressed in further discrete tissues that I may have missed 
thus far. We are also developing antibodies to recognise mouse Arhgap36 for this 
purpose. This will allow us to assess the specific subcellular localisation of 
Arhgap36 wherever it is expressed. Ultimately, these approaches will help to 
establish whether Arhgap36 acts in a local or global manner to inhibit and degrade 
PKAC. 
 
I described in Chapter 3 that ARHGAP36 can localise to the primary cilium (Figure 
3.4 & 5). It will be interesting to see if this is the case during muscle development. It 
was recently shown that primary cilia are dynamically regulated during myogenesis 
(Fu et al, 2014). Interfering with cilia formation inhibits myogenic differentiation and 
instead promotes proliferation. Fu and colleagues also showed that these cilia 
contribute to Hh signalling in myoblasts. Cell lines derived from Arhgap36 KO mice 
will allow us to assess whether Arhgap36 plays a role in cilia formation and 
maintenance. We will also be able to explore whether Arhgap36 enables Hh 
signalling via PKAC inhibition in this context. PKAC is generally thought to be 
localised at the basal body (Tuson et al, 2011), however it was recently detected 
within the cilium itself (Mick et al, 2015). Furthermore, overexpression of a cilia-
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  targeted PKI caused a reduction in Gli3 repressor processing, indicating a role for 
PKAC within the cilium (Mick et al, 2015). As ARHGAP36 can localise to the cilium 
independently, it could be a physiological and dynamic regulator of PKAC within 
cilia.  
 
Maciej Czajkowski (AG Rocks, MDC) has already started to generate complete KO 
mice. So far only heterozygous females have been born, suggesting that deletion in 
males of the one and only copy of Arhgap36, encoded on the X-chromosome, is 
embryonically lethal.  
 
6.3.2. ARHGAP36 and the cAMP-PKA axis in oncogenesis 
6.3.2.1. ARHGAP36 upregulation in cancer 
ARHGAP36 is upregulated in neuroblastoma (nextbio.com) and was identified as 
part of a neuroblastoma signature (Lee et al, 2014). I could show in Chapter 5 that 
ARHGAP36 is expressed in neuroblastoma cells, and it can modulate both PKAC 
activity and stability in an endogenous setting. ARHGAP36 has also very recently 
been shown to be upregulated in pheochromocytoma (Croisé et al, 2016). This 
tumour arises from the chromaffin cells of the adrenal medulla. It is interestingly also 
of neural crest origin, and has similarities to neuroblastoma in its genetic landscape 
(Castro-Vega et al, 2016). It will be interesting to see if ARHGAP36 is also 
upregulated in other cancers of neural crest origin, such as melanoma, glioma and 
glioblastoma. As described in Chapter 3, ARHGAP36 was also found upregulated in 
a subset of medullablastoma. 
 
6.3.2.2. The diverse roles of PKAC in cancer 
As in normal physiology, PKAC plays complicated and sometimes seemingly 
opposing roles in cancer biology. PKAC has been identified as both an oncogene 
and tumour suppressor in a variety of malignancies (Sapio et al, 2014).  
 
Much attention has been given recently to the discovery that activating mutations of 
PKAC result in tumours of the adrenal cortex leading to Cushing’s syndrome 
(Beuschlein et al, 2014; Cao et al, 2014; Goh et al, 2014; Sato et al, 2014). These 
mutations are thought to inhibit PKAR binding. A fusion protein of PKAC has also 
been described in fibrolamellar hepatocellular carcinoma (FL-HCC) (Honeyman et 
al, 2014). PKAC is fused to the C-terminus of the molecular chaperone DNAJB1. 
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  PKAC retains kinase activity and is overproduced under the control of the DNAJB1 
promoter. In both cases signalling is thus uncontrolled. There were conflicting 
reports on whether the DNAJB1-PKAC fusion also retained PKAR binding 
(Honeyman et al, 2014; Cheung et al, 2015).  It would be interesting to see if these 
mutant proteins can still bind ARHGAP36, as Cao and colleagues claimed PKI could 
still inhibit activity of the PKAC Leu206 mutant. Peptides based on ARHGAP36 may 
be an option for targeted therapy to inhibit this mutant PKAC.  
 
GPCR coupled GαS signalling through PKA is thought to be tumour suppressive in 
medulloblastoma (He et al, 2014). This supports our hypothesis that the reason 
ARHGAP36 is upregulated in medulloblastoma is that it oncogenically activates 
Hedgehog signalling via inhibition of PKAC.  
 
The GαS-PKA axis is also thought to act as a tumour suppressor pathway in basal-
cell carcinoma (Iglesias-Bartolome et al, 2015). It was even shown that PKI is 
oncogenic in this context: transgenic mice expressing PKI in the epidermis rapidly 
develop skin lesions. We would thus expect ARHGAP36 to have a similar, if not a 
more extreme phenotype. It would be interesting to see if ARHGAP36 is 
upregulated in this cancer. Iglesias-Bartolome and colleagues showed that GαS 
mediated activation of PKA normally leads to Shh pathway inhibition, as well as 
Hippo pathway inhibition. PKA has recently been implicated in regulating Hippo 
signalling (Kim et al, 2013; Yu et al, 2013). This is yet another pathway where 
ARHGAP36 could modulate the tumour suppressive function of PKAC. 
 
Most recently PKA has been in the spotlight for regulating mesenchymal to epithelial 
transition (MET) in a number of cancer cell lines (Pattabiraman et al, 2016). This is 
partially via phosphorylation and activation of PHF2, a histone demethylase, which 
derepresses genes required for the epithelial state. Importantly PKA-induced MET 
renders cells much more susceptible to chemotherapeutics and dramatically 
reduces their potential to metastasise and initiate secondary tumours. The PKA 
pathway has thus had a recent revival as a potential drug target in cancer. It would 
be interesting to know if ARHGAP36 can contribute to epithelial to mesenchymal 
transition (EMT) via suppression of PKA signalling. Tumour-initiating cells with 
mesenchymal properties may be more likely to express ARHGAP36 in order to 
suppress PKAC and the epithelial state. The study from Pattabiraman and 
colleagues also highlights the importance of heterogeneity within tumour cell 
populations. It further identifies PKAC transcriptional signatures that can be utilised 
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  as a readout for future studies, such as an increase in E-Cadherin and a decrease 
in EMT-inducing transcription factors Snail, Twist1 and Zeb1 (Pattabiraman et al, 
2016). It will be interesting to see whether ARHGAP36 upregulation in cancer 
negatively correlates with this signature, and vice versa.  
 
Dependent on the tissue setting and signalling context in which PKA functions, 
aberrant ARHGAP36 expression could have either tumour suppressive or 
oncogenic roles. In terms of targeting oncogenic PKA signalling, ARHGAP36 as a 
pseudosubstrate inhibitor should be very specific for PKA as opposed to other 
kinases. Its bimodal inhibitory mechanism also indicates it could be a much more 
potent suppressor of PKA than PKI, which is only a transient inhibitor of activity. 
Dissecting the role of ARHGAP36 and its interplay with PKAC will allow further 
understanding of the context-specific roles of PKA signalling, and its impact in both 
development and disease.  
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